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Synopsis         . 
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           The research work incorporated in the thesis with the title “STUDIES ON 
CHEMICAL ENTITIES OF MEDICINAL INTEREST” has been described as under the 
following parts. 
 
PART[A] : STUDIES ON ISOPROPYL BENZOIC ACID DERIVATIVES 
PART[B] : STUDIES ON THIOPHENE-2-CARBALDEHYDE DERIVATIVES 
PART[C] : STUDIES ON IMIDAZO [1,2-α]PYRIDINE DERIVATIVES 
  
PART [A] : STUDIES ON ISOPROPYL BENZOIC ACID DERIVATIVES 
 
Isopropyl benzoic acid and their derivatives constitute an important class of organic 
compounds with diverse agricultural, industrial and biological activities. The synthesis of this 
moiety has received considerable attention in recent years. Isopropyl benzoic acid is also 
known as Cumic acid.  
 The chemistry of 1,2,4-triazole has assumed importance because of their versatility in 
the synthesis of many heterocyclic compounds. The synthesis of these heterocycles has 
received considerable attention in recent years. 
With a view to supplement of these valid observations and to evaluate its 
pharmacological profiles, it was thought worthwhile to synthesized some new heterocycles 
bearing 1,2,4-triazole nucleus, which have been described as under. 
 
PART-I: STUDIES ON 1, 3, 4-THIADIAZOLE DERIVATIVES 
 
The synthesis of compounds incorporating 1,3,4-thiadiazole rings has been attracted 
widespread attention due to their diverse pharmacological properties like antibiotic, 
antifungal, herbicidal, antitubercular, etc. To approach this goal synthesis of some 1,3,4-
thiadiazole have been undertaken, which have been described as under. 
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SECTION-I : Synthesis and biological screening of 6-Aryl-3-(4-isopropylphenyl)- 
  [1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles 
CH3
CH3
N
N
N
N
S
R  
Type (I)  R= Aryl 
1,3,4-Thiadiazole derivatives of Type (I) have been synthesized by the condensation 
of 1-amino-3-[4-(propan-2-yl)phenyl]-1H-1,2,4-triazole-5-thiol with different aromatic acids 
in the presence of POCl3. 
SECTION-II : Synthesis and biological screening of 5,6 Dihydro-6-aryl-3-(4-
isopropylphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles 
                                          
 
CH3
CH3
N
N
N
NH
S
R  
Type (II)  R= Aryl 
 
1,3,4-Thiadiazole derivatives of Type(II) have been synthesized by the condensation 
of 1-amino-3-[4-(propan-2-yl)phenyl]-1H-1,2,4-triazole-5-thiol with different aromatic 
aldehydes in the presence of p-toluenesulphonic acid. 
 
PART-II : STUDIES ON THIADIAZINES 
 
Literature survey reveals that various 1,3,4-thiadiazines have resulted in many 
potential drugs and known to exhibit a broad spectrum of biological activities such as 
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antibacterial, cardiovascular, antifungal, antitubercular, etc. Hence it was considered 
worthwhile to synthesized 1,3,4-thiadiazine derivatives for better drug potential, which have 
been described as under. 
 
SECTION-I : Synthesis and biological screening of 6-Aryl-3-(4-isopropylphenyl)-7H-
[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines  
CH3
CH3
N
N
N
N
S
R  
Type (III) R=Aryl 
 
Thiadiazines of Type (III) have been synthesized by the condensation of 1-amino-3-
[4-(propan-2-yl)phenyl]-1H-1,2,4-triazole-5-thiol with different substituted phenacyl 
bromides. 
PART-III : STUDIES ON OXADIAZOLES 
 
1,3,4- Oxadiazoles are associated with broad spectrum of pharmacological activity 
like anesthetic, hypnotic, antibacterial, hypoglycemic and antifungal. These valid 
observations promoted us to synthesis 1,3,4- oxadiazole derivatives with better therapeutic 
value have been described as under. 
 
SECTION-I : Synthesis and biological screening of 2-(4-Isopropylphenyl)-5-aryl-1,3,4-
oxadiazoles 
                                       
CH3
CH3
N
O
N
R 
Type (IV) R=Aryl 
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Oxadiazoles of type (IV) have been synthesized by the cyclo condensation of 
isopropylbenzohydrazide with different aromatic acids in the presence of POCl3. 
 
 
PART-IV: STUDIES ON IMIDAZOLONES  
 
 The discovery of imidazolones as potent biologically active agent has led to the 
exploration of large number of structural variants, containing imidazolones moiety as an 
invariable ingredient. Its derivative have shown various biologically activities such as 
anathematic, antimicrobial, antihistamine, anti-inflammatory, antibacterial etc. in order to 
develop therapeutically important compounds, it was consider of interest to synthesize some 
imidazolones shown as under. 
 
SECTION-I : Synthesis and biological screening of N-((E)-4-(Arylidene)-5-oxo-2- 
  phenylimidazolidin-1-yl)-4-isopropylbenzamides 
 
 
 
 
 
 
 
 
 
 
Type (V) R=Aryl 
 
 The synthesis of imidazolones of type–(V) have been under taken by the reaction of 
4- isopropylbenzohydrazide with substituted azalactones which in turn have been prepared by 
well known Erlenmeyer azalactone synthesis. 
 
 
 
 
CH3
CH3
O
NH N
NH
O
R
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PART [B] : STUDIES ON THIOPHENE-2-CARBALDEHYDE DERIVATIVES 
 
 Heterocyclic compounds bearing thiophene-2-carbaldehyde ring system and their 
derivatives are demonstrates various biological and pharmacological activities. Our works are 
paying attention on introduction of chemical multiplicity in the molecular frame work, in 
order to synthesizing active molecules of widely different composition. Literature assessment 
reveals that sulfur containing heterocyclic compounds have acknowledged considerable 
attention in remedial science due to their biological and pharmacological activities such as 
anti-HIV, antitubercular, antimicrobial, anticonvulsant, anticancer, antiviral etc. Considering 
the increasing importance of thiophene-2-carbaldehyde nucleus, we have undertaken the 
synthesis of some new arylaminomethyl and oxadiazole derivatives bearing thiophene-2-
carbaldehyde nucleus, which have been described as under. 
 
PART - I : STUDIES ON INDAZOLES 
 
 Cyclohexenone and indazole derivatives have been found to be associated with 
various pharmacological activities such as antifungal, antibacterial, anticoagulant, antipyretic, 
anti-inflammatory etc., led by these considerations some new indazole have been synthesized 
which have been described as under.  
 
SECTION - I : Synthesis and biological screening of Ethyl 6-oxo-4-aryl-2-(thiophen-2-
       yl)cyclohex-1-enecarboxylates  
 
S
R
O
O O CH3 
Type (VII) R=Aryl 
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 Cyclohexenone derivatives of Type-(VII) have been synthesized by the 
cyclocondensation of the chalcones of ethyl acetoacetate in presence of sodium ethoxide. 
 
SECTION -II : Synthesis and biological screening of 4,Dihydro-4-aryl-6-(thiophen-2-
        yl)-2H-indazole-3(3aH)-ones 
 
S N
NH
O
R
 
  
Type (VII) R=Aryl 
 
 Indazole derivatives of Type-(VIII) have been prepared by the condensation of 
cyclohexenone derivatives of Type-(VII) with hydrazine hydrate. 
PART- II : STUDIES ON AMINOBENZYLATED MANNICH BASES 
 
 Mannich bases containing bridged head N-atom exhibit pronounced biological 
activities. It play an important role as intermediate in synthesis of various organic 
compounds.Mannich base also exhibit complexation characteristics with many transition 
metal atoms. Hence, it is pertient to synthesize some novel mannich base with a hope that 
these compound may have biological activies. 
 
SECTION-I : Synthesis and biological screening of N,N-((Dialkyl/aryl amino)(thiophen-
   2-yl)methyl)acetamides  
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S
NH
CH3
O
N
R2
R1
 
Type (VIII) R1,R2 =Aryl 
 
 The preparation of mannich bases of type (IX) has been under taken by the 
undertaken by the condensation of acetamide with secondary amine and thiophene-2-
carbaldehyde. 
 
PART [C] : STUDIES ON IMIDAZO[1,2-α] PYRIDINES 
 
Heterocyclic compounds bearing imidazo[1,2-α]pyridine ring system are endowed 
with variety of biological activities. Our strategy is based on to develop new bioactive entities 
especially with pharmacological activities bearing heterocyclic ring system. Literature survey 
reveals that nitrogen containing heterocyclic compounds like imidazo[1,2-α]pyridines have 
received considerable attention in medicinal science due to their biological and 
pharmacological activities like anti-inflammatory, herbicidal, hypnotic, sedative, 
antimicrobial, antitubercular, CNS depressant, antithyroid and many other therapeutic 
activities. 
These valid observations prompted us to design and synthesize some            
heterocycles like chalcones, pyrazolines, cyanopyridines, mannich bases, pyrimidines, 
isoxazoles, imidazolinones etc., bearing imidazo[1,2-α]pyridine nucleus, which have been 
described as under. 
PART-I  : STUDIES ON PYRAZOLINES 
 
Among a wide variety of heterocycles that have been explored for developing 
biologically active molecules like pyrazolines have played important role in medicinal 
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chemistry. Pyrazolines have been found to posses bactericidal, fungicidal, antiviral and other 
pharmacological properties like anticonvulsant, antidepressant and anti-inflammatory. These 
valid observations led us to synthesize some new pyrazoline derivatives for better drug 
potential which have been described in following sections. 
 
SECTION-I  : Synthesis and biological screening of (2E)-3-(2-(4-fluorophenyl)-6- 
    methylH-imidazo[1,2-α]pyridin-3-yl)-1-arylprop-2-en-1-ones 
 
N
N
F
O
CH3
R  
Type (X) R= Aryl 
 
The chalcones of Type(X) have been synthesized by the condensation of 2-(4-Fluoro 
phenyl)imidazo[1,2-α]pyridin-3-carbaldehyde with different aryl ketones in the presence of 
40% NaOH. 
SECTION-II  : Synthesis and biological screening of 1-(5-(2-(4-fluorophenyl)-6- 
     methyl-H-imidazo[1,2-α]pyridin-3-yl)-4,5-dihydro-3-arylpyrazol-1- 
     yl)ethanones.                                             
 
N
N
F
N
N
O
CH3 R
CH3
 
Type (XI) R= Aryl 
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Pyrazoline derivatives of Type(XI) have been synthesized by the cyclocondensation 
of the chalcones of Type (X) with hydrazine hydrate in glacial acetic acid. 
 
PART-II  : STUDIES ON ARYLAMINOMETHYL DERIVATIVES 
 
 Arylaminomethyl derivatives represents one of the modest class of biological  active 
agents which have been deeply studies during search on new potential agents. These have 
been reported to be active as antimicrobial, antitubercular, anticancer, insecticidal etc. In 
view of these valid observations, it was contemplated to synthesis some new 
arylaminomethyl derivatives possessing higher biological activity which have been described 
as under. 
 
SECTION-I :Synthesis and biological screening of (17E)-N-((2-(4-fluorophenyl)-6- 
  methylH-imidazo[1,2-α]pyridin-3-yl]methylene)-4-arylamines. 
                              
N
N
F
N
R
CH3
                                   
Type (XII)  R= Aryl 
 
 The azomethines of Type (XII) have been prepared by the condensation of 2-(4-
Fluorophenyl)imidazo[1,2-α]pyridin-3-carbaldehyde with different aromatic amines. 
SECTION-II :Synthesis and biological screening of N-((2-(4-fluorophenyl)-6-methylH-
    imidazo[1,2-α]pyridin-3-yl)methyl)-4-arylamines. 
 
 
 10 
 
N
N
F
NH
R
CH3
 
 
Type (XIII) R= Aryl 
 
The compound of Type (XIII) have been synthesized by the reaction of arylamines of 
Type (XII) with an. NaBH4. 
The constitution of all the synthesized compounds have been characterized using 
elemental analysis, FT-IR and 
1
H NMR spectroscopy and further supported by mass 
spectroscopy. Purity of all the compounds have been checked by thin layer chromatography. 
All the compounds have been evaluated for their antibacterial activity towards Gram 
+ve and Gram -ve bacterial strains and antifungal activity towards Aspergillus niger at a 
concentration 2000/1000/500 µg/ml. The biological activities of the synthesized compounds 
have been compared with standard drugs. 
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INTRODUCTION 
 
 Research programs for the discovery of new drugs and for improving the evolution 
criteria are under way in many laboratories. In addition knowledge of specific constituents of the 
mycobacterium cell and their biochemical roles have advanced considerably in the recent years 
and may permit a more rational approach to the design of new drug action on specific targets. 
Also, recent improvements in the knowledge of the mechanism of action of available drugs and 
the biochemical mechanism of resistance to them may be used as a basis for design new and 
better weapons to fight the mycobacterium diseases. 
 The last few decades have witnessed massive advances in biochemistry, physiology, 
pharmacology and genetics. This has to a better understanding of working the body at the 
molecular level. This in turn has resulted a much better understanding of the structure and 
function of important drug targets e.g. enzymes and receptors and that how drugs can be 
designed for these targets. Advances in organic chemistry have made possible the synthesis of 
complexes molecules. Enantiometry is an important process in medicinal chemistry since life is 
inherently chiral and the drug targets within the body are chiral. As such, they can distinguish 
between the enantiomers of a chiral drug, so the use of recemic drug is inherently wasteful, since 
only one enantiomer is ideally designed to interact with its target. Moreover, the existences of 
the “wrong” enantiomer could create problems if it interacted with a different receptor, resulting 
inside effects.  
 A prerequisite for the design of safe drugs is knowledge about the various metabolic 
reactions that xenobiotics and endogenous compounds undergo in the organism. Because 
pharmacological activity depends on molecular structure, the medicinal chemist is restricted in 
the choice of functional groups for the design of new drugs. Often he finds or she encounters a 
situation where a structure has adequate pharmacologic activity but has an inadequate 
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pharmacokinetic profile (i.e., absorption, distribution, metabolism and excretion). This is because 
pharmacology and pharmacokinetic departments in the pharmaceutical industry often do not 
collaborate at the early stage of drug development. It is only later, when the new compound is 
tested in animals or in humans, that pharmacokinetic disadvantages become obvious. 
 Modern drug discovery starts with the identification of a pharmacologic target that is 
hypothetically the primary cause of disease. Potential targets include host cell genes, receptors, 
signaling systems, organelles and biochemical such as enzymes. Additionally, an element of a 
disease modifying process, such as anti-inflammatory mediator, may be a target. Biological 
processes required for propagation of infectious agents have also proven to be therapeutically 
useful targets; examples include protease and reverse transcriptase of the human immuno 
deficiency virus (HIV). Common to all targets selected as therapeutic opportunities is the 
hypothesis that some type of pathogenetic linkage exists to the disease causing process, rather 
than to specific signs, symptoms, or effects. 
 Heterocyclic compounds have great applicability in pharmaceutics because they have 
specific chemical reactivity and provides false synthons in biosynthetic process or block the 
normal functioning of biological receptors. The inhibition of amide resonance resulting into 
more susceptibility of ß-lactam to nucleophile is considered at least in part responsible for 
antibacterial property, apparently by acetylating transpeptidase and thus inhibiting bacterial cell 
wall biosynthesis.  
 Most of the alkaloids which are nitrogenous bases occurring in plants and many 
antibiotics including penicillin and streptomycin have also heterocyclic ring system. Many 
natural pigments such as indigo, hemoglobin and anthocyanin are heterocycles. Most of the 
sugars are their derivatives including Vitamin C for instance, exist largely in the form of five 
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membered. Vitamin B6 (Pyridoxine) is a derivative of pyrimidine essential in amino acid meta- 
bolism.  
 Important drugs, poisons and medicines (both natural and synthetic) such as 
sulphathiazole, pyrenthrin, rotenmone, alpidem, zolpidem, fluconazole, strychnine, reserpine, 
certain of the antihistamines, the ergot alkaloids caffeine, cocaine, barbiturates, etc. are 
heterocyclic compounds.  
 Research in the field of pharmaceutical has its most important task in the development of 
new and better drugs and their successful introduction into clinical practice. Central to these 
efforts, accordingly stand the search for pharmaceutical substances and preparation which are 
new and original. In addition to these objectives the searching for drug which exhibit a clear 
advantage over a drug already known. Such advantages may be qualitative or quantitative 
improvement in activity, the absence of undesirable side effect, a lower toxicity, improved 
stability or decreased cost. It is important at the outset to note that drug discovery is not an 
unambiguous term in the pharmaceutical Research and Development world. For example, it can 
be defined using either programmatic or organizational approaches (or both), with several 
options on each category. Hence, it is important first to understand this variability and to adopt a 
specific definition for the purpose of this discussion. 
 During the period of 1930-1950 there was an urgent need for new drug to treat disease 
which had a high mortality rate, there was only limited appreciation of the hazard such drugs 
might present, and toxicological studies before clinical trials were fairly rudimentary. Proving 
the proverb Necessity is the mother of invention, during the decade of 30 and 40s a large 
number of drugs introduced. Therefore this period is regarded as Golden Period of new drug 
discovery. 
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 The contribution of organic chemistry to be development of scientific medicine in the 19th 
century mainly from acyclic and carbocyclic compounds, although the pyrazoline antipyrin (1) 
was introduced as an antipyretic and analgesic in 1984 and the first barbiturate baritone (veranol) 
(2) in 1903. Guttmann treated, malaria with methylene blue in 1891, with slight success, and in 
1912 he introduced acriflavine as trypancide, it has proved to be more valuable as an antiseptic. 
Phenazopyridini (pyridium) (3) was introduced for the same purpose in 1926, and although it is 
relatively ineffective it has continued to be used since it has some analgesic action. 
N
N
CH3
Ph
O
N NH2
N
N
Ph
(1) (2) (3)
NHNH
O
O O
CH3 CH3
 
 
AIM AND OBJECTIVES 
 Taking in view of the applicability of heterocyclic compounds, we have undertaken the 
preparation of heterocycles bearing isopropylbenzoic acid, thiophene-2-carbaldehyde and 
imidazo[1,2-α]pyridine nucleus. The placements of a wide variety of substituents on these nuclei 
have been designed in order to evaluate the synthesized products for their pharmacological 
profile against selected strains of bacteria and fungi. During the course of our work, looking to 
the application of heterocyclic compounds, several entities have been designed, generated and 
characterized using spectral studies. The details are as under. 
[1] To generate several derivatives of Isopropyl benzoic acid and their fused derivatives such 
as Thiadiazoles, Thiadiazines, Oxadiazoles, Imidazolones. 
[2]  To generate Chalcones, Indazoles and Mannich base derivatives. 
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[3] To generate Acetyl pyrazoline and Arylaminomethyl derivatives like Schiff’s base and         
 it’s reduction. 
[4] To check purity of all synthesized compounds using thin layer chromatography. 
[5] To characterize these synthesized products for structure elucidation using various     
 spectroscopic techniques like IR, 
1
H NMR, mass spectral studies and C, H, N analysis. 
[6] To evaluate these new synthesized products for better drug potential against different     
strains of bacteria (Staphylococcus aureus, Bacillus substilis, Escherichia coli,   
Salmonella Paratyphi) and fungi (Aspergillus  niger, Candida albicans). 
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Studies on Isopropyl Benzoic Acid  
Derivatives 
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INTRODUCTION 
 
 Isopropyl benzoic acid (1) and their derivatives constitute an important class of 
organic compounds with diverse agricultural, industrial and biological activities. The 
synthesis of this moiety has received considerable attention in recent years. Isopropyl 
benzoic acid is also known as cumic acid or cuminic acid and cumin (2) has also known 
as  
CH3CH3
OOH
CH3CH3
(1) (2)  
 Triazoles are well known five membered heterocyclic compounds and several 
procedures for their synthesis have been extensively studied. Such studies 
have been stimulated by various promising applications, especially in the case of 
nitrogen containing heterocyclic entities. Triazoles have occupied an important 
place in the drug industry. In fact, certain nitrogen containing heterocycles are 
used as pharmaceuticals e.g. analgesic, anti-inflammatory, antipyretic, 
agrochemicals where as some other is being studied for their medicinal interest. 
The knowledge of such applications has pointed out that nitrogen containing 
heterocycles are important target to be prepared to our research on medicinally 
interesting chemical entities. 
 During our prior art studies we observed research carried on the triazoles of 
isopropyl benzoic acid.  We found that triazoles of isopropyl benzoic acid have not been 
synthesized yet. Thus taking into the consideration that probably the synthesized 
compounds may prove to be very potent analgesic, anticoagulant, anti-inflammatory, 
antipyretic agents. For the same purpose we carried out some microbial studies which 
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are showing some positive results.  
Triazoles are of two types 1,2,3-triazole (3) and 1,2,4-triazole (4). 
 
N
N
H
N
N
N
H
N
1,2,3-Triazole (3)
N
H
N
N N
N
H
N
N
H
N
N
1,2,4-Triazole (4)  
 
Hao Z
1 
and Staben Steven
2 
have been studied briefly with the chemistry of 
1,2,4- triazoles. Bladin
3,4 
is a pioneer scientist in the field of triazole, who had 
synthesized the first derivative of 1,2,4-triazole in 1885. 1,2,4-triazole derivatives not 
only known for their medicinal applications, but they are also used as analytical 
reagents
5
, dyes and photographic chemicals
6
 corrosion inhibitors
7,8 
and in the 
preparation of polymers
9
. 
SYNTHETIC ASPECT 
 
Several methods have been reported in the literature for the synthesis of 1,2,4- 
triazoles. The starting material for the synthesis of triazoles is thiosemicarbazide or 
dithiocarbamate derivatives having nitrogen containing functions. The procedures for 
synthesizing 1,2,4-triazoles have been described as under. 
1. Reid and heindel10 reported that the reaction of aryl acid hydrazide with CS2/ 
 KOH and hydrazine hydrate yields triazoles (5).  
R
O
NH NH2
CS2
KOH
R
O
NH
NH S
S
-
K
+
NH2NH2H2O
N
N N
NH2
CH3 CH3
(5)  
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2. K. S. Bhat et al.11 have synthesized 4-amino-3-(2,4-dichloro-5-fluorophenyl)
 1,2,4-triazol-5-thiol (6) with the help of thiocarbohydrazide and 2,4 dichloro-5
 fluoro benzoic acid. 
F
Cl
Cl
COOH +
NH2 NH
S
NH
NH2
N N
N
Cl
Cl
F
NH2
SH
(6)  
3. N. U. Guzeldemirci et al.12 have prepared 1,2,4 triazole (7) in the presence of
 NaOH  from aryl acid hydrazide.  
R NH
O
NH2
RNCS
NH
NH
NH
S
R
R
O
NaOH
N
N N
H
S
NH2
R
(7)  
4. C. S. Andotra and Sukhbinder Kaur13 synthesized triazole pyrimidine (8) by the 
 reaction of aromatic acid with substituted hydrazino pyrimidines. 
NN
R R1
NH
NH2
R2-COOH NN
NN
R R1
R2
(8)  
 
 
5. S. F. Barbuceanu et al.14 have reported 5-[4-(4-chlorophenylsulfonyl)phenyl]-4H-
 1,2,4-triazole-3-thioles (9) and It is prepared from 4-(4-chlorophenylsulfonyl)-
 benzoic acid hydrazides. 
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SO2
NH
O
NH2Cl
KSCN
H
+
SO2
NH
O
NHCl NH2
S
SO2
Cl
N
N
H
N
SH
(9)
HO
-
 
6. Sumesh eswaran et al.15 also synthesized 1,2,4 triazole (10) from 4-hydroxy-8- 
 (trifluoromethyl)quinoline-3- carbohydrazide. 
N
OH
NH
O
NH2
CF3
N
OH
NH
O
CF3
NH NH
S
R
1
N
OH
CF3
N
N
N
SH
R
1
(10)
 
 
7. Zhizhang Li16 prepared the sulphhydryl derivative (11) of 1,2,4-triazole by the
 reaction  of 4-amino-5-phenyl-2H-1,2,4-triazole-3(4H)-thione. 
NH
O
NH2
O NH
N
S
N NH
N
S
NH2
(11)  
8. L. Labanauskas et al.
17 
have prepared triazoles (12) by the addition reaction
 of thiosemicarbazide with substituted benzoyl chloride in the presence of
 pyridine. Then the substituted thiosemicarbazide cyclised in water in the
 presence of alkaline catalyst. 
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NH
NH
O
S
NHR
1 N
N
NH
SR1
Alkaline
Catalyst
R R
(12)  
9. Vikrant S. Palekar et al.18 have prepared 1,4-phenylenebis(4-amino-4H-1,2,4-
 triazole-3-thiol) (13) from bis-dithiocarbazinate in the presence of potassium 
 hydroxide, carbon disulphide and hydrazine hydrate. 
ONH
NH2
NH O
NH2
CS2/KOH
NH NH
NH
S
-
K
+
NHNH
NH
K
+
S
-
O
O
S
S
NH2NH2
N
N
N
N
N
N
NH2 NH2
SH SH
(13)  
BIOLOGICAL EVALUATION 
 
Triazoles are potential bioactive agents due to their wide spectrum of therapeutic 
importance. Drug molecules having 1,2,4-triazole nucleus with good activity are 
listed as under. 
N
N
N
N
Cl
1. Estazoalm
Receptor Agonist
N
N
N
NC CN
2. Letrozole
Antineoplastic
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3. Fluotrimazole
N
N
N
CF3
Fungicide
4. Rif av irin
O
N
N
N
OH
OH
OH
Antiv iral, Antiinf ection
5. Triazolam
N
N
N
N
CH3
Cl
Plant growth regulator
6. Triadimenol
N
N
N
O
CH3
CH3CH3
O Cl
Fungicide
O O
Cl
Cl
N
N
N
N
N
N
N
O
CH3
CH3
O
Cl
Cl
7. Azaconazole
Antif ungal
8. Rilmazaf one
Sedative,hypnotic
Sn
N
N
N
N
N
N
H
NH2
9. Azocyclotin
Pesticide
10. Amitrole
Antithy roid activ ity
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N
N
CH3
CH3
O
CH3
CH3
11. Ibudilast
Antiallergic
N
H
O
O CH3
CH3
CH3CH3
O
O
CH3
12. Isradipine
Antagonist  
 Literature survey reveals that various 1,2,4-triazole derivatives display 
significant biological  activities.  3-Amino-1,2,4-triazole  was  the  first  1,2,4-
triazole  to  be manufactured  on  large  scale  from  amino guanidine  format,  useful  
as  herbicides
19 
Therapeutic activity of 1,2,4-triazoles are as under. 
1.  Bactericidal
20
 
2.  Diuretic
21
 
3.  Fungicidal
22
 
4.  Herbicidal
23
 
5.  Insecticidal and acaricidal
24
 
6.  Plant growth regulator
25
 
7.  Anticancer and Anti-HIV
26
 
8.  Antileshmanial
27
 
9.  Antitumor
28,29
 
10. Antidepressant and anxiolytic
30 
11. Antimicrobial
31
 
12. Antiviral
32
 
13. Antiinflammatory
33
 
14. Antihypertensive
34
 
15.  Anticonvulsant
35 
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 B. Kahveci et a l .
3 6
h a v e  prepared 4-arylmethylideneamino-3-(R- benzyl) 
-4,5-dihydro-1H-1,2,4-triazol-5-ones via microwave assisted which exhibited 
remarkable anti fungal activity. Ram Janam Singh et al.
37 have synthesized 4-aryl-5-
(isomeric pyridoyl)-3H-1,2,4-triazoles as potent bacteriocidal agents which active 
against S. aureus, E. coli, B. subtilis and P. aeruginosa. Najim A. Al-Masoudi et al.
38  
have suggested 5-amino-4-phenyl-4H-1,2,4-triazole-3-thiol and their metal complexes 
which posses  vitro anti-HIV activity. E. De Clercq et al.
39 screened ribavarin (14) for 
their antiviral and antimetabolic activities. 
O
N
N
H
NOH
OH OH
CONH2
NHN
N
H
N
H
OEt
F
SO2
NH
Cl
Cl
(14) (15)  
 Hoong-Kun Fun et al.
40 
have investigated 4-Amino-3-(1-naphthyloxymethyl)-
1H-1,2,4-triazole-5(4H)-thione. B. Kahveci et al.
41 
have suggested 3-aryl-4-
arylmethylideneamino-4,5-dihydro-1H-1,2,4-triazol-5-ones derivatives useful as 
an antifungal agents. Mckendry and co-workers
42 have synthesized triazole 
derivatives (15) and reported them as broad spectrum broadleaf herbicides. H. A. 
Abdel-Aziz et al.
43 have synthesized some piperidine-based 1,3-thiazole, 1,3,4-
thiadiazole, and 1,3-thiazolo[2,3-c]-1,2,4-triazole derivatives which posses anti-
arrhythmic activity. B. F. Abdel-Wahab et al.
44 
have reported 1,2,4-triazoles useful for 
antimicrobial agent. 
R. P. Dickinson and co-workers
45 have prepared Voriconazole (16) and found 
highly active against Aspergillus fumigatus and a-(hetero-arylmethyl)-1H-1,2,4-triazole- 
1-ethanol derivatives ( 1 7 ) are active against Candida albicans and Cryptococous 
neofermans . 
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(16) (17)
NN
N
N
N
F
OH
CH3
F
F
NN
N
N
N
F
OH
CH3
F
F
 
Daniele Binchi et al.
46 
have screened pure stereoisomer of two new triazole 
derivatives (18,19) for their antifungal activity against variety of fungi showing an 
activity ratio R-form / S-form up to 400. 
Cl
Cl
OH
N
N
N
(18)
N
N
N
OCF2CHF2
Cl
Cl
(19)  
  
 M. A. Kaldrikyan et al.
47
 have discovered some benzofuryl-substituted 1,2,4-
triazoles and reported their antitumor activity. Dae-Kee Kim et al.
48 
have been 
synthesized 1,2,4-triazole derivatives (20) and screened for their significant ALKS 
inhibitory activity. K. J. Fisher et al.
49
 have synthesized 1,2,4-triazole derivatives 
(21) to study their pesticidal  and  herbicidal  activity. Xiang-Shu Cui et  al.
50 have 
formulated 3-substituted-4-(4-hexyloxyphenyl)-4H-1,2,4-triazoles as anticonvulsa- 
nt agent. Maarouf et al.
51 
have documented analgesic and anti-inflammatory activity 
of 1,2,4-triazole derivatives. 
N
N
N
N
R3
R2
R1
(20)
NH
SN
H
NN
H
Cl
Cl
O
F3C
Et
(21)  
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 Thus the important role displayed by triazole moiety for various therapeutic and 
medicinal activities prompted us to synthesize some new thiadiazoles, 
thiadiazines, thiadiazepines, aryl triazoles, sulphonamides, aryl amides and mannich 
bases bearing triazole moiety, in order to achieve compounds having better drug 
potential. This study is described in the following parts. 
 
PART-I : SYNTHESIS, CHARACTERIZATION AND   
   BIOLOGICAL SCREENING OF THIADIAZOLES. 
PART-II : SYNTHESIS, CHARACTERIZATION AND    
   BIOLOGICAL SCREENING OF THIADIAZINES. 
PART-III : SYNTHESIS, CHARACTERIZATION AND  
   BIOLOGICAL SCREENING OF OXADIAZOLES. 
PART-IV : SYNTHESIS, CHARACTERIZATION AND  
   BIOLOGICAL SCREENING OF IMIDAZOLONES. 
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REACTION SCHEME 
 
 
CH3
CH3 O
O CH3
Hydrazine Hydrate
MeOH
CH3
CH3 O
NH NH2
CS2/KOH
MeOH
CH3
CH3 O
NH NH
S
-
K
+
S
Hydrazine Hydrate
CH3
CH3
N
N
N
NH2
SH
 
 
 
 
CH3
CH3 O
OH
Con.H 2SO4
MeOH
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INTRODUCTION 
 Thiadiazole derivatives have played an important role in pharmaceutical  
industries and exhibited various biological activities due to the presence of –N=C–S  
group
1
. In thiadiazole ring system one sulphur and two nitrogen atoms are present in a 
five membered ring. According to their position, thiadiazole systems are classified as 
1,2,3-thiadiazoles (1), 1,2,4-thiadiazoles (2), 1,3,4-thiadiazoles (3), and 1,2,5-
thiadiazoles(4). 
S
N
N
S
N
N
S
N N
S
N N
(1) (2) (3) (4)  
 Among these four types of thiadiazole, 1, 3, 4-thiadiazole is well known. 1,3,4-
Thiadiazole is used to formulate finished greases, lubricating oils, gear, automatic 
transmission. It is used as an ash less copper corrosion inhibitor and extreme pressure 
(EP) agent.  
SYNTHETIC ASPECT 
 Literature survey reveals that several publications and patents
2
 described the 
synthesis of 1,3,4-thiadiazole as under 
1. Prakash Karegoudar et al.3 have prepared thiadiazole derivatives (5) by the 
cyclization of aromatic acid with triazole in presence of POCl3 
Cl
Cl Cl
N
N
N
N
S
Ar
Cl
Cl Cl
N
N
N
NH2
SH
ArCO2H
POCl 3
(5)
 
2. Li-xue Zhang et al.4 have synthesized 1,3,4-thiadiazoles (6) by the cyclization of 
 aromatic acid with triazole in presence of POCl3. 
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N
N
NO
NH2 SH
Ar-CH2COOH
POCl3
N
N
N
O
N S
Ar
(6)  
3. Jag Mohan et al.5 have prepared thiadiazole derivatives (7) by the cyclization of 
amino mercapto triazole and aryl aldehydes in presence of p-Ts-OH. 
R
N
N
N
NH2
Ar-CHO
P-Ts-OH
N
H
N
SN
H
N
R
R1
(7)  
4. Zhong-Yi et al.6 have been prepared thiadiazole derivatives (8) from amino 
mercapto triazole and aryl aldehydes in presence of L-(+)-tartaric acid. 
NN
N
NH2
SHR R-CHO
L- (t)- tartaric acid
N
NN
S
N
H
R
R
(8)  
5. Q. Bano and co-workers7 have been prepared 6-phenyl amino-1,3,4-thiadiazole 
(9) by reacting triazole with amino acid. 
N N
N
N
S
O
R
CH3
O
N
N
H
N
SH
 
6. Alaa Hassan et al.8 have prepared 1,3,4-thiadiazoles (10) by the cyclization of 
tetracyanoethene and 4-phenyl thiosemicarbazides.    
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R
NH NH
NH2
S
+
N
NN
N
S
N
N
CH3 N
N
(10)  
7. Khosrow Zamani et al.9 have prepared thiadiazoles (11) from the 
thiosemicarbazide by the cyclization in sulphuric acid. 
N
NH
O
NH
NH
S
CH3
Con.H 2SO4
N
N
S
N
NH
CH3
(11)  
BIOLOGICAL EVALUATION 
 Literature survey revealed that various thiadiazoles have resulted in many 
potential drugs and are known to exhibit a broad spectrum of pharmacological properties. 
The specific pharmacological activities associated are as under. 
1.  Antitumor
10
 
2.  Antiviral
11
 
3.  Antibacterial
12
 
4.  Amoebicidal
13
 
5. Antiinflammatory
14
 
6.  Antitubercular
15
 
7.  Antipyretic
16
 
8.  Anticancer
17
 
9.  CNS depressant
18
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10.  Antischistosomal
19
 
11.  Herbicidal
20
 
12.  Insecticidal
21
 
13.  Pesticidal
22
 
14.  Hypoglycemic
23
 
 Vergne Fabrice et al.
24
 have synthesized 1,3,4-thiadiazole derivatives (12) and 
screened for their anti-inflammatory, anticancer and anti-HIV activity. Laddi U.V. et al.
25
 
have discovered thiadiazoles possessing antimicrobial and antituberculosis activity. D.A. 
Ibrahim
26
 has reported thiadiazoles as anti-tumor agents. Mohd. Amir et al.
27
 have 
investigated 1,3,4-thiadiazoles and tested for analgesic activity. Vinod Mathew et al.
28
 
have prepared thiadiazole derivatives showed antifungal and antibacterial activity. 
N
S
N
N
CH3
SO2
Cl
NH2
(12)  
 Celine Chazalete et al.
29
 have synthesized acetazolamide (13) possessing 
diuretics and antiglaucoma activity. V S. Palekar et al.
30
 have synthesized 1,3,4-
thiadiazole derivatives and screened for their anti-inflammatory, antibacterial activity. 
C. X. Tan et al.
31
 have investigated 1,3,4-thiadiazoles and tested for electrochemical 
properties. Bernard Masercel et al.
32 
have synthesized 1,3,4-thiadiazoles 
possessing potent carbonic anhydrase inhibitor properties and also prepared 5-valproyl 
amino 1,3,4-thiadiazole-2- sulphonamide (14)  as strong anticonvulsant. 
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S
NN
SO2NH2
NH
O
CH3
CH3
S
NN
MeHNOC SO2NH2
(13) (14)  
  
  
T M. Abdel-Rahman
33
 has prepared 1,3,4-thiadiazole derivatives and possessing 
anticancer activity. A. M. Taha
34 
synthesized thiadiazoles containing anti-microbial 
activity. J. M. Colacino et al.
35 
have documented anti-influenza virus act ivity of 
thiadiazoles. L. M. Thomasco et al.
36
 have prepared 1,3,4-thiadiazole (15) 
possessing potent antibacterial activity against Gram positive and Gram negative 
organisms. S. A. Carvalho and co-workers
37 have documented antitrypanosomal profile 
of 1,3,4-thiadiazole derivatives (16). Zahra Kiani et al.
38 
have discovered 
thiadiazoles as antituberculosis agent. 
 
S
N
N
R
F
N
O
O
NH
O
CH3
(15)
N
S
N
N
N
NH
N
OH
OH
CH3N
+O
-
O
(16)
 
 
 Alireza faroumadi et al.
39 have synthesized 1,3,4-thiadiazoles (17) and studied 
their leishmanicidal activity. Hatice Dogan et al.
40 have prepared 2,5-disubstituted-
1,3,4-thiadiazolo derivatives as anticonvulsant and antimicrobial agent. Nalan Terzioglv 
and Aysel Gursoy
41 have discovered thiadiazoles and studied their anticancer activity. 
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Alireza Foroumadi and co-workers
42 have documented antituberculosis activity and 
cytotoxicity of 1,3,4-thiadiazoles. 
N
S
N
X
N
Y
N
+
O
-
O
X = O,S 
Y = CH2, O, NR
(17)  
 S. Karakus and S. Rollas
43 
have screened thiadiazoles for their 
antituberculosis activity. Jui-Yi Chou et al.
44 
have synthesized thiadiazoles and reported 
them as anticancer agents. 
 
Work done from our laboratory  
 K. M. Thaker
45
 have
 
synthesized 2-(3',5'-dichlorobenzo[b]thiophen-2'-yl)-5-
arylamino-1,3,4-thiadiazoles from triazole. S. L. Vasoya
46
 have synthesized some new 
thiosemicarbazide and 1,3,4-thiadiazole  heterocycles bearing the benzo[b]thiophene 
nucleus as potent antitubercular and antimicrobial agents.  
 In light of wide varities of therapeutic activities exhibited by thiadiazole, we have 
embarked upon the synthesis of some new thiadiazole derivatives which have been 
described in following sections. 
SECTION-I:   SYNTHESIS AND BIOLOGICAL SCREEINING OF 6-              
    ARYL-3-(4-ISOPROPYLPHENYL)-[1,2,4]TRIAZOLO[3,4-b]   
    [1,3,4] THIADIAZOLES. 
SECTION-II: SYNTHESIS AND BIOLOGICAL SCREENING OF 5,6-  
      DIHYDRO-6-ARYL-3-(4-ISOPROPYLPHENYL)-   
      [1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZOLES 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL SCREENING OF 6-ARYL-3-(4-ISOPROPYL- 
PHENYL)-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZOLES. 
 Thiadiazole derivatives are associated with broad spectrum of biological 
activities. In view of these finding it appeared of interest to synthesize some newer 
thiadiazole derivatives, with better potency. Thiadiazoles of type (I) have been 
prepared by cyclocondensation of 1-amino-3-[4-(propan-2-yl) phenyl]-1H-1,2,4-
triazole-5-thiol with different aromatic acids in the presence of POCl 3 as shown in 
reaction scheme.    
CH3
CH3
N
N
N
N
S
R
CH3
CH3
N
N
N
SH
NH2
R-COOH
POCl
3
Type (I) R=Aryl  
 The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further 
supported by mass spectrometry. Purity of all the compounds have been checked 
by thin layer chromatography. 
 All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger, Candida albicans at a 
concentration of 2000/1000/500 µg/ml. The biological activities of the synthesized 
compounds have been compared with standard drugs. Some compounds have been 
found to have moderate activity as compared to known antibiotics recorded on Table 
No.1b. 
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ANTIMICROBIAL ACTIVITY 
 
Method   : Mueller Hinton Agar Medium Method
51
 
 
Gram Positive Cocci   : Staphylococcus aureus  
Gram positive Rods   : Bacillus subtilis   
Gram Negative Rods  : Escherichia coli, Salmonella Paratyphi  
Multicellular Fungi  : Aspergillus niger 
Unicellular Fungi  : Candida albicans 
 
Concentration   : 2000 μg / ml, 1000 μg / ml, 500 μg /ml 
 
Solvent   : DMSO 
 
Standard drugs  : Ciprofloxacin 
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IR SPECTRAL STUDIES OF 6-(4-CHLOROPHENYL)-3-(4-ISOPRO 
PYLPHENYL)- [1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZOLE 
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Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr 
pallet method) 
Type Vibration Mode 
Frequency in cm
-1
 
Ref. 
Observed Reported 
Alkane 
C-H str. 
(asym.) 
2958 2975-2950 47 
C-H str. 
(sym.) 
2889 2880-2860 49 
C-H def. 
(asym.) 
1460 1470-1435 47 
C-H def. 
(sym.) 
1344 1385-1370 50 
Aromatic 
C-H str. 3055 3080-3030 47 
C=C str. 1518 1585-1480 47 
C-H i.p. (def) 1066 1145-1090 50 
C-H def. (sym.) 1014 1070-1000 50 
Isopropyl -CH(CH3)2 2889 2800-2900 48 
Triazole 
C=N str. 1593 1612-1593 47 
C-N str. 1344 1380-1310 48 
C-N-C str. 1170 1146-1132 47 
N-N str. 1014 1050-1010 49 
Thiadiazole C-S-C str. 698 720-570 47 
Halide C-Cl str. 769 800-600 49 
CH3
CH3
N
N
N
N
S
Cl
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NMR SPECTRAL STUDIES OF 6-(4-CHLOROPHENYL)-3-(4-ISOPRO- 
PYLPHENYL)-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZOLE 
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (400MHz) 
Sr. 
No. 
Chemical shift 
in ppm 
Relative No. 
of proton 
Multiplicity Inference J value in Hz 
1 1.26-1.28 6H doublet -CH3 6.88 
2 2.96-3.00 1H multiplet -CH - 
3 7.31-7.34 2H doublet -Ar-Ha-a' 8.2 
4 7.36-7.38 2H doublet -Ar-Hb, b' 8.4 
5 7.72-7.74 2H doublet -Ar-Hc,c' 8.28 
6 7.85-7.87 2H doublet -Ar-Hd,d' 8.24 
CH3
CH3
N
N
N
N
S
Cl
a b
a' b'
c
d
c'
d'
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Expanded aromatic region of NMR spectra 
 
MASS SPECTRAL STUDIES OF 6-(4-CHLOROPHENYL)-3-(4-ISOPRO 
PYLPHENYL)-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZOLE 
CH3
CH3
N
N
N
N
S
Cl
m/z = 354
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PROPOSED MASS FRAGMENTATION OF  6-(4-CHLOROPHENYL)-3-(4-
ISOPROPYLPHENYL)-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZOLE
CH3
CH3
N
N
N
N
S
Cl
m/z = 354
C18H15ClN4S
CH3
CH3
N
N
N
N
S
Cl
m/z = 310 (M
-1
)
C17H18N4S
CH3
CH3
N
N
N
N
S
CH3
CH2
m/z = 284
C15H16N4S
CH3
CH3
N
N
N
N
S
CH2
m/z = 270 (M
-2
)
C14H14N4S
CH3
N
N
N
N
S
Cl
C10H7ClN4S
m/z = 250 (M
-2
)
+ +
+
+
CH3 N
N
N
N
S
Cl
m/z = 340 
C17H13ClN4S
N
N
N
N
S
+
m/z = 202
C9H6N4S
CH3 N
N
N
N
S
C17H14N4S
m/z = 306
+
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary 
bath on controlled temperature heating mental. The crystallization of all the compounds 
was carried out in appropriate solvents. TLC was carried out on silica coated aluminum 
sheet (Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
[A]  Preparation of Po tas s ium 4-isopropylbenzyl dithiocarbamate. 
 To   a   mixture   of   potassium   hydroxide   (8.40g, 0.15mol)   and 4-
isopropyl benzohydrazide (17.8g, 0.1mol) in methanol (25 ml), carbon disulphide 
(11.4g, 0.15mol) was added. This mixture was stirred for 12-14 hrs. It was then 
diluted with dry ether (200 ml) and thus the solid obtained was filtered and washed 
with ether and dried. There is no need to purify the salt for further reaction. 
[B] Preparation of 1-Amino-3-[4-(propan-2-yl)phenyl]-1H-1,2,4-triazole-5-thiol. 
 A suspension of the potassium salt (29.2g, 0.1mol), hydrazine hydrate (10 ml, 
0.2mol) and water (2 ml) was refluxed with stirring for 3 hrs. The color of the reaction 
mixture changed to green, hydrogen sulfide was evolved (lead acetate paper and odor) 
and a homogeneous solution resulted. Dilute the solution with cold water (100 ml) and 
neutralized with glacial acetic acid, precipitated a white solid. The product was 
filtered, washed with cold water and crystallized from dioxane yield 60%, m.p.      
190 °C. 
[C] Preparation of 6 -(4-Chlorophenyl) -3-(4-isopropylphenyl)-[1,2,4] triazolo 
[3,4-b][1,3,4]thiadiazole. 
 A mixture of p-chloro benzoic acid (1.56g, 0.01mol) and 1-amino-3-[4-
(propan-2-yl)phenyl]-1H-1,2,4-triazole-5-thiol (2.34g, 0.01mol) in POCl
3 
(25 ml) 
was refluxed for 10 hrs. The reaction mixture was poured onto crushed ice and 
thus solid separated out was filtered, washed with water and crystallized from 
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methanol. Yield 64%, m.p. 210 °C Anal.Calcd. For C18H15ClN4S; C, 60.92; H,4.26; 
N,15.79 %; Found: C,61.33; H,4.39; N,15.93 % 
 Similarly other thiadiazoles were prepared and the physical constants are 
recorded in Table No.1a. 
[D] Antimicrobial activity of 6-Aryl-3-(4-isopropylphenyl)-[1,2,4]triazolo[3,4-
b][1,3,4]thiadiazoles. 
 All the compounds have been evaluated for antimicrobial activity as described 
under. 
 Preparation of Agar dilution plates  
(1) Appropriate dilutions i.e. 1 ml quantity of antimicrobial solution are added to 
mueller hinton agar (19 ml quantity) that have been allowed to equilibrate in a 
water bath to 45 to 50 °C. One part of antimicrobial solution is added to nine 
parts of liquid agar.  
(2) The agar and antimicrobial solution were mixed thoroughly and the mixture 
was poured into borosil glass petri dishes having 9 cm diameter on a level 
surface to result in an agar depth of 3 to 4 mm.  
(3) The plates should be poured as quickly after mixing as possible to prevent 
cooling and partial solidification in the mixing container, avoiding bubbles.  
(4) The agar was allowed to solidify at room temperature, and the plates were 
either used immediately or stored in sealed plastic bags at 2 to 8 °C for up to 
five days for reference work, or longer for routine tests.  
(5) Plates stored at 2-8 °C were allowed to equilibrate at room temperature before 
use, assuring that the agar surface was dry before inoculating the plates. If 
necessary, plates were placed in an incubator or laminar flow hood for 
approximately 30 minutes with their lids. It helps agar to hasten drying of the 
agar surface.  
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 Preparation of solutions of antimicrobial agents to be incorporated into 
 the agar based medium:  
 10 mg of the antimicrobial agent was dissolved in 5 ml of DMSO to prepare 
the main stock of the compound to be tested. 1 ml of this main stock was added to 19 
ml of mueller hinton agar medium to take the final concentration of 500 μg / ml in the 
agar medium. The main stock solution was further diluted in demineralized water by 
two fold dilution procedure to obtain the desired concentration in the agar medium, 
i.e. 2000 μg /ml, 1000 μg / ml, 500 μg/ml.  
 Preparation of inoculum of the test cultures: 
 One loopful of culture from the slant was inoculated into 5 ml mueller hinton 
broth in a test tube. The tube was incubated at 32 °C for 4 to 6 hours till the 
absorbance at 625 nm, equals that of 0.5 mac farland standards. (Section 5, NCCL 
guidelines). The absorbance readings were taken against a sterile mueller hinton broth 
media blank. The density of the suspension was adjusted to 10
8
 colony forming units 
(CFU) per milliliter by comparing its turbidity to a mac farland 0.5 BaSO4 standard.  
 Preparation of 0.5 Mac Farland standard:  
 It was used as a reference for turbidity measurement for bacterial cultures 
before they were used as inoculum for spot inoculate the mueller hinton agar media 
containing antimicrobial agents. Briefly, 0.5 ml of 1.175% w/v BaCl2 solution was 
added to 99.5 ml of 1 % v/v H2SO4 solution with constant stirring, the absorbance of 
the solution was measured 625nm against demineralized water blank by UV 
spectrophotometer. The absorbance was in the range of 0.08 to 0.1 optical densities.  
 Interpretation of Results:  
(1) In case of positive control, plate due to complete absence of antimicrobial 
agent and its solvent bacterial / fungal cultures gave luxuriant growth.  
(2) In the solvent control plate inhibition of growth of microbes due to presence of 
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organic solvent DMSO.  
(3) The microbial cultures, if shown 1-5 colonies per spot inoculated instead of 
confluent growth as in the control plate, it was considered to be inhibited by 
test antimicrobial compounds.  
(4) The microorganisms that were sensitive to the concentration of antimicrobial 
in mueller hinton agar plate did not produce a circle of growth at the inoculum 
site.  
(5) The microbes that were resistant to it appeared as circular colonies. The agar 
plates were marked with a grid so that each microorganism could be identified 
by a number.  
 Antibacterial Activity Determination:  
  Organic compounds may be bacteriostatic or bacteriocidal for microbial 
cultures. To check this, from the mueller hinton agar plates (showing no visible 
growth of bacteria), sub culturing was carried out on nutrient agar plates (Collins, 
1967). After streaking, nutrient agar plates were incubated for 24 hrs at 37°C. Then 
after observation was made to see the colonies formed. If  colonies were found, the 
dilution was considered as bacteriostatic and if no colonies observed, it was 
considered as bactericidal. Bacteriocidal dilutions of the organic compounds were 
considered as exact minimum inhibitory concentration (MIC) for a particular organic 
compound. 
 Antifungal Activity Determination:  
 For fungal cultures the fungal media yeast nitrogen base agar plate (YNBG) 
6.7 g and glucose 10 g, dissolved in 100 ml of distilled water and filter sterilized was 
used. The inoculum was prepared from 3-4 days old sabouraud’s dextrose agar slants. 
The growth was uniformly mixed with distilled water. The Size of inoculum prepared 
for inoculating YNBG agar plates was 10
2–103 cfu/ml, adjusted with mac farland 
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solution. After inoculation of properly diluted fungal solution, the plates were 
incubated at 37 °C for 48 hrs.  
 Antimicrobial testing were carried out as described in part - I, Section - I (D). The 
zones of inhibition of test solutions are recorded in Table No. 1b. 
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Table-1a: Physical constants of 6-Aryl-3-(4-isopropylphenyl)-[1,2,4]triazole [3,4-
  b][1,3,4]thiadiazoles. 
CH3
CH3
N
N
N
N
S
R
 
 
 
 
 
 
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd./Found 
C H N 
1a 4-OCH3-C6H4- 
C19H18N4OS 
350.43 
250 68 
65.12 
(65.02) 
5.18 
(5.08) 
15.99 
(15.86) 
1b 2,4-(OH)2-C6H3- 
C18H16N4O2S 
352.41 
195 62 
61.35 
(61.12) 
4.58 
(4.22) 
15.90 
(15.84) 
1c 2-CH3-C6H4- 
C19H18N4S 
334.43 
180 56 
68.23 
(68.01) 
5.42 
(5.21) 
16.75 
(16.44) 
1d 3-OC6H5-C6H4- 
C24H20N4OS 
412.50 
190 62 
69.88 
(69.34) 
4.89 
(4.87) 
13.58 
(13.33) 
1e 4-Br-C6H4- 
C18H15BrN4S 
399.30 
230 65 
54.14 
(54.02) 
3.79 
(3.61) 
14.03 
(13.85) 
1f 4-Cl-C6H4- 
C18H15ClN4S 
354.85 
245 54 
60.92 
(60.86) 
4.26 
(4.08) 
15.79 
(15.66) 
1g 4-NO2-C6H4- 
C18H15N5O2S 
365.40 
240 45 
59.16 
(59.09) 
4.14 
(4.10) 
19.17 
(19.06) 
1h 3-NO2-C6H4- 
C18H15N5O2S 
365.40 
210 53 
59.16 
(59.01) 
4.14 
(4.03) 
19.17 
(19.01) 
1i 2-OH-C6H4- 
C18H16N4OS 
336.41 
190 59 
64.26 
(64.08) 
4.79 
(4.20) 
16.65 
(16.08) 
1j 2-Cl-C6H4- 
C18H15ClN4S 
354.85 
165 65 
60.92 
(61.35) 
4.26 
(4.09) 
15.79 
(15.30) 
TABLE 1A: ANTIMICROBIAL ACTIVITY OF 6-ARYL-3-(4- ISOPROPYLPHENYL)-[1,2,4] TRIAZOLO [3,4-b] [1,3,4] 
THIADIAZOLES.(in µg/ml) 
 
Where (+)  =  New synthesized compounds were active against microorganism 
      (-)  =  New synthesized compounds were inactive against microorganism 
No. Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus aureus Bacillus subtilis Escherichia coli Salmonella paratyphi B Aspergillus niger Candida albicans 
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500
1. 1a + + - + + + + + - + + - + + + + + - 
2. 1b + + - + + + - - - + + - + + + - - - 
3. 1c + + + + + + + + + + + + + + - + + - 
4. 1d + + - + + - + + - + + - + + - + + - 
5. 1e - - - + + - + + - + + - - - - - - - 
6. 1f - - - + + - + + - + + - - - - - - - 
7. 1g + + - + + + - - - + + - + + + - - - 
8. 1h + + + + + + + + + + + + + + - + + - 
9. 1i + + + + + + + + + + + - + + - - - - 
10. 1j + + - + + + - - - - - - + + - + + - 
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SECTION-II 
SYNTHESIS AND BIOLOGICAL SCREENING OF 5,6-DIHYDRO-6-ARYL-3-
(4-ISOPROPYLPHENYL)-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZOLES 
 Thiadiazole derivatives are endowed with variety of biological activities. Looking 
to the interesting properties of thiadiazoles, it was considered worthwhile to synthesize a 
series of 5,6-dihydro-6-aryl-3-(4-isopropylphenyl)-[1,2,4]triazoles[3,4-b][1,3,4] thiadi- 
azoles of type (II) for obtaining biologically potent agents. Thiadiazoles of type (II) have 
been synthesized by cyclocondensation of 1-amino-3-[4-(propan-2-yl)phenyl]-1H-
1,2,4-triazole-5-thiol with different aromatic aldehydes in presence of p-TsOH (p-
toluene sulphonic acid) as a catalyst, as shown under. 
CH3
CH3
N
N
N
NH
S
R
CH3
CH3
N
N
N
SH
NH2
p-Ts-OH
Type (II) R=Aryl
R-CHO
 
 The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and further 
supported by mass spectrometry. Purity of all the compounds have been checked 
by thin layer chromatography. 
 All the compounds have been screened for their in  vitro  biological assay 
like antibacterial activity towards Gram positive and Gram negative bacterial 
strains and antifungal activity towards  Aspergillus  niger, Candida albicans at a 
concentration of 2000/1000/500 µg/ml. The biological activity of the synthesized 
compounds has been compared with standard drugs. Some compounds have been 
found to have moderate activity as compared to known antibiotics recorded on 
Table No.2b. 
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IR SPECTRUM OF 5,6-DIHYDRO-3-(4-ISOPROPYLPHENYL)-6-(4-NITRO- 
PHENYL)-[1,2,4]TRIZOLO[3,4-b][1,3,4]THIADIAZOLE 
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Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr 
pallet method) 
Type Vibration Mode 
Frequency in cm
-1
 
Ref. 
Observed Reported 
Alkane 
C-H str. 
(asym.) 
2962 2975-2950 47 
C-H str. 
(sym.) 
2887 2880-2860 49 
C-H def. 
(asym.) 
1458 1470-1435 47 
C-H def. 
(sym.) 
1344 1385-1370 50 
Aromatic 
   C-H str. 3059 3080-3030 47 
    C=C str. 1525 1585-1480 47 
C-H i.p. (def) 1068 1145-1090 50 
C-H def. (sym.) 1014 1070-1000 50 
Isopropyl    -CH(CH3)2 2887 2800-2900 48 
Triazole 
C=N str. 1595 1612-1593 47 
C-N str. 1344 1380-1310 48 
    C-N-C str. 1174 1176-1132 47 
N-N str. 1014 1050-1010 49 
Thiadiazole    C-S-C str. 682 720-570 47 
Nitro N=O str 1525 1560-1515 49 
 
CH3
CH3
N
N
N
NH
S
N
+
O
-
O
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NMR SPECTRAL STUDIES OF 5,6-DIHYDRO-3-(4-ISOPROPYLPHEN 
YL)-6-(4-NITROPHENYL)-[1,2,4]TRIZOLO[3,4-b][1,3,4]THIADIAZOLE  
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (400MHz) 
Sr. 
No. 
Chemical shift in 
ppm 
Relative No. of 
proton 
Multiplicity Inference J value in 
Hz 1.  1.26-1.33 6H doublet -CH3 - 
2.  2.18 1H singlet -CH  
3.  2.93-3.03 1H multiplet -CH - 
4.  7.29-7.39 2H multiplet -Ar-Ha-a' - 
5.  7.76-7.90 2H multiplet -Ar-Hb,b' - 
6.  7.95-8.05 2H multiplet -Ar-Hc,c' - 
7.  8.32-8.35 2H multiplet -Ar-Hd,d' - 
8.  8.71 1H singlet -NH - 
 
 
 
 
 
 
 
CH3
CH3
N
N
N
NH
S
N
+
O
-
O
a b
a' b'
c
d
c'
d'
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Expanded region of Aromatic region 
 
MASS SPECTRAL STUDIES OF 5,6-DIHYDRO-3-(4-ISOPROPYLPHENYL)-
6-(4-NITROPHENYL)-[1,2,4]TRIZOLO[3,4- b][1,3,4]THIADIAZOLE 
 
 
 
CH3
CH3
N
N
N
NH
S
N
+
O
-
Om/z = 367
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PROPOSED MASS FRAGMENTATION OF 5,6-DIHYDRO -3-(4-ISOPRO- 
PYLPHENYL)-6-(4-NITROPHENYL)-[1,2,4]TRIZOLO[3,4-b][1,3,4]THIADI- 
AZOLE. 
CH3
CH3
N
N
N
NH
S
N
+
O
-
O
m/z = 367
C18H17N5O2S
CH3
CH3
N
N
N
NH2
SH
m/z = 234
C11H14N4S
CH3
CH3
N
N
N
NH
S
N O
m/z = 351(M
-1
)
C18H17N5OS
CH3
N
N
H
N
SH
CH3
m/z = 219
C11H13N3S
N
N
N
CH3
CH3
NH2
m/z = 202(M
+2
)
C11H14N4
N
N
H
N
CH3
CH3
m/z = 187(M
+1
)
C11H13N3
N
N
H
N
CH3
CH3
m/z = 177
C10H15N3
CH3
CH3
m/z = 120
C9H12
CH3
CH3
N
N
N
NH
S
NH2
m/z = 337(M
-2
)
C18H19N5S
CH3
CH3
N
N
N
NH
S
N
+
O
-
O
m/z = 322(M
-2
)
C18H18N4S
+
+
+
+
+
+
+
+
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary bath 
on controlled temperature heating mental. The crystallization of all the compounds was 
carried out in appropriate solvents. TLC was carried out on silica coated aluminum sheet 
(Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
[A] Preparation of Po tass ium 4-isopropylbenzyl dithiocarbamate 
 See Part-I, Section-I [A] 
[B] Preparation of 1-Amino-3-[4-(propan-2-yl)phenyl]-1H-1,2,4-triazole-5-thiol. 
 See Part-I, Section-I [B] 
[C] Preparation of 5,6-Dihydro-3-(4-isopropylphenyl)-6(4-Nitrophenyl)-[1,2,4] 
triazole [3,4-b][1,3,4]thiadiazole  
 A mixture of 1-amino-3-[4-(propan-2-yl)phenyl]-1H-1,2,4-triazole-5-thiol 
(2.34g, 0.01mol), p-nitrobenzaldehyde (1.65g, 0.01mol) and p-Ts-OH (50 mg) in dry 
DMF (50 ml) was refluxed with stirring for 10 hrs. The reaction mixture was poured on 
to crushed ice and thus solid separated was filtered, washed with water and 
crystallized from methanol yield 60%, m.p. 265 °C Anal. Calcd. For C18H17N5O2S; C, 
58.84; H,4.66; N,19.06 %; Found: C,58.53; H,4.93; N,19.32 %. 
 Similarly other aromatic aldehyde has been condensed. The physical constants 
are recorded in Table No. 2a. 
[D] Antimicrobial activity of 5,6-Dihydro-6-aryl-3-(4-isopropylphenyl)-[1,2,4] 
triazole [3,4-b][1,3,4]thiadiazoles.  
 Antimicrobial testing was carried out as described in Part-(I), Section-I (D). 
The zones of inhibition of the test solution are recorded in Table No. 2b. 
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Table-2a: Physical constants of 5,6-Dihydro-6-aryl-3-(4-isopropylphenyl)-[1,2,4]  
  triazole [3,4-b][1,3,4]thiadiazoles  
 
CH3
CH3
N
N
N
NH
S
R
 
  
  
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd./Found 
C H N 
2a 4-OCH3-C6H4- 
C19H20N4OS 
352.45 
231 58 
64.75 
(65.19) 
5.72 
(5.36) 
15.90 
(16.26) 
2b 3,4-(OCH3)2-C6H3- 
C20H22N4O2S 
382.47 
196 54 
62.80 
(62.16) 
5.80 
(5.46) 
14.65 
(14.32) 
2c 4-NO2-C6H4- 
C18H17N5O2S 
367.42 
180 60 
58.84 
(58.79) 
4.66 
(4.23) 
19.06 
(18.85) 
2d 2-NO2-C6H4- 
C18H17N5O2S 
367.42 
185 61 
58.84 
(58.53) 
4.66 
(4.17) 
19.06 
(19.02) 
2e 4-OH-C6H4- 
C18H18N4OS 
338.42 
221 64 
63.88 
(63.75) 
5.36 
(5.09) 
16.56 
(16.03) 
2f C6H5- 
C18H18N4S 
322.42 
195 53 
67.05 
(66.94) 
5.63 
(5.34) 
17.38 
(17.09) 
2g 3-Cl-C6H4- 
C18H17ClN4S 
356.87 
180 49 
60.58 
(60.36) 
4.80 
(4.68) 
15.70 
(15.43) 
2h 4-CH3-C6H4- 
C19H20N4S 
336.45 
154 45 
67.83 
(67.64) 
5.99 
(5.45) 
16.65 
(16.41) 
2i 4-F-C6H4- 
C18H17FN4S 
340.41 
184 58 
63.51 
(63.27) 
5.03 
(4.82) 
16.46 
(16.29) 
2j 2-OH-C6H4- 
C18H18N4OS 
338.42 
193 45 
63.88 
(63.68) 
5.36 
(5.11) 
16.56 
(16.23) 
 
TABLE 2A:  ANTIMICROBIAL ACTIVITY OF 5,6-DIHYDRO-6-ARYL-3-(4-ISOPROPYLPHENYL)-[1,2,4]  
           TRIAZOLO[3,4-b][1,3,4]THIADIAZOLES.(in µg/ml)  
No. Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus aureus Bacillus subtilis Escherichia coli Salmonella paratyphi B Aspergillus niger Candida albicans 
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500
1. 2a + + - + + + + + - + + - + + + + + - 
2. 2b + + - + + + - - - + + - + + + - - - 
3. 2c + + + + + + + + + + + + + + - + + - 
4. 2d + + - + + - + + - + + - + + - + + - 
5. 2e - - - + + - + + - + + - - - - - - - 
6. 2f + + - + + + - - - - - - + + - + + - 
7. 2g + + + + + + - - - - - - - - - - - - 
8. 2h + + + + + + - - - - - - + + - + + - 
9. 2i + + - + + + + + - + + - + + + + + - 
10. 2j + + - + + + - - - + + - + + + - - - 
  Where (+)  =  New synthesized compounds were active against microorganism 
               (-)  =  New synthesized compounds were inactive against microorganism 
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INTRODUCTION 
 Thiadiazine is a six membered heterocyclic ring system having two 
nitrogen atoms and one sulphur atom. These may be of four types 2H-1,2,4-
Thiadiazine (1), 2H-1,2,6-Thiadiazine (2), 2H-1,3,4-Thiadiazine (3) and 2H-1,3,5-
Thiadiazine (4).  
NH
S
N
NH
S
N
N
S
N
N
S
N
(1) (2) (3) (4)  
 The literature survey reveals that there are not many examples of triazoles fused 
with thiadiazines. Those incorporating the N-C-S linkage as in the skeleton of 1,2,4-
triazolo[3,4-b][1,3,4]thiadiazine exhibit a broad spectrum of antimicrobial activity.
1-3  
Many 1,3,4-thiadiazine derivatives involve in many biological processes and serves as a 
medicinally interesting compounds. 
SYNTHETIC ASPECT 
 Different methods for the preparation of 1,3,4-thidiazine derivatives 
described in literature are as follows. 
1. M. M. Heravi et al.4 have reported that the cyclization of 4-amino-3-mercapto 
6-methyl-[1,2,4]triazine-5-one with phenacyl bromide to give 1,3,4-thiadiazine 
derivatives (5). 
 
 
 
 
2. K. S. Bhat et al.
5
 have designed thiadiazine ring system (6) by the reaction of 
triazole with phenacyl bromide. 
N
N
N
NH2
SH
CH3
O
+ PhCOCH2Br
N
N
N
N
S
Ph
O
CH3
(5)
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N
N
N
SH
Cl
Cl
F
NH2
+ PhCOCH2Br
(6)
N
N
N
S
N
R
F
Cl Cl
R=Ph,4-Br-C6H4
80-90'C,6h
CH3CO2Na
 
  
3. B. Shivarama Holla et al.
6 have synthesized triazole thiadiazines (7) by the 
cyclization of 2,3-dibromo-1-aryl-3-[5-(p-nitrophenyl)-2-furyl]-2-propen-1-
ones and substituted 1,2,4-triazole. 
O
O
O2N
Br
Br
R
+
N
N N
NH2
R' SH
SN
N
NN
O
R'
R
NO2
(7)
 
4. S. Peri Aytaç et al.7 have prepared 1,3,4-thiadiazine by the condensation of 4-
amino-3-substituted-1,2,4-triazole-5-thiones with phenacyl bromides. 
5. W. L. Alberecht et al.8 have synthesized s-triazolocycloalkyl hydro- 
thiadiazines (8) by the cyclization  of a-haloketones  with 5-substituted-4-
amino-4H-1,2,4-triazole-3-thiols. 
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(CH2)n Br
O +
N
N
NH
SH
NH2
Et
(CH2)n
N
S
N
H
N
N
Et
(8)  
6. N. N. Kuzmich et al.9 have synthesized triazolothiadiazines (9) by the reaction 
of thiobenzohydrazide with oxalyl chloride. 
NH
NH
SR
1
R
2
+
Cl
Cl
O
O
CHCl3,CCl4
60'-80' C
N
S
N
R
2
R
1
O
O
(9)
R1,R2=H or Ph  
BIOLOGICAL EVALUATION 
 Literature survey shows that various 1,3,4-thiadiazines have resulted in many 
potential drugs and are known to exhibit a broad spectrum of biological 
activities. 
          1,3,4-Thiadiazine derivatives possess wide range of therapeutic activities  
which are as under. 
1. Antifungal
10
 
2. Antibacterial
11  
3. Antimicrobial
12  
4. Antiinflammatory
13
 
5. Cardiovascular
14
 
6. AntiHIV
15    
7.  Antidiabetic
16
 
8. Antidepressant
17
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 R. D. Patil and J. S. Biradar
18 have reported triazole thiadiazine derivatives as 
anthelmintic, anti-inflammatory and anticatatonic active agents (10). G. Turan-Zitouni 
et al.
19 
have demonstrated analgesic activity of triazole thiadiazines (11).  
N
H
N
N
N
N
S
Ph
Ph(10)
OCH2
N
N
N
N
S
R1
R2
(11)
R1=H, R2=Cl,NO2
R1=OH, R2=OCH3  
G. Mazzone et al.
20-21 
reported 1,3,4-thiadiazine derivatives as weak anti-
inflammatory agent and also reported their analgesic activity. Jonas Rochus et al.
22-23 
have prepared new thiadiazine derivatives useful as phosphodiesterase IV inhibitors (12) 
and cardiovascular agents (13). 
NH
SR5ZN
R2
R3
R4
R2
R1
O (12)
S
N N
O
CH3
R
N
O
OMe
(13)
Z= bond OR alky lene R1,R2 = H OR Halo
R5= Substituted Pheny l R3,R4 = OH, alkoxy , halo  
 Z. A. Kaplancıklı et al.24 have reported antimicrobial activity of thiadiazines. 
Prakash Karegoudar et al.
25 
have documented thiadiazine derivatives as anti-
inflammatory agent. B. Kalluraya et al.
26-27 have reported 3-substituted-7H-6-(6-
bromo-3-coumarinyl)-s-triazolo[3,4,b][1,3,4]thiadiazines and subjected to antibac- 
terial activity (14).  
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O
N
N
S
N
N
O
R
(14)  
 B. A. Nadkarni et al.
28 have reported anthelmintic activity of 1,3,4-thiadiazines. 
A. N. El-Shorbagi et al.
29 renowned antimicrobial activity of thiadiazine derivatives. B. 
S. Holla et al.
30 have also reported antibacterial and anticancer activity of 1,3,4- 
thiadiazines. C. B. Vicentini et al.
31 
have renowned thiadiazines as fungicides. 
 The diverse biological activities have been encountered in compounds containing 
triazolothiadiazine ring system. Therefore it was considered worthwhile to synthesize 
1,3,4-thiadiazine derivatives which have been described as under. 
 
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF 6-ARYL-3-               
(4-ISOPROPYLPHENYL)-7H-[1,2,4]TRIAZOLO[3,4b][1,3,4] 
THIADIAZINES.
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SECTION-I 
SYNTHESIS AND BIOLOGICAL SCREENING OF 6-ARYL-3-(4-
ISOPROPYLPHENYL)-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES. 
 Thiadiazine derivatives represent on of the most active class of compounds 
having a wide spectrum of biological activities. With an aim to getting better therapeutic 
agent, the preparation of 1,3,4-thiadiazine of type (IV) have been undertaken by 
the condensation of 1-amino-3-[4-(propan-2-yl)phenyl]-1H-1,2,4-triazole-5-thiol 
with different substituted phenacyl bromides. 
 
CH3
CH3
N
N
N
N
S
R
CH3
CH3
N
N
N
NH2
SH
R-COCH 
2
Br
Type -(IV) R = Aryl  
 The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 
1
H nuclear magnetic resonance spectroscopy and 
further supported by mass spectrometry. Purity of all the compounds have been 
checked by thin layer chromatography. 
 All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger, Candida albicans at a 
concentration of 2000/1000/500 µg/ml. The biological activity of the synthesized 
compounds have been compared with standard drugs. Some compounds have been 
found to have moderate activity as compared to known antibiotics recorded on Table 
No.3b. 
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IR SPECTRAL STUDIES OF 6-(4-FLUOROPHENYL)-3-(4-ISOPROPYL- 
PHENYL)-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINE.  
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KAJ-PHV-1
Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr pallet 
method) 
Type Vibration Mode 
Frequency in cm
-1
 
Ref. 
Observed Reported 
Alkane 
C-H str. (asym.) 2955 2975-2950 36 
C-H str. (sym.) 2864 2880-2860 37 
 C-H def. (asym.) 1458 1470-1435 35 
C-H def. (sym.) 1388 1385-1370 36 
Aromatic 
 C-H str. 3088 3095-3050 35 
  C=C str. 1581 1585-1480 35 
C-H i.p. (def) 1103 1125-1000 36 
C-H o.o.p. (def) 765 835-810 36 
Isopropyl      -CH(CH3)2 2955 2800-2900 36 
Triazole 
C=N str. 1581 1650-1580 37 
C-N str. 1014 1050-1010 35 
N-N str. 1141 1220-1020 36 
Thiadiazine    C-S-C str. 765 720-570 37 
Halide C-F str. 1141 1200-1000 37 
CH3
CH3
N
N
N
N
S
F
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NMR SPECTRAL STUDIES OF 6-(4-FLUOROPHENYL)-3-(4-ISOPRO 
PYLPHENYL)-7H-[1,2,4]TRIAZOLO[3,4 b][1,3,4]THIADIAZINE.  
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (400MHz) 
 
Sr. No. 
Chemical shift in 
ppm 
Relative No. of 
proton 
Multiplicity Inference 
J value 
in Hz 
1 1.27-1.31 6H doublet -CH3 6.92 
2 2.97-3.01 1H multiplet -CH  
3 4.95 2H singlet -CH2  
4 7.20-7.24 2H triplet -Ar-Ha,a' 8.56 
5 7.36-7.38 2H doublet -Ar-Hb,b' 8.32 
6 7.93-7.95 2H doublet -Ar-Hc,c' 8.32 
7 8.10-8.14 2H multiplet -Ar-Hd,d'  
 
 
 
 
CH3
CH3
N
N
N
N
S
F
a
b
a'
b'
c
c'
d
d'
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Expanded aromatic region of NMR spectra 
 
MASS  SPECTRAL STUDIES OF 6-(4-FLUOROPHENYL)- 3-(4- ISOPROPYL 
PHENYL)-7H-[1,2,4] TRIAZOLO[3,4-b][1,3,4]THIADIAZINE.   
 
 
CH3
CH3
N
N
N
N
S
F
m/z = 352
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PROPOSED MASS FRAGMENTATION OF  6-(4-FLUOROPHENYL)- 3-(4-ISO 
PROPYLPHENYL)-7H-[1,2,4] TRIAZOLO[3,4-b][1,3,4]THIADIAZINE.  
CH3
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NH
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N
N
N
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CH3 N
N
N
N
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F
m/z = 338(M
-1
)
C19H17FN 4S
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N
N
N
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S
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+1
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C12H11FN 4S
CH3 N
N
N
N
S
m/z = 244(M
-1
)
C12H12N4S
N
N
N
N
S
m/z = 216
C10H8N4S
CH3
N
N
N
N
S
m/z = 168(M
-1
)
C6H8N4S
m/z = 147
C10H13N
m/z = 130
C3H6N4S
N
N
N
NH2
SH
CH3
NH
N
S
m/z = 102(M
+1
)
C3H6N2S
+
++
+
+
++
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary bath 
on controlled temperature heating mental. The crystallization of all the compounds was 
carried out in appropriate solvents. TLC was carried out on silica coated aluminum sheet 
(Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
[A] Preparation of Potassium 4-isopropylbenzyl dithiocarbamate 
See Part-I, Section-I (A). 
[B] Preparation of 1-Amino-3-[4-(propan-2-yl)phenyl]-1H-1,2,4-triazole-5- 
 thiol 
See Part-I, Section-I (B). 
[C] Preparation of  4-Fluorophenacyl bromide. 
To a well stirred solution of 4-fluoro acetophenone (1.38g, 0.01mol) in  
glacial acetic acid (20 ml) and  hydrochloric acid (0.11 ml) at ambient temperature, 
bromine (0.8g, 0.01mol) in glacial acetic acid (10 ml) was added over a period of 1hr. 
The reaction mixture was diluted with water (500 ml) and extracted with chloroform. 
The combined extracts were dried (over MgSO4) and concentrated to give 4-fluoro 
phenacyl bromide. 
Similarly other substituted phenacyl bromides were prepared by using 
literature methods.
32  
[D] Preparation of 6-(4-Fluorophenyl)-3-(4-isopropylphenyl)-7H-[1,2,4] triaz- 
olo[3,4-b][1,3,4]thiadiazine.  
A mixture of 1-amino-3-[4-(propan-2-yl)phenyl]-1H-1,2,4-triazolo-5-thiol 
(2.34g, 0.01mol) and p-fluoro phenacyl bromide (2.17g, 0.01mol) in dry methanol (50 
ml) was heated under reflux for 5 hrs. The content was cooled and neutralized with 
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aqueous potassium carbonate solution. The solid separated was filtered out and washed 
with water. The product was crystallized from ethanol. Yield 57%, m.p. 210 °C. Anal. 
Calcd. For C19H17FN4S; C, 64.75; H,4.86; N,15.90 %; Found: C,64.68; H,4.67; N,15.79%  
 Similarly other phenacyl bromides have been condensed. The physical 
constants are recorded in Table No.3a. 
[E] Antimicrobial activity of 6-Aryl-3-(4-isopropylphenyl)-7H-[1,2,4]triaz- 
olo[3,4-b][1,3,4]thiadiazines. 
 Antimicrobial testing was carried out as described in part-(I), section-I(D). 
The zones of inhibition of compounds are recorded in Table No.3b. 
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Table-3a: Physical constants of 3-(4-Isopropylphenyl)-6-aryl-7H-[1,2,4]triazolo[3,4- 
       b][1,3,4] thiadiazines. 
 
CH3
CH3
N
N
N
N
S
R
 
 
 
 
 
 
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd./Found 
C H N 
3a 4-F-C6H4- 
C19H17FN4S 
352.42 
205 57 
64.75 
(64.68) 
4.86 
(4.67) 
15.90 
(15.79) 
3b 4-Cl-C6H4- 
C19H17ClN4S 
368.88 
180 45 
61.86 
(61.48) 
4.65 
(4.31) 
15.19 
(15.02) 
3c 4-Br-C6H4- 
C19H17BrN4S 
413.33 
205 40 
55.21 
(54.03) 
4.15 
(3.98) 
13.55 
(13.23) 
3d C6H4- 
C19H18N4S 
334.43 
178 46 
68.23 
(68.08) 
5.42 
(5.16) 
16.75 
(16.49) 
3e 4-NO2-C6H4- 
C19H17N5O2S 
379.43 
169 56 
60.14 
(60.06) 
4.52 
(4.16) 
18.46 
(18.23) 
3f 2-OH-C6H4- 
C19H18N4OS 
350.43 
175 58 
65.12 
(65.09) 
5.18 
(4.86) 
15.99 
(15.71) 
3g 4-OCH3-C6H4- 
C20H20N4OS 
364.46 
159 51 
65.91 
(65.48) 
5.53 
(5.37) 
15.37 
(15.22) 
3h 4-CH3-C6H4- 
C20H20N4S 
348.46 
180 50 
68.93 
(68.74) 
5.79 
(5.47) 
16.08 
(16.01) 
 
TABLE 3A :  ANTIMICROBIAL ACTIVITY OF 6-ARYL-3-(4-ISOPROPYLPHENYL)-7H-[1,2,4]  
    TRIAZOLO[3,4-b][1,3,4]THIADIAZINES. (in µg/ml) 
No. Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus 
aureus 
Bacillus subtilis Escherichia coli
Salmonella 
paratyphi B 
Aspergillus niger Candida albicans
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500
1.  3a + + + + + - + + + + + - + + - + + - 
2.  3b + + + + + - + + + + + - + + - + + - 
3.  3c + + + + + + + + + + + + + + + + + + 
4.  3d - - + + + - + + + - - - + + - + + + 
5.  3e + + + + + + + - - + - - + + - + + - 
6.  3f + + - + + + + + - + + - + - - + - - 
7.  3g + + - + + + + + - + + - - - - - - - 
8.  3h + - + + + + + - + + - + + - + - + + 
  Where (+)  =  New synthesized compounds were active against microorganism 
 (-)  =  New synthesized compounds were inactive against microorganism 
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INTRODUCTION 
 
 Oxadiazoles belong to an important group of heterocyclic compounds 
having –N=C–O– linkage. It is well documented that oxadiazole system contains 
the following members which are numbered by designating the hetero atoms at 
particular position. 
O
N
N
O
N
N
O
N N
(1) (2) (3) (4)
O
N N
 
 1,3,4-Oxadiazole is a heterocyclic molecule with oxygen atom at 1 and two 
nitrogen atoms at 3 and 4 position. 1,3,4-Oxadiazole is a thermally stable aromatic 
molecule
1
. They have been known for about 80 years it is only in the last decade 
that investigations in this field have been intensified. This is because of large number 
of applications of 1,3,4-oxadiazoles in the most diverse areas viz.drug synthesis, 
dye stuff industry, heat resistant materials, heat resistant polymers and scintillators. 
Reviews of the relevant literature prior to 1965 are available
2 . 
SYNTHETIC ASPECT 
 
 Most 1,3,4-oxadiazoles are best obtained by synthesis from acyclic precursors. 
Such reactions are „one bond‟ or „two bond‟ cyclization. Different methods for the 
synthesis have been cited in literature.
3-8 
1. Hansong Chen et al.9 have synthesized oxadiazoles (5) by the reaction of 
hydrazide and aromatic acid in presence of POCl3. 
 
N
N
O
NH
NH2
ClEt
CH3
+ R1-COOH
NN
Cl
Et
CH3
O
N N
R1
(5)  
2. D. Ramesh and B. Sreenivasan10 have synthesized 1,3,4-oxadiazoles (6) from 
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semicarbazide in presense of POCl3. 
N
N
NH
O
NH NH
O
CH3
CH3
POCl 3
Ref. 4hrs.
N
N
NH
N
O
N
R
CH3
(6)  
3. K. Mogilaiah and B. Sakram
11 
have prepared 1,3,4-oxadiazole (7) from aceto- 
phenone-2-trifluoromethyl- 1,8-naphthyridine-3-carbonyl hydrazone in prese- 
nce of acetic anhydride. 
N N
NH
O
CF3
N CH3
Ar
AC2O
N N CF3
N
O
N
CH3
O
Ar
CH3
(7)  
4. Yu Yuve have reported microwave assisted synthesis protocol with 91 % of the     
yield
12
. 
R NH
O
NH2 +
R
1
O
OH
POCl3
MW, 12 min
O
N N
R R
1
(8)  
5. L. Somogyi13 synthesized 1,3,4-oxadiazole (9) from several steps, from aryl 
hydrazide and aryl aldehyde. 
R
NH
O
NH2
+ R
1
O
+ Ac Cl
O
N N
R R
1
(9)  
6. Silica sulfuric acid catalyst used for the rapid and ecofriendly synthesis of 1,3,4-
oxadiazoles (10) at ambient temperature by M. Dabiri et al
14
. 
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R C(OEt)3 + R
1
NH
O
NH2
O
N N
R R
1
Silica, H2SO4
MW,10min
(10)  
 
7. Green chemistry and one-pot, solvent-free using microwave radiated synthesis of 
1,3,4-oxadiazoles (11) were reported by V. Polshettiwar
15 
R C(OEt)3 + R
1
NH
O
NH2
O
N N
R R
1
MW
80 °C, 10 min
(11)  
  
BIOLOGICAL  EVALUATION  
 2,5-Disubstituted-1,3,4-oxadiazole derivatives have been tested for various 
pharmacological activities, which have been summarized as under. 
1. Antibacterial
16
 
2. Antiinflammatory
17
 
3. Analgesic
18
 
4. Antiviral and anticancer
19
 
5. Antihypertensive
20
 
6. Anticonvulsant
21
 
7. Antiproliferative
22
 
8. Antifungal
23
 
9. Cardiovascular
24
 
10. Herbicidal
25
 
11. Hypoglycemic
26
 
12. Hypnotic and Sedative
27
 
13. MAO inhibitor
28
 
14. Insecticidal
29
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 Bhardwaj Niti et al.
30 have screened oxadiazoles for their antimicrobial activity. 
A. El-Azzouny et al.
31 have synthesized 1,3,4-oxadiazole derivatives and evaluated for 
their analgesic, anti-inflammatory, ulcerogenic effects and inhibitory activity on 
plasma prostaglandin E
2  
(PGE
2
) Level. 
 Santos Filho et al.
32 
have reported 1,3,4-oxadiazoles for their anti-
inflammatory activity. Song Cao et al.
33 have investigated some oxadiazoles possessing 
insecticidal activity. Krishna Kant Jha et al.
34 have discovered oxadiazole derivatives 
and reported their antimycobacterial activity. Ali Almasired et al.
35 have prepared 1,3,4- 
oxadiazoles of type (12) as anticonvulsant agent. Meria Grazia Mamolo et al.
36 have 
synthesized 3-substituted-5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-one of type (13) and 
studied their antimycobacterial activity. 
O
N N
O
NH2
F
(12)
N
O
N N
X
O
(13)  
 H. Rajak. et al.
37 
have reported antimicrobial activity of oxadiazole derivatives. J. 
A. Christopher. et al.
38 
have documented human immunodeficiency virus infection of 
1,3,4-oxadiazole derivatives. B. Jayashankar et al.
39 have synthesized some oxadiazoles 
as anti-inflammatory and analgesic agents. K. Subrahmanya Bhat et al.
40 have prepa- 
red new fluorine containing 1,3,4-oxadiazoles (14) and reported them as potential 
antibacterial and anticancer agents. T. P. Mohan et al.
41 
have synthesized 2,5-disub- 
stituted-1,3,4-oxadiazole derivatives (15) and screened for their insecticidal activity. 
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Cl
N N
O
RF
Cl
(14)
O
CH3 CH2
O
N N
R
(15)  
 Ronald Kim et al.
42 have discovered oxadiazole derivatives useful as protease 
inhibitors. Mohd Amir and Kumar Shikha
43 
have documented anti-inflammatory, 
analgesic and ulserogenic activity of some newly synthesized oxadiazoles. Ali A.et 
al.
44 
have investigated some oxadiazole derivatives possessing antimicrobial and anti-
HIV-1 activity. Sherif A. et al.
45 have reported oxadiazoles as potential antitumor and 
anti-HIV agents. Afshin Zarghi et al.
46 have synthesized R-substituted-5-(2-
benzyloxyphenyl)-1,3,4-oxadiazoles (16) possessing anticonvulsant activity. Mahamud 
Tareq et al.
47 have synthesized 2,5-disubstituted-1,3,4-oxadiazoles (17) useful as 
tyrosinase inhibitors. 
N
O
N
NH2
O
F
(16)
N
O
N
Br
N
(17)  
 
Work done from our laboratory 
 K. M. Thaker
48 
have synthesized 2-(3',5'-dichlorobenzo[b]thiophen-2'-yl)-5-
aryl-1,3,4-oxadiazoles in the presence of aromatic acid. S. L. Vasoya
49
 reported facile 
synthesis of some new azetidinones and acetyl oxadiazoles bearing benzo[b]thiophene 
nucleus as a potent biological active agent. Synthesis and antimicrobial activity of 2-
aryl-5-(5',7'-diiodo-8'-quinolinoxy)-1,3,4-oxadiazoles have been reported by H. S. 
Joshi
50
. 
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 Thus with an effort to capitalize the biological potential of the heterocyclic 
system and to provide more interesting compounds for biological screening, we have 
under taken the synthesis of several oxadiazoles which has been described as under.  
  
 
 
SECTION-I : SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4- 
   ISOPROPYLPHENYL)-5-ARYL-1,3,4-OXADIAZOLES 
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SECTION-I 
 
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-(4-ISOPROPYLPHENYL)-
5-ARYL-1,3,4-OXADIAZOLES 
 Oxadiazole derivatives have been drawn the attention of chemist due to 
diversified biological activities associated with it. In view of these facts, it was 
contemplated to synthesize some newer oxadiazole derivatives with better potency. 
Oxadiazoles of type (IV) have been prepared by condensation of 4-
isopropylbenzohydrazide with different aromatic acid in presence of POCl3.  
 
  
CH3
CH3
N
O
N
R
CH3
CH3 NH
O
NH2
R-COOH
POCl 3
Type (IV) R=Aryl  
 The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 
1
H nuclear magnetic resonance spectroscopy and further 
supported by mass spectrometry. Purity of all the compounds have been checked by thin 
layer chromatography. 
 All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger, Candida albicans at a concentration of 
2000/1000/500 µg/ml. The biological activity of the synthesized compounds have been 
compared with standard drugs. Some compounds have been found to have moderate activity 
as compared to known antibiotics recorded on Table No.4b. 
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IR SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-5-(4-ISOPROPYL- 
PHENYL)-1,3,4-OXADIAZOLE. 
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Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr pallet 
method) 
Type Vibration Mode 
Frequency in cm
-1
 
Ref. 
Observed Reported 
Alkane 
  C-H str. (asym.) 2960 2975-2950 51 
C-H str. (sym.) 2870 2880-2860 51 
   C-H def. (asym.) 1454 1470-1435 51 
C-H def. (sym.) 1346 1385-1370 51 
Aromatic 
C-H str. 3049 3080-3030 52 
 C=C str. 1523 1585-1480 52 
C-H i.p.(def) 1062 1125-1000 52 
C-H o.o.p. (def) 850 835-810 51 
Isopropyl CH(CH3)2 2870 2800-2900 36 
Oxadiazole 
 C=N str. 1606 1650-1580 52 
-N-N- str. 1116 1220-1020 52 
-C-O-C- str. 1062 1075-1020 52 
Halide C-Cl str.(asym.) 746 800-600 53 
 
CH3
CH3
N
O
N
Cl
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NMR  SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-5-(4-ISOPROPYL- 
PHENYL)-1,3,4-OXADIAZOLE. 
 
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (400MHz) 
 
 
Sr.No. Chemical shift in 
ppm 
Relative No. of 
proton 
Multiplicity Inference J value in Hz 
1 1.21-1.23 6H doublet -CH3 6.96 
2 2.88-2.95 1H multiplet -CH - 
3 7.30-7.32 2H 
doublet Ar-Ha,a' 8.28 
4 7.42-7.44 2H 
doublet Ar-Hb,b' 11.32 
5 7.97-8.0 4H multiplet Ar-H  
CH3
CH3
N
O
N
Cl
a
a'
b
b'
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Expanded aromatic region of NMR s pectra  
 
MASS  SPECTRAL STUDIES OF 2-(4-CHLOROPHENYL)-5-(4-ISOPROPYL- 
PHENYL)-1,3,4-OXADIAZOLE. 
 
CH3
CH3
N
O
N
Clm/z = 298
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PROPOSED MASS FRAGMENTATION OF 2-(4-CHLOROPHENYL)-5-(4-ISOPR 
OPYLPHENYL)-1,3,4- OXADIAZOLE. 
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CH3
N
O
N
Cl
m/z = 298
C17H15ClN2O
CH3 N
O
N
Cl
m/z = 284
C16H13ClN2O
N
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Cl
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-1
)
C9H7ClN2O
CH2
CH3
N
O
N
CH3
m/z = 164(M
+1
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C9H12N2O
CH3 NH
CH3
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C10H13N
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N
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+
+
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N
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CH3
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C12H14N2O
N
O
N
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C8H6N2O
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary 
bath on controlled temperature heating mental. The crystallization of all the compounds 
was carried out in appropriate solvents. TLC was carried out on silica coated aluminum 
sheet (Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
 
[A] Preparation of 4-Isopropylbenzohydrazide. 
 A mixture of methyl 4-isopropylbenzoate (1.78g, 0.01mol) and hydrazine hydrate 
(2.0 ml, 0.02mol) in ethanol was refluxed in water bath for 2 hrs. The reaction mixture 
was poured onto crushed ice. Crude product was isolated and crystallized from 
ethanol.  
[B] Preparation of 2-(4-Chlorophenyl)-5-(4-isopropylphenyl)-1,3,4-oxadiazole 
 A mixture of 4-Isopropylbenzohydrazide (1.78g, 0.01mol) and 4-chloro benzoic 
acid (1.56g, 0.01mol) in phosphorous oxychloride (10 ml) was refluxed for 6 hrs. The 
content was cooled, poured onto crushed ice and neutralized with sodium bicarbonate 
solution. Crude product was isolated and crystallized from ethanol. Yield 60%, m.p 78 
°C Anal. Calcd C17H15ClN2O; C,68.34; H,5.06; N,9.38 %; Found: C,68.70; H,4.83; 
N,9.49 %.  
 Similarly other oxadiazoles have been prepared. The physical data are recorded 
in table No. 4a.  
[C] Antimicrobial activity of 2-(4-Isopropylphenyl)-5-aryl-1,3,4-oxadiazoles.  
Antimicrobial testing was carried out as described in Part-I, Section (D). 
The zones inhibition of the compounds are recorded in Table No.4b. 
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Table-4a:      Physical constants of  2-(4-Isopropylphenyl)-5-aryl-1,3,4-oxadiazoles 
 
CH3
CH3
N
O
N
R
 
 
 
  
 
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield % 
% Composition 
Calcd./Found 
C H N 
4a 4-OCH3-C6H4- 
C18H18N2O2 
294.34 
240 68 
73.45 
(73.09) 
6.16 
(6.13) 
9.52 
(9.21) 
4b C6H5- 
C17H16N2O 
264.32 
210 54 
77.25 
(77.03) 
6.10 
(6.05) 
10.60 
(10.22) 
4c 2-CH3-C6H4- 
C18H18N2O 
278.34 
200 56 
77.67 
(77.61) 
6.52 
(6.26) 
10.06 
(10.01) 
4d 4-Br-C6H4- 
C17H15BrN2O 
343.21 
250 62 
59.49 
(59.32) 
4.41 
(4.13) 
8.16 
(8.09) 
4e 3-Cl-C6H4- 
C17H15ClN2O 
298.76 
265 69 
68.34 
(68.13) 
5.06 
(4.86) 
9.38 
(9.27) 
4f 4-NO2-C6H5- 
C17H15N3O 
309.31 
190 58 
66.01 
(65.86) 
4.89 
(4.65) 
13.58 
(13.42) 
4g 3-NO2-C6H4- 
C17H15N3O 
309.31 
160 66 
66.01 
(65.83) 
4.89 
(4.61) 
13.58 
(13.19) 
4h 4-Cl-C6H4- 
C17H15ClN2O 
298.76 
251 64 
68.34 
(68.19) 
5.06 
(5.00) 
9.38 
(9.19) 
4i 4-NH2-C6H4- 
C17H17N3O 
279.33 
240 68 
73.10 
(73.04) 
6.13 
(6.08) 
15.04 
(15.00) 
4j 2-OH-C6H4- 
C17H16N2O2 
280.32 
220 50 
72.84 
(72.79) 
5.75 
(5.59) 
9.99 
(9.84) 
TABLE 4B :  ANTIMICROBIAL ACTIVITY OF 2-(4-ISOPROPYLPHENYL)-5-ARYL-1,3,4-OXADIAZOLES 
      (in µg/ml) 
 
No. 
 
Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus 
aureus 
Bacillus subtilis Escherichia coli 
Salmonella paratyphi 
B 
Aspergillus niger Candida albicans
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500
1. 4a + + - + + + + + - - - - + + - + + + 
2. 4b + + - + - + + - + - + + - + - + + - 
3. 4c - - - + + - - - - + + - + + + + + - 
4. 4d - - - + + - - - - - - - + + - + + - 
5. 4e + + + + + + - - - - - - - - - - - - 
6. 4f + + - - - - - - - + + - - - - - - - 
7. 4g + + - + + + + + - - - - + + - + + + 
8. 4h + + + + + + + + - + + - + + - + + - 
9. 4i + + - + + - + + + + + - + + + + + + 
10. 4j + + + + + + + + - + + - + + + + + + 
Where  (+)  =  New synthesized compounds were active against microorganism 
               (-)  =  New synthesized compounds were inactive against microorganism 
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INTRODUCTION 
 Imidazolinone, a five membered heterocycle having 2-nitrogen atoms at the 1 and 
3-positions and C=O group at following positions: 2-oxo-imidazoline (1), 4-oxo-
imidazoline (2), 5-oxo-imidazoline (3). Imidazolines are structurally related to guanidines 
and amidines. 
N
H
N
H
O
N
H
N
H
O
N
H
N
H
O
(1) (2) (3)  
 The discovery of the 2-substituted-5-imidazolines dates back to the year 1888, 
when A. W. Hoffmann
1
 for the first time discovered 5-oxo-imidazoline by heating N
1
-
diacetyl ethylene diamine in a stream of dry hydrogen chloride and moreover the same 
compound was prepared by A. Ladenburg
2
 by the fusion of two equivalents of sodium 
acetate with one equivalent of ethylene diamine dihydrochloride.  
 Imidazolinone has been used extensively as a corrosion inhibitor on certain 
transition metals, such as copper. Preventing copper corrosion is important, especially in 
aqueous systems, where the conductivity of the copper decreases due to corrosion. 
SYNTHETIC ASPECT 
 Various methods have been reported for the synthesis of imidazolinones in 
literature
3
. Aminolysis of oxazolone with amines led to the formation of imidazolinones 
which has been reported in literature
4
. 
1. A. Saxena et al.5 have synthesized new imidazolinone derivatives (4). 
N
O
Ar
O
O
NH NH2
Cl
dry pyridine
N
N NH
OAr
O
Cl
(4)  
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2. X. Huang6 et al. have synthesized some new imidazolinone derivatives (5).  
 
Cl
COOEt
N=C=S
R
1
NH2
CH3CN
Cl
NH
N
O
R
1
S
R2X,CH3CN
K2CO3
Cl
N
N
O
SR
2
R
1
R1=n-Pr,R2=Ary l
(5)
 
 
3. A. V. Patel et al.7 have synthesized new Imidazolinone derivatives by convention- 
nal method. 
4.  Zeng, Han et al.8 have synthesized 5-imidazolinone derivatives with 2-bromo- 
acetic acid as a starting material. 
MECHANISM  
 Azalactone reacts with variety of compounds such as water, alcohols, amines and 
hydrogen halides. Amides of α-acylamino acrylic acids obtained from the condensation of 
azalactone and primary amine can be converted to imidazolinone as shown under. 
N O
O
R
X X
O
NH NH
O
R
R'
R'-NH2 POCl 3
N N
CH2
R
X
R'
R' = NH2,Dry  C5H5N/Abs.C2H5OH,K2CO3  
 The ring closer can be effected under a variety of conditions. Substituted anilides 
have been converted to imidazolinone derivatives by the action of POCl3. 
BIOLOGICAL  EVALUATION  
 Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various 
imidazolinone derivatives which have been used as adrenergic stimulants and tolazoline 
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and phentolamine as adrenergic blocking agents. Various imidazolinones are known to 
exhibit a broad spectrum of biological activities such as: 
1.  Antitubercular
9
 
2.  Anti cancer
10
 
3.  Insecticidal
11
 
4.  Antiviral
12
 
5.  Hypertensive
13
 
6.  Antiinflammatory
14
 
7.  Glucagon antagonists
15
 
8.  Antimicrobial
16
 
9.  Antihistaminic
17
 
10.  Antidiabetic
18
 
 Bascou and co-workers
19
 have prepared some new imidazolinones and reported 
their agrochemical activity. Kolhe Vishnu et al.
20
 have reported anti AIDS, antibacterial 
and fungicidal activity of 5-oxo-imidazolines. Herbicidal activity of imidazolinone 
derivatives have been reported by U. Akyoshi et al.
21
 Ding M. et al.
22
 and Pilkington B. et 
al.
23
 have reported a new series of biologically active analogues of 5-oxo-imidazolines. 
Imidazolinone derivatives
24 
which possess antifungal activity have been reported. Some 
new 5-oxoimidazolines
25 
as antimicrobial agents have been investigated.
 
L. Joseph Patel 
and co-workers
26
 have prepared substituted imidazolinones which inhibited the abnormal 
cell growth in human body. B. Kalluraya et al.
27
 (IV) have reported antibacterial, 
antifungal, anti-inflammatory and analgesic activity of 5- oxo-imidazolines. 
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N
N N
OAr
N
NH
R
(6)  
Work done from our laboratory 
 A. M. Vyas
28
 have synthesized some new imidazolones. Synthesis of some new 
imidazolones and 1,2,4-triazoles bearing benzo[b]thiophene nucleus as antimicrobial 
agents have been reported by K. M. Thakar
29
. 1-N-substituted benzalaminothiocarbonyl-
2-methyl-4-(8'-hydroxyquinolin-7'-yl)methine-5-imidazolones have been reported by A. 
M. Vyas
30
.  
 Literature survey reveals that the compounds bearing imidazolones moiety 
possess potential drug activity. Looking to the diversified biological activities we have 
synthesized some pyrazole derivatives in order to achieving better therapeutic agents. 
These studies are described in following section. 
SECTION - I : SYNTHESIS AND BIOLOGICAL SCREENING OF N-(4-   
   (ARYLIDENE)-4,5-DIHYDRO-5-OXO-2-PHENYLIMIDAZOL-1- 
      YL)-4- ISOPROPYLBENZAMIDES 
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SECTION – I 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-(4-(ARYLIDENE)-4,5- 
DIHYDRO-5-OXO-2-PHENYLIMIDAZOL-1-YL)-4-ISOPROPYLBENZAMIDES.  
 Various imidazolinones have resulted in many potential drugs and are known to 
possess a broad biological spectrum. In view of getting better therapeutic agents and 
considering the association of various biological activities with 4-
isopropylbenzohydrazide nucleus, the preparation of 5-imidazolones of type-(V) have 
been undertaken by the condensation of 4-isopropylbenzohydrazide  with substituted 
azalactones which in turn have been prepared by well known Ertenmeyer azalactone 
synthesis. 
CH3
CH3
O
NH N
N
O
R
CH3
CH3
O
NH NH2
O N
H5C6
O
R
Pyridine 
 
         Type (V) R= Aryl 
 The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 
1
H nuclear magnetic resonance spectroscopy and 
further supported by mass spectrometry. Purity of all the compounds have been 
checked by thin layer chromatography. 
 All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger, Candida albicans at a 
concentration of 2000/1000/500 µg/ml. The biological activity of the synthesized 
compounds have been compared with standard drugs. Some compounds have been 
found to have moderate activity as compared to known antibiotics recorded on Table 
No.5b.
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IR SPECTRAL STUDIES OF N-(4-BENZYLIDENE-4,5-DIHYDRO-5-OXO-2-
PHENYLIMIDAZOL-1-YL)-4-ISOPROPYLBENZAMIDE 
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3
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KAJ-IMI-1
  
Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr pallet 
method) 
 
Type Vibration Mode 
Frequency in cm
-1
 
Ref. 
Observed Reported 
Alkane-CH3 
C-H str. 
(asym.) 
2941 2975-2940 31 
C-H str. (sym.) 2858 2880-2860 31 
C-H def. 
(asym.) 
1448 1470-1435 31 
C-H def. (sym.) 1375 1395-1370 31 
Aromatic 
C-H str. 2941 2980-2930 32 
 C=C str. 1523 1585-1480 32 
C-H I.p.(def) 1067 1125-1000 32 
   C-H o.o.p. 
(def) 
663 700-600 31 
Isopropyl -CH(CH3)2 2893 2800-2900 36 
Imidazoline 
C=N str. 1635 1650-1580 32 
C=O str. 1753 1760-1700 32 
C-N str. 1010 1050-1010 33 
Amide N-H bend. 1635 1630-1550 33 
CH3
CH3
O
NH N
N
O
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NMR SPECTRAL STUDIES OF N-(4-BENZYLIDENE-4,5-DIHYDRO-5-
OXO-2-PHENYLIMIDAZOL-1-YL)-4-ISOPROPYLBENZAMIDE 
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (400MHz) 
 
Sr. No. Chemical shift 
in ppm 
Relative No. 
of proton 
Multiplicity Inference J value in Hz 
1 1.42-1.46 6H doublet -CH3 6.88 
2 2.78-2.84 1H multiplet -CH --- 
3 7.07-7.09 2H doublet -Ar-Ha,a' 7.72 
4 7.28 1H singlet -CH --- 
5 7.36-7.44 6H multiplet -Ar-H --- 
6 7.60-7.62 2H doublet -Ar-Hb,b' 7.60 
7 7.96-7.98 2H doublet -Ar-Hc,c' 7.16 
8 8.19-8.21 2H doublet -Ar-Hd,d' 7.68 
9 9.74 1H singlet -NH --- 
CH3
CH3
O
NH N
N
O
a
b
a'
b'
c
c'
d
d'
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Expanded aromatic region of NMR spectra 
 
MASS SPECTRAL STUDIES OF N-(4-BENZYLIDENE-4,5-DIHYDRO-5 OXO-2-
PHENYLIMIDAZOL-1-YL)-4-ISOPROPYLBENZAMIDE 
CH3
CH3
O
NH N
N
O
m/z = 409
Studies on chemical…   
101             Imidazolones 
PROPOSED MASS FRAGMENTATION OF N-(4-BENZYLIDENE-4,5-DIHYDRO-
5-OXO-2-PHENYLIMIDAZOL-1-YL)-4-ISOPROPYLBENZAMIDE 
 
CH3
CH3
O
NH N
N
O
NH2 N
N
O
m/z = 263(M
+1
)
C16H13N3O3
NH
N
O
m/z = 248(M)
C16H12N2O
CH3
CH3
O
NH N
N
O
m/z = 245(M
-1
)
C13H15N3O2
O
NH N
N
O
m/z = 203(M
-1
)
C10H9N3O2
NH
N
O
m/z = 160(M
+1
)
C9H8N2O
NH
N
m/z = 146(M
-1
)
C9H10N2
NH2
NH
m/z = 120(M
+1
)
C7H8N2
NH
m/z = 105(M
+1
)
C7H7N
CH3
m/z = 92(M
+1
)
C7H8 m/z = 409
C26H23N3O2
+ + +
+ +
+ +
+
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary bath 
on controlled temperature heating mental. The crystallization of all the compounds was 
carried out in appropriate solvents. TLC was carried out on silica coated aluminum sheet 
(Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
[A] Synthesis of 4-Isopropylbenzohydrazide. 
 A mixture of methyl 4-isopropylbenzoate (1.78g, 0.01mol) and hydrazine hydrate 
(2.0 ml, 0.02mol) in ethanol was refluxed in water bath for 2 hrs. The reaction mixture 
was poured onto crushed ice. Crude product was isolated and crystallized from 
ethanol.  
[B]  Synthesis of 4-Arylidene-2-phenyl-5-oxazolinones. 
            These were prepared by the condensation of substituted benzaldehyde with 
benzoyl glycine in presence of sodium acetate and acetic anhydride as described by 
Vogel
34
. 
[C] Synthesis of N-(4-Benzylidene-4,5-dihydro-5oxo-2-phenylimidazol-1-yl)-4-iso 
 propylbenzamide isopropyl benzamide.  
 To a mixture of (4Z)-4-benzylidene-2-phenyloxazol-5(4H)-one(2.49g 
0.01mol) and 4-isopropylbenzohydrazide (1.78g, 0.01mol) in 20ml of pyridine were 
refluxed for 6-8 hrs. The excess of solvent was removed under reduced pressure and 
reaction mixture was poured in crushed ice. The product was isolated and 
crystallized from benzene. Yield 64%, m.p 130 °C Anal. cald. for C26H23N3O2; C, 
76.26; H,5.66; N,10.26 %; Found: C,76.23; H,5.88; N,10.65 % 
 Similarly other substituted imidazolones have been prepared. The physical 
constants are recorded in Table No.5a. 
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[D] Antimicrobial activity of N-(4-(Arylidene)-4,5dihydro-5-oxo-2-phenylimida- 
 zol-1-yl)-4-isopropylbenzamides. 
Antimicrobial testing was carried out as described in Part-I, Section (D). 
The zones inhibitions of the compounds are recorded in Table No.5b. 
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Table-5a: Physical constants of N-(4-Arylidene-4,5-dihydro-5oxo-2-phenyl  
  imidazol-1-yl)-4-isopropylbenzamides  
CH3
CH3
O
NH N
N
O
Ph
 
 
 
  
 
Sr. No. 
 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd./Found 
C H N 
5a C6H5- 
C26H23N3O2 
409.47 
240 65 
76.26 
(76.13) 
5.66 
(5.38) 
10.26 
(10.03) 
5b 3-NO2-C6H4- 
C26H22N4O4 
454.47 
205 58 
68.71 
(68.45) 
4.88 
(4.47) 
12.33 
(12.18) 
5c 4-NO2-C6H4- 
C26H22N4O4 
454.47 
190 42 
68.71 
(68.36) 
4.88 
(4.58) 
12.33 
(12.06) 
5d 4-OH -C6H4- 
C26H23N3O3 
425.47 
240 55 
73.39 
(73.05) 
5.45 
(5.28) 
9.88 
(9.61) 
5e 2-NO2-C6H4- 
C26H22N4O4 
454.47 
195 49 
68.71 
(68.36) 
4.88 
(4.76) 
12.33 
(12.06) 
5f 2-OCH3-C6H5- 
C27H25N3O3 
439.50 
220 53 
73.78 
(73.33) 
5.73 
(5.61) 
9.56 
(9.33) 
5g 4-F-C6H4- 
C26H22FN3O2 
427.47 
228 65 
73.05 
(72.00) 
5.19 
(4.93) 
9.83 
(9.75) 
5h 4-Cl-C6H4- 
C26H22ClN3O2 
443.92 
198 45 
70.34 
(70.13) 
5.00 
(4.95) 
9.47 
(9.40) 
5i 4-OCH3-C6H4- 
C27H25N3O3 
439.50 
208 66 
73.78 
(73.35) 
5.73 
(5.44) 
9.56 
(9.26) 
        TABLE 5B: ANTIMICROBIAL ACTIVITY OF N-4-(ARYLIDENE)-4,5DIHYDRO-5-OXO-2-PHENYL- 
     IMIDAZOL-1-YL)-4-ISOPROPYLBENZAMIDES.  (in µg/ml) 
No. Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus 
aureus 
Bacillus subtilis Escherichia coli 
Salmonella 
paratyphi B 
Aspergillus niger Candida albicans
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 
1. 5a + + + + + + + + + + + + + + + + + + 
2. 5b + + - + + - + + - - - - + + - - - - 
3. 5c + + - + + - - - - - - - + + + + + + 
4. 5d + + + + + + + + - - - - + + - - - - 
5. 5e + + - + + - + + - + + + - - - + + - 
6. 5f - - - + + - + + + + + - + + + + + + 
7. 5g + - + + - - - + - + + - - - + - + + 
8. 5h + + - + + + + + + + + + + + - + + - 
      Where (+)  =  New synthesized compounds were active against microorganism 
         (-)  =  New synthesized compounds were inactive against microorganism 
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INTRODUCTION 
Thiophene-2-carbaldehyde (1) is an aromatic heterocyclic compound consisting 
of four carbon atoms and one sulfur atom in a five-membered ring. Thiophene was 
discovered by Viktor Meyer in 1883 as a contaminant in benzene
1
. Related to thiophene 
are benzothiophene and dibenzothiophene, containing the thiophene ring fused with one 
and two benzene rings. 
It was observed that isatin forms a blue dye if, it is mixed with sulfuric acid and 
crude benzene. Victor Meyer was able to isolate the substance responsible for this 
reaction from benzene. This new heterocyclic compound was thiophene
2
. 
S
O
(1)  
Thiophenes are important class of heterocyclic compounds and are recurring 
building blocks in organic chemistry with applications in pharmaceuticals. The benzene 
ring of a biologically active compound may often be replaced by a thiophene without loss 
of activity
3
. Thiophene and its derivatives occur in petroleum, sometimes in 
concentrations up to 1-3%. The thiophenic content of liquids from oil and coal is 
removed via the hydrodesulfurization (HDS) process. 
SYNTHETIC ASPECT 
Various methods for the preparation of thiophene derivatives have been cited in 
literature, some of the methods are as under. 
1. A. Y. Kopylov and co-workers4 synthesized thiophene via butane, (methyldi- 
sulfanyl)ethane and (ethyldisulfanyl)ethane, using alluminium oxide as a catalyst. 
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CH3
CH3
+
CH3
S S
CH3
Et S
S Et
+
S
Al2O3, 450 °C
75 min
 
2. Liang, Xinmiao and workers5 synthesized thiophene using ferrous nitrate and 
cyno methane. 
S
OH SFe(NO3)3,CH3CN
12 hrs , RT
 
3. Moon, Jeongju and workers6 synthesized thiophenes and 2,2'-bithiophene using 
Sodium butoxide  and cyclohexenone, palladium as catalyst. 
S
Br NaoBu, Cyclohexanol
Ph2,Pentadienone Pd
S
S S
+
 
 
4. N. T. Berberova et al.7 synthesized thiophenes and thiophene-2-thiol via dichloro 
methane and hydrogen sulphide at 20-25 °C. 
O S
SH
+
SH2S, CH2Cl2
 
 
5. A. R. Katritzky et al.8 synthesized thiophenes from 2,5-dimethylthiophene using 
hydrophosphoric acid. 
S
CH3CH3
S
H3PO4
 
6. E. N. Deryagina and worker9 synthesized thiophenes from 2-chlorothiophene and 
ethyne.  
S
Cl
S
CH CH
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BIOLOGICAL EVALUATION 
 Over recent years there has been an increasing interest in the chemistry of 
thiophene because of their biological significance.  
1. Analgesic
10-12
  
2. Antimicrobial
13-15
   
3. Anticonvulsant
16,17
  
5. Antifungal
18,19
 
6. Antihistaminic
20,21
   
7. Antiinflammatory
22-25
 
8. Antitumor
26-28
   
9. Antiviral
29-31
 
10. β-Adrenergic32  
11. Diuretic
33
 
12. Insecticidal
34-36
 
13. antipsychotic
37,38
  
14. Anticancer
39-42
 
 S. F. Mohmad
43
 have prepared {[4-(thiophen-2-yl)-3,4,5,6-tetrahydrobenzo 
[H]quinazolin-2-yl]sulfanyl} acid (2) as a anti viral and anti cancer agent. 
NH
N
S
S
OOH
(2)   
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 Gautam Panda
44
 have prepared 2-{phenyl[4-(2-phenylethoxy)phenyl] methyl} 
thiophene (3)  and tested for its antitubercular activity. 
S
O
R
(3)  
 M. S. Malamas and coworkers
45
 have synthesized novel thiophene derivatives 
inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. S. S. 
Perez et al.
46
 developed 5-substituted thiophene derivatives with dual action at 5-HT1A 
serotonin receptors and serotonin transporter as a new class of antidepressants. Synthesis 
and serotonergic activity of thiophene-4-piperazine derivatives as novel antagonists for 
the vascular 5-HT1B receptor has been achieved by G. P. Moloney and group
47
.  
Derivatives of benzo[b]thiophene are also available as drug, some of them are shown 
as under:  
S
N
CH3
OH NH2
O
Zileuton (ZYFLOTM)
Antiashthamatic
S
OH
OH
O
O
N
Raloxifene
Anticancer/Osteroporosis
S
Cl
O
N
N
Cl
Cl
Sertaconazole
Anti fungal   
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Work done from our laboratory  
V. V. Kachhadia
48,49 
have synthesized cyclohexenones,
 
thiohydantoins and 
thiazolidinones derivatives bearing benzo[b]thiophene nucleus and reported their antitub- 
ercular and antimicrobial activity. 
S. L. Vasoya
50,51,52
 reported facile synthesis of some new azetidinones, acetyl 
oxadiazoles, thiosemicarbazides, 1,3,4-thiadiazoles, thiosemicarbazide as a potent 
antitubercular and antimicrobial agents bearing benzo[b]thiophene nucleus.  
In view of procuring highly potent biodynamic agents after this literature survey 
and on continuation of our on going work on thiophenes derivatives for their various 
methods of synthesis and different biological activities, synthesis of thiophene have been 
undertaken in order to achieving superior therapeutic agents. This can be summarized in 
the following sections as under.  
PART-I: 
SECTION:I SYNTHESIS, CHARACTERIZATION AND     
            BIOLOGICAL SCREENING OF CYCLOHEXENONES. 
SECTION:II SYNTHESIS, CHARACTERIZATION AND       
            BIOLOGICAL SCREENING OF INDAZOLES.  
PART-II:  SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL  
  SCREENING OF MANNICH BASES. 
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INTRODUCTION  
 Cyclohexenones are derivatives of cyclohexane with carbonyl group at position-1 
and double bond at position-2. There are different types of cyclohexenone derivatives but 
the greatest difference in structure and properties is exerted by the groups attached to 
carbon atom.  
 Cyclohexenones is the parent of a series of compounds that is important in 
agricultural and medicinal chemistry. Cyclohexenones can be conveniently synthesized 
by the treatment of α, β-unsaturated carbonyl compounds with ethyl acetoacetate in basic 
media. 
 
  
 
 Cyclohexenone derivatives have gained lot of interest because of their prominent 
pharmaceutical properties. 
 SYNTHETIC ASPECT  
 Various method for the synthesis of cyclohexenone derivatives have been 
described in literature
1-9
.
  
1. A review of the earlier literature by Gerald et al.10 described representative 
synthetic procedure of cyclohexenone derivatives. 
Br
CH3
O
+
CH2
R OH
1. cat. Pd
2. H+
O
R
 
2. Byong-Don Chong et al.11 have been prepared cyclohexenone derivatives by 
 tandem michael addition-aldol condensation of β-keto esters to conjugate enones
 (or enals) in t-BuOH. 
O
(1)
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CH3
O O
O
CH3
+ CH3
O
t - BuOK
CH3
O
CH3
COOEt
 
3. Andrea Buzas et al.12 have been prepared cyclohexenone by reaction of various 
 substituted 5-en-2-yn-1-yl acetates with using biphenyl phosphine as catalyst in 
 methanol in basic media. 
Ph
OAc
O
CH3
CH3
O
CH3Ph
K2CO3AcO
Ph
CH3
CH2
1. 1% A, MeOH
2. K2CO3, MeOH
P
t-Bu
t-Bu Au - NTf2
 
4. Ken Tanaka et al.13 have synthesized cyclohexenone from 4-alkynals and alkynes 
in presence of Rh catalyst via novel [4+2] annulations. 
 
O
R
1
R
2
R
3
+
R
5
R
4
Rh catalyst
CH2Cl2
O
R
3
H
R
5
R
4
R
1
R
2
 
5. Surya Prakash Rao and co workers14 reported solvent-free microwave mediated 
 Michael addition reactions to form cyclohexenones with 98 % yield. 
Ph
O
Ph
+
R
1
O
CH3
K2CO3
MW, 450 W
Ph
Ph O
R
1
 
 
6. H. A. Eman et al.15 have synthesized cyclohexenone derivatives from chalcone.  
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X N S
O
O
O
R
 EAA
Acetone
X N S
O
O
R
OO
O
CH3
R= Ary l
(2)  
7. Page Philip C. and co-workers16 have prepared ethyl substitute cyclohexenone 
 derivatives.  
8. S. S. Lokanatha Rai et al.17 have reported synthesis of 6-methoxy-7-methyl-3-
 aryl-cyclohexyl-4-oxo-2-napthoate derivatives.  
MECHANISM 
 
 
R
O
R1
R CH
+
CH
-
C
O
R1
[A]
+H+ R CH
+
O
R1
 
CH3
O
COOC2H5
CH3 C
O
CH
-
COOC2H5
+
OH
-
R CH
+
O
R1
+
CH3CH
-
O
H5C2OOC
CH3
O
H5C2OOC
R R1
O
O
H5C2OOC
R R1
-H2O
H
+
[B]
 
 The addition reaction between ethyl acetoacetate and α,β-unsaturated ketone give 
cyclohexenone via michael addition. This reaction has been carried out in basic media by 
using sodium ethoxide or anhydrous K2CO3 in acetone. During the reaction, nucleophillic 
addition of carbanion take place to the C=C of the acceptor. The α,β-unsaturated 
compounds is known as acceptor and ethyl aceto acetate is known as donor.  
Studies on chemical… 
120      Indazole 
 
BIOLOGICAL EVALUATION  
Cyclohexenone and its derivatives are widely used in pharmaceutical industries 
some of them are as under.  
1. Analgesic18
 
 
2. Antibiotic19 
3. Anticancer20 
4. Anticonvulsant21 
5. Antitumor22 
6. Cardiovascular23 
7. Neurotropic activity24 
8. Antiplatelet25 
9. Antifungal26 
Zhang Guo-Liang et al.
27
 have reported some new cyclohexenones as anti-HIV-1 
agents. Felix et al.
28
, Nippon
29
 
and Engel Stephan et al.
30
 (3) and (4) have been 
synthesized cyclohexenone derivatives as herbicidal agent.  
O
O
CH3
CH3
O
OH
Cl
Cl
CH3
CH3
O
O
OH
CH3
CH3
SO2
N
CH3 CH3
(4)(3)  
 R. Joachim et al.
31
 and Yoshida Shigeo et al.
32
 have reported cyclohexenone 
derivatives having plant growth regulators which proved more effective than chlormequat 
chloride.  
Moreover K. Reiner et al.
33
 
have reported cyclohexenone (5) derivatives having 
herbicidal agent. Gonzalez de Aguilar et al.
34
 have reported some new cyclohexenones as 
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Neurotropic agents which have useful in cultured central nervous system neurons. 
Cyclohexenones possess inhibitory activity against the growth of lettuce seedling found 
by Kimara et al.
35 
H. S. Joshi et al.
36
 have synthesized and reported their antitubercular 
and antimicrobial activity.  
Br
R
OO
O
CH3
(5) R=Aryl  
 
Thus, with an effort to capitalize the biological potential of the heterocyclic system 
and to provide more interesting compounds for biological screening, we have undertaken 
the synthesis of several cyclohexenone derivatives which has been described as under.   
SECTION - I :SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL 6-OXO-4- 
  ARYL-2-(THIOPHEN-2-YL)CYCLOHEX-1-ENECARBOXYLATES 
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SECTION - I 
SYNTHESIS AND BIOLOGICAL SCREENING OF ETHYL 6-OXO-4-ARYL-2-
(THIOPHEN-2-YL)CYCLOHEX-1-ENECARBOXYLATES. 
 Cyclohexenone possess a various pharmaceutical activities such as anticonvulsant, 
antidiabetic etc. Looking to the interesting properties of cyclohexenones, it was 
considered worthwhile to synthesize a series of cyclohexenones of type (VII) by the 
cyclocondensation of chalcones with ethyl cyano acetate in sodium ethoxide.  
S
R
O
NaOEt
CH3
COOEt
O
S
O
O
CH3
O
R
Type (VII) R = Aryl  
 The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and 
further supported by mass spectrometry. Purity of all the compounds have been 
checked by thin layer chromatography. 
All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger, Candida albicans at a concen- 
tration of 2000/1000/500 µg/ml. The biological activity of the synthesized compou- 
nds have been compared with standard drugs. Some compounds have been found to 
have moderate activity as compared to known antibiotics recorded on Table No.7b. 
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IR SPECTRAL STUDIES OF ETHYL 4-(4-CHLOROPHENYL)-6-OXO-2-
(THIOPHEN-2-YL)CYCLOHEX-1-ENECARBOXYLATE.  
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Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr pallet 
method) 
Type Vibration Mode 
Frequency in cm
-1
 
Ref. 
Observed Reported 
Alkane 
C-H str. 
(asym.) 
2970 2975-2940 79 
C-H str. (sym.) 2870 2880-2860 78 
C-H def. 
(asym.) 
1410 1470-1435 78 
C-H def. (sym.) 1373 1395-1370 78 
Aromatic 
C-H str. 2970 2980-2940 77 
C=C str. 1537 1585-1480 80 
C-H I.p.(def) 1006 1125-1000 80 
C-H o.o.p. 
(def) 
704 700-600 77 
Thiophene >C=S str. 1579 1590-1550 79 
Cyclohexenone >C=O str. 1697 1700-1675 79 
Ester >C=O str. 1753 1735-1750 81 
Ether C-O-C str. 
(sym.) 
1006 1075-1020 80 
Halide -C-Cl str. 704 800-600 77 
S
O
O O CH3
Cl
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NMR SPECTRAL STUDIES OF ETHYL 4-(4-CHLOROPHENYL)-6-OXO-2-
(THIOPHEN-2-YL)CYCLOHEX-1-ENECARBOXYLATE.  
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (500MHz) 
Sr. No. 
Chemical shift in 
ppm 
Relative No. of 
proton 
Multiplicity Inference 
J value in 
Hz 
1.  1.29-1.31 3H triplet -CH3 4.5 
2.  2.10-2.37 2H doublet -CH2 4.5 
3.  3.00-3.02 1H multiplet -CH - 
4.  3.13-3.23 2H doublet -CH2 2.0 
5.  4.10-4.27 2H doublet -CH2 4.5 
6.  7.09-7.11 2H triplet Ar-Ha,a' 5.0 
7.  7.27-7.30 1H multiplet Ar-H - 
8.  7.44-7.48 2H multiplet Ar-Hb,b' - 
9.  7.94-7.97 2H multiplet Ar-H - 
 
S
O
O O CH3
Cl
a a'
b b'
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       Expanded aromatic region of NMR spectra 
 
MASS SPECTRAL STUDIES OF ETHYL 4-(4-CHLOROPHENYL)-6-OXO-2-
(THIOPHEN-2-YL)CYCLOHEX-1-ENECARBOXYLATE. 
 
S
O
O O CH3
Cl
m/z = 360
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PROPOSED MASS FRAGMENTATION OF ETHYL 6-OXO-4-ARYL-2-(THIOPHEN-2-
YL)CYCLOHEX-1-ENECARBOXYLATE. 
S
O
O O CH3
Cl
C19H17ClO3S
m/z = 360
S
O
O O CH3
C19H18O3S
m/z = 326 M
+2
S
O
O O
CH3
m/z = 312 M
-2
C18H16O3S
S
O
CH3
Cl
m/z = 302 M
-1
C17H15ClOS
S
O
Cl
m/z = 288 M
-1
C16H13ClOS
CH3 O
O O CH3
m/z = 258
C16H18O3
O
O O CH3
Cl
m/z = 278 M
-2
C15H15ClO3
CH3 O
O
Cl
m/z = 248 M
-1
C14H13ClO2
CH3 O
O OH
m/z = 230
C14H14O3
S
O
m/z = 148 M
-1
C7H6OS
+ + +
+
+
+
+
+
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary bath 
on controlled temperature heating mental. The crystallization of all the compounds was 
carried out in appropriate solvents. TLC was carried out on silica coated aluminum sheet 
(Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
 
[A] Preparation of (E)-1-Phenyl-3-(thiophen-2-yl)prop-2-en-1-ones  
These were prepared by condensation of thiophen-2-carbaldehyde and substituted 
acetophenone in the presence of sodium hydroxide as described by N. M. Rateb
82
 and 
Dalla Via
83
, M. M. Hania
84
  
[B] Preparation of Ethyl 4-(4-chlorophenyl)-6-oxo-2-(thiophen-2-yl)cyclohex-1-
enecarboxylate 
A mixture of (E)-1-(4-chlorophenyl)-3-(thiophen-2-yl)prop-2-en-1-one (2.48gm, 
0.01mol) and ethyl acetoacetate (1.3 ml, 0.01mol) in solid sodium ethoxide (25 gm) was 
refluxed for 8 hrs. The crude product was isolated by pouring the mixture into ice-cold 
water followed by neutralization with conc. HCl and crystallized from ethanol. Yield 
68%, M. P. 140 °C, Anal. Calcd. for C19H17ClO3S requires: C, 63.24; H, 4.75; O, 13.30%, 
Found: C, 63.28; H, 4.71; O, 13.33%.  
Similarly other Ethyl 6-oxo-4-aryl-2-(thiophen-2-yl)cyclohex-1-enecarboxylate 
were prepared. The physical data are recorded in Table No. 7a.  
[C] Antimicrobial activity of Ethyl 6-oxo-4-aryl-2-(thiophen-2-yl)cyclohex-1-
enecarboxylates 
Antimicrobial testing were carried out as described in part - I, Section - I (D). The 
zones of inhibition of test solutions are recorded in Table No. 7b.  
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Table-7a: Physical constants of Ethyl 6-oxo-4-aryl-2-(thiophen-2-yl)cyclohex-1- 
  enecarboxylates 
S
O O CH3
O
R
 
 
 
 
 
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd./Found 
C H N 
7a C6H5 
C19H18O3S 
326.40 
110 66 
69.91 
(69.74) 
5.56 
(5.30) 
- 
7b 2-Cl-C6H4- 
C19H17ClO3S 
360.85 
95 58 
63.24 
(63.06) 
4.75 
(4.55) 
- 
7c 4-Cl-C6H4- 
C19H17ClO3S 
360.85 
120 54 
63.24 
(63.07) 
4.75 
(4.68) 
- 
7d 3-Cl-C6H4- 
C19H17ClO3S 
360.85 
115 63 
63.24 
(63.04) 
4.75 
(4.61) 
- 
7e 4-NO2-C6H4- 
C19H17NO5S 
371.40 
114 55 
61.44 
(61.23) 
4.61 
(4.11) 
3.77 
(3.59) 
7g 4-NH2-C6H4- 
C19H17NO3S 
341.42 
119 52 
66.84 
(66.57) 
5.61 
(5.54) 
4.10 
(4.05) 
7h 2-OH-C6H4- 
C19H18O4S 
342.40 
124 45 
66.65 
(66.38) 
5.30 
(5.04) 
- 
7i 4-OH-C6H4- 
C19H18O4S 
342.40 
109 49 
66.65 
(66.48) 
5.30 
(5.24) 
- 
      TABLE 7B : ANTIMICROBIAL ACTIVITY OF ETHYL 6-OXO-4-ARYL-2-(THIOPHEN-2-YL)CYCLOHEX-1-  
       ENECARBOXYLATES (in µg/ml) 
No. Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus 
aureus 
Bacillus subtilis Escherichia coli 
Salmonella 
paratyphi B 
Aspergillus niger Candida albicans
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 
1. 7a + + + - - + + + + + + + + + - + + + 
2. 7b + + + + + + + + + + + + + + + + + - 
3. 7c + + + + + + - - - + + - + + - + + - 
4. 7d + + + + + + + + + + + + + + - + + - 
5. 7e + + - + + + + + - - - - + + - + + - 
6. 7g + + + + + + + + + + + + + + - + + - 
7. 7h + + + - - + + + + + + + + + - + + + 
8. 7i - - - - - - - - - + + - - - - - - - 
    Where (+)  =  New synthesized compounds were active against microorganism 
   (-)  =  New synthesized compounds were inactive against microorganism 
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SECTION-II 
 
INTRODUCTION 
Indazole was first described in 1869, by Buchner that the benzo derivatives of 
pyrazole is called benzopyrazole or indazole (6). Indazoles can be considered as either 
azaindazoles or azaisoindazoles. The compounds of medicinal interest in this group so far 
have been non-steroidal anti-inflammatory agents or analgesic.  
N
N
H
(6)  
 
SYNTHETIC ASPECT  
 Literature
37-39
 survey different methods are available for the preparation of 
indazoles. Some of them are as under.  
1. Indazoles can be synthesized from chalcone derivatives via cyclohexenone 
derivatives
40,41
.  
R R'
O K2CO3
EAA in dry 
acetone
R R'
O
COOEt
NH2NH2
CH3COOH
N
H
N
O
R R'
(7)  
2. Indazoles42 can prepared by the cyclization of 2,3-dialkoxy or hydroxyl 
acetophenones hydrazones in presence of PPA. 
3. Cyclocondensation of activated acetylene with hydrazine afforded indazole 
derivatives
43
 
R
Cl
NO2
NH2NH2
N
N
H
R Cl
NO2
(8)  
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4. Reaction of substituted azo sulfides with potassium-t-butoxide in DMSO led to 
the corresponding 1-H indazole derivatives
44
.  
5. Okhim L-Yu et al.45
 
synthesized some indazole derivatives by heating benzylidene 
aniline derivatives in DMF.  
6. Indazole ring system46 can also be designed by the diazotization of substituted 
anilines eg. o-toludine.  
7. Caron Stephane and co-workers47 have described that the condensation of 2-acyl 
aryl mesylates with hydrazines affords corresponding indazole derivatives.  
CH3
N
N SCH3
DMSO
t-BuOK N
N
H
R
R
(9)  
BIOLOGICAL EVALUATION 
 
Indazole derivatives are biologically interesting class of compounds. They are 
associated with various pharmacological properties such as.  
1 Antiallergic48 
2 Antihypertensive49
 
 
3 Antiinflammatory50 
4 Antineoplastic51
 
 
5 Antipyretic52 
6 Antipsychotics53
 
 
7 Antitumor54
 
 
8 Antiviral55
 
 
9 Cytotoxic56
 
 
10 Enzyme inhibitors57
 
 
11 Fungicidal58
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12 Herbicidal59
 
 
13 Pesticidal60
 
 
14 Sedative61
 
 
Indazoles are non-steroidal anti-inflammatory agents or analgesic. The prototype 
is Benzydamine
62
 
(10), a fairly potent nonsteroidal anti-inflammatory agent with 
significant antipyretic and analgesic properties. The other example are Bendazue
63
 (11) 
and Tetrydamine
64
 (12).  
NH
N
O
N CH3
CH3
(10)
N
N
NH CH3
CH3
(11)
N
N
OCH2COOH
(12)  
 
Ooe Taka nori et al.
65
 reported some indazoles as hematinics, immuno stimulants 
and antitumor agents. Some indazole derivatives
66
 showed activity for enhancing 
macrophage phagocytosis, improving immunity and antitumor activity. Yamaguchi 
Masahisa et al.
67
 prepared some indazole derivatives as novel antiasthamatic agents with 
dual activities of thromboxane-α
2
 synthetic inhibitor and bronchodialations.  
Lavielle Gilbert et al.
68
 documented the [(pyrrolidinyl) methyl]-indazoles (13) as 
5-HT
3
 like antagonist and remedy for the treatments of migrains and Schizoprenia
69
. 
Meshaw Richard Eric et al.
70
 have synthesized 4-amino ethoxy indazoles useful as 
dopamine D2
 
agonists. Allan David and co-workers
71
 
have synthesized some indazole 
derivatives (14) and postulated them as fibrinogen antagonist.  
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N
H
N
N
CH3
(13)
R
N
N
N
R
R'
HOOC
(14)  
 Effland Richard Charles et al.
72
synthesised 3-(pyridyl amino)-indazoles (15) and 
reported their use as antidepressants and anxiolytics. Some sulfonyl indazoles (16) 
synthesized by Duzinska-usareulicz et al.
73
 
have been found to possess anti-inflammatory 
activity.  
N
H
N
NH
N
(15)
S
O
O
N
H
N
R'
R
(16)
 
Several co-workers have patented indazole derivatives useful as hypolipidemic or 
hypocholersterolemic
74
 and cardiovascular
75
 agents.  
Among variety of pharmacological properties have been encountered with 
indazole systems. Keeping the above in mind some novel indazole derivatives have been 
synthesized which have been described as under.  
Work done from our laboratory 
H. S. Joshi et al
76
 have synthesized some indazoles (17) and reported their 
antitubercular and antimicrobial activity.  
N
H
N
O
Cl
R
(17)  
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K. H. Popat
76 
have synthesized 6-carbethoxy-5-(3'-chlorophenyl)-3-aryl-2-
cyclohexenones as a anticancer, antitubercular and antimicrobial agent. 6-Aryl-4-(3'-
chlorophenyl)-3-oxo-2,3a,4,5-tetrahydro-1H-indazoles have been reported by V. V. 
Kachhadiya.
77
 D. H. Vyas
1
 have synthesized some cyclohexenones and indazoles 
derivatives as an antimicrobial and antitubercular agent. 
Thus with an effort to capitalize the biological potential of the heterocyclic 
system and to provide more interesting compounds for biological screening, we have 
under taken the synthesis of several indazoles which has been described as under. 
   
SECTION - II: SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL- 
              4,5DIHYDRO-6-(THIOPHEN-2-YL)-2H-INDAZOLE3(3aH)-ONES.
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SECTION - II 
 SYNTHESIS AND BIOLOGICAL SCREENING OF 4-ARYL-4,5DIHYDRO-6-
(THIOPHEN-2-YL)-2H-INDAZOLE-3(3aH)-ONES. 
The synthesis of indazole has attracted the attention of chemists because of their 
potential pharmacodynamic properties. Looking to the interesting properties of indazoles, 
it appeared to synthesize a series of 4-aryl-4,5dihydro-6-(thiophen-2-yl)-2H-indazole-
3(3aH)-one of type (VIII) for obtaining biologically potents molecules by reacting ethyl 
6-oxo-4-aryl-2-(thiophen-2-yl)cyclohex-1-enecarboxylate of type (VII) with hydrazine 
hydrate in presence of glacial acetic acid.  
S
O
O
CH3
O
R
NH2.NH2.H2O S N
NH
O
R
Type (VIII) R=ArylType (VII)  
 
 The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and 
further supported by mass spectrometry. Purity of all the compounds have been 
checked by thin layer chromatography. 
All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards  Aspergillus niger, Candida albicans at a concen- 
tration of 2000/1000/500 µg/ml. The biological activity of the synthesized compo- 
unds have been compared with standard drugs. Some compounds have been found to 
have moderate activity as compared to known antibiotics recorded on Table No.8b. 
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IR SPECTRAL STUDIES OF 4-ARYL-4,5DIHYDRO-6-(THIOPHEN-2-YL)-2H-INDA 
ZOLE-3(3aH)-ONE.  
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Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr pallet 
method) 
 
 
Type Vibration Mode 
Frequency in cm
-1
 
Ref. 
Observed Reported 
Alkane 
C-H str. 
(asym.) 
2964 2975-2940 79 
C-H str. (sym.) 2870 2880-2860 78 
C-H def. 
(asym.) 
1471 1470-1435 78 
C-H def. (sym.) 1369 1395-1370 78 
Aromatic 
C-H str. 2964 2980-2930 77 
C=C str. 1535 1585-1480 80 
C-H I.p.(def) 1058 1125-1000 80 
C-H o.o.p. 
(def) 
648 700-600 77 
Thiophene >C=S  str. 1585 1590-1550 79 
Indazole  >C=N  str. 1735 1735-1717 79 
Amide >C=O  str. 1735 1735-1717 81 
Amine -NH- str. 3122 3350-3000 77 
Halide C-Cl str. 648 800-600 80 
S N
NH
O
Cl
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NMR SPECTRAL STUDIES OF 4-ARYL-4,5DIHYDRO-6-(THIOPHEN-2-
YL)-2H-INDAZOLE-3(3aH)-ONE. 
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (500MHz) 
 
Sr. No. 
Chemical shift in 
ppm 
Relative No. of 
proton 
Multiplicity Inference 
J value in 
Hz 
1 2.10-2.37 2H doublet -CH2 4.5 
2 2.78 1H singlet -CH - 
3 2.81 1H multiplet -CH - 
4 5.48 1H singlet -CH - 
5 6.92-6.95 2H multiplet Ar-Ha,a' - 
6 7.29-7.30 1H doublet Ar-H 7.5 
7 7.41-7.42 2H doublet Ar-Hb,b' 7.5 
8 7.68-7.69 2H doublet Ar-2H 7.5 
9 8.02 1H singlet -NH - 
     
S N
NH
O
Cl
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    Expanded aromatic region of NMR spectra 
 
MASS  SPECTRAL STUDIES OF 4-ARYL-4,5DIHYDRO-6-(THIOPHEN-2-YL)-2H-
INDAZOLE-3(3aH)-ONE 
 
S N
NH
O
Cl
m/z = 328
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PROPOSED MASS FRAGMENTATION OF 4-ARYL-4,5DIHYDRO-6-(THIOPHEN-2-
YL)-2H-INDAZOLE-3(3aH)-ONE. 
 
S N
NH
O
Cl
m/z = 328
C17H13ClN2OS
S
CH3
Cl
m/z = 288 (M
-1
)
C17H13ClS
N
NH
O
CH2
m/z = 162(M
-2
)
C9H10N2O
S
CH2
CH3
m/z = 138(M
-1
)
C8H10S
N
NH
O
CH3
m/z = 112(M
+1
)
C5H8N2O
N
NH
O
CH3
m/z = 97(M
-1
)
C4H6N2O
CH3
NH2
NH
O
m/z = 74(M
+1
)
C2H6N2O
CH3
CH3
m/z = 58(M
-1
)
C4H10
+
+ +
+
+ +
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary bath 
on controlled temperature heating mental. The crystallization of all the compounds was 
carried out in appropriate solvents. TLC was carried out on silica coated aluminum sheet 
(Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
[A] Synthesis of (E)-1-Phenyl-3-(thiophen-2-yl)prop-2-en-1-ones   
   See Part - I, Section - II (A). 
[B] Synthesis of Ethyl-4-(4-chlorophenyl)-6-oxo-2-(thiophen-2-yl)cyclohex-1-enecar- 
boxylate 
See Part - I, Section - II (B).   
[C] Synthesis of 4-(4-Chlorophenyl)-4,5-dihydro-6-(thiophen-2-yl)-2H-indazole-3(3a 
H)one  
To a solution of Ethyl-4-(4-chlorophenyl)-6-oxo-2-(thiophen-2-yl)cyclohex-1-
enecarboxylate(3.60gm, 0.01mol) in ethanol hydrazine hydrate (0.76gm, 0.01mol) was 
added and mixture was refluxed at 90 °C for 6 hrs on waterbath. The solid obtained upon 
cooling was filtered and crystallized from methanol. Yield 72%, M.P. 220 °C, Anal 
Calcd. for C17H13ClN2OS Cald.: C, 62.10; H, 3.98 N, 8.52%, Found: C, 62.05; H, 3.95; 
N, 8.56%.  
   Similarly other 4-aryl-4,5dihydro-6-(thiophen-2-yl)-2H-indazole-3(3aH)-ones 
were prepared. The physical data are recorded in Table No. 8a.  
[D] Antimicrobial activity of 4-Aryl-4,5dihydro-6-(thiophen-2-yl)-2H-indazole-
3(3aH)-ones. 
Antimicrobial testing were carried out as described in Part-I, Section-I (D). The 
zones of inhibition of test solutions are recorded in Table No. 8b 
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Table-8a: Physical constants of 4-Aryl-4,5dihydro-6-(thiophen-2-yl)-2H-inda-  
             zole-3(3aH)-ones 
S N
NH
O
R
 
 
 
 
 
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd./Found 
C H N 
8a C6H5 
C17H14N2OS 
294.37 
135 52 
69.36 
(69.19) 
4.79 
(4.54) 
9.52 
(9.36) 
8b 2-Cl-C6H4- 
C17H13ClN2OS 
328.81 
124 59 
62.10 
(62.04) 
3.98 
(3.90) 
8.52 
(8.37) 
8c 4-Cl-C6H4- 
C17H13ClN2OS 
328.81 
156 62 
62.10 
(62.00) 
3.98 
(3.69) 
8.52 
(8.28) 
8d 3-Cl-C6H4- 
C17H13ClN2OS 
328.81 
142 58 
62.10 
(62.01) 
3.98 
(3.86) 
8.52 
(8.49) 
8e 4-NO2-C6H4- 
C17H13N3O3S 
339.36 
149 51 
60.17 
(60.02) 
3.86 
(3.79) 
12.38 
(12.29) 
8g 4-NH2-C6H4- 
C17H15N3OS 
309.38 
154 44 
66.00 
(65.88) 
4.89 
(4.73) 
13.58 
(13.32) 
8h 2-OH-C6H4- 
C17H14N2O2S 
310.37 
162 38 
65.79 
(65.61) 
4.55 
(4.46) 
9.03 
(8.97) 
8i 4-OH-C6H4- 
C17H14N2O2S 
310.37 
148 64 
65.79 
(65.64) 
4.55 
(4.48) 
9.03 
(8.91) 
        TABLE   8B : ANTIMICROBIAL ACTIVITY OF 4-ARYL-4,5DIHYDRO-6-(THIOPHEN-2-YL)-2H-INDAZOLE- 
         3(3aH)-ONES (in µg/ml)  
No. 
Code 
No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus 
aureus 
Bacillus subtilis Escherichia coli
Salmonella 
paratyphi B 
Aspergillus niger Candida albicans
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500
1. 8a + + - + + - + + + + + + + + + + + - 
2. 8b + + - + + + + + + + + - + + + + + + 
3. 8c + + + + + + + + + + + + + + + + + + 
4. 8d + + - + + - + + + + + + + + + + + - 
5. 8e + + + + + + + + + + + - + + + + + + 
6. 8g + + + + + + + + + + + - + + - + + - 
7. 8h + + - + + - + + + + + + + + + + + - 
8. 8i + + - + + - + + + + + - - - - - - - 
             Where (+)  =  New synthesized compounds were active against microorganism 
       (-)  =  New synthesized compounds were inactive against microorganism 
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INTRODUCTION  
 The study of mannich reaction attracted a great deal of attention to the chemists 
because it plays a vital role due to their wide range of biological and industrial 
applications. Mannich bases are also employed as intermediate in chemical synthesis.
1-3 
  
Much interest has been focused on the synthesis of mannich bases due to its wide 
variety of pharmacological activities. Mostly, they are found to be antineoplastic, 
analgesic and antibiotic drugs. Several therapeutic important molecules prepared through 
mannich reaction have received more attention in recent years.
4-6
 Mannich bases have 
gained important because of their technological application in polymer chemistry
7
, 
especially as paints and surface active agent and it also exhibits complexation 
characteristic with many transition metal ions. 
SYNTHETIC ASPECT 
  Different methods have been cited to synthesized some new mannich bases by 
several co-workers using various interesting substrates. 
1. Several new aminobenzylated mannich bases (2) have been prepared by 
condensing reaction between heterocyclic secondary amines, aldehydes and 
acetamide, urea and thiourea.
11
 
X NH +
HO
R
O
NH2 CH3
X N
H
OH
X N
H
NH NH
H
N X
S
R R
(2)
R=Ary l
X=O/CH 2
 
2. B. Anil Reddy9 have synthesized benzimidazole using mannich base. 
3. E. Philip Jesudason10 have prepared mannich bases of benzimidazoles. 
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4. Gabriela Laura Almajan et al.8 synthesized mannich bases (1) from some triazole 
moiety. 
X S
O
O
N
NH
N
S
N
Ar
X S
O
O
N
N
N
S
N
Ar
N
O
morpholine, CH2O
X=H,Cl
(1)
 37 % reflux
 
BIOLOGICAL EVALUATION  
A wide variety of pharmacological properties and industrial applications have 
been encountered with several mannich bases such as, 
1. Antibacterial12 
2. Antitumor13 
3. Antiinflammatory14 
4. Cytotoxic Activity15 
5. AntiHIV16 
6. Antimalarial17 
7. Antiproliferation18 
8. Antiparasitic19 
9. Antitubercular20 
10. Antifungal21  
11. Anticancer22 
 Several therapeutic important molecules containing heterocyclic secondary 
amines are well known. For example, Manafflazineis a famous antiarthritic agent and 
minorine is used as antidepressant. 
 S. K. Sridhar
23
 have synthesized some new mannich bases and screened for anti-
inflammatory activity. A. R. Bhat et al.
24 
have reported mannich bases of quinoxaline and 
evaluated for their antibacterial, antifungal and antitubercular activities. 
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 P. Y. Shirodkar and M. M. Vartak
25
 have studied the antitubercular activity of 
mannich bases of 6-nitro-3-N-arylamino methyl-1,2,3,4-tetrahydro-4-oxo-2-thioquinoxa- 
lines (3). 
N
N
H
O2N
O
NH
R
(3)  
 Craig J. Roxburgh
26
 et al have reported mannich bases and tested them for local 
anesthetic activity (4). 
H
S
O
O
N
(4)  
 Christina Reichwald et al.
27
 have synthesized mannich bases of 9-tert-Butyl-2-
phenylethinylpaullone from 1,3-diarylpropenones using aromatic aldehydes and 
acetophenone derivatives as starting materials and studied their antileishmanial activity. 
N
H O
C(CH3)3
(5)  
 Yan Huang, et al.
28
 have synthesized some mannich bases and reported as 
anticancer agent. Ya. L. Garazd et al.
29
 have prepared mannich bases of hydroxyl- 
coumarines (6) which posses various biological activities. 
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O
N
X
O
OH
CH3
(6)
X = NCH3
 
Work done from our laboratory  
K. S. Nimavat
30
 have synthesized some new aminobenzylated mannich bases 
from 3-bromobenzaldehyde and reported as an antimicrobial agent. Mannich bases of 
4-amino-3-mercapto-5-pyridin-3'-yl-[1,2,4]-triazole reported by T. K. Dave
31
. Green 
chemistry approach to potentially bioactive aminobenzylated mannich bases through 
active hydrogen compounds reported by S. L. Vasoya
32
. 
 Thus with an effort to capitalize the biological potential of the heterocyclic 
system and to provide more interesting compounds for biological screening, we have 
under taken the synthesis of several mannich bases which has been described as under. 
 . 
SECTION-I : SYNTHESIS AND BIOLOGICAL SCREENING OF N,N- 
    ((DIALKYL/ARYLAMINO)(THIOPHEN-2- YL)METHYL)  
     ACETAMIDES. 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL SCREENING OF N,N-((DIALKYL/ARYL 
AMINO)(THIOPHEN-2-YL)METHYL)ACETAMIDES 
 Mannich bases compounds have gained interest in last several year due to their 
biological, physiological and therapeutic activity. With an intention to synthesizing better 
therapeutic drugs, we have synthesized some new amino benzylated mannich bases of 
type (IX) by condensation of acetamide with secondary amine and thiophene-2-
carbaldehyde. 
R-H
+
NH2-CO-CH3
H
N
S
R
H O
CH3
Type (IX)  
S
O
R = 
N
,
N
,
N
O
&
N
N
CH3  
 The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and 
further supported by mass spectrometry. Purity of all the compounds have been 
checked by thin layer chromatography. 
All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger, Candida albicans at a 
concentration of 2000/1000/500 µg/ml. The biological activity of the synthesized 
compounds has been compared with standard drugs. Some compounds have been 
found to have moderate activity as compared to known antibiotics recorded on Table 
No.9b. 
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IR SPECTRAL STUDIES OF N-(MORPHOLINO(THIOPHEN-2-YL) METH- 
YL)ACETAMIDE. 
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Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr pallet 
method) 
 
Type Vibration Mode 
Frequency in cm-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Ref. Observed Reported 
Alkane 
C-H str. 
(asym.) 
2929 2975-2940 33 
C-H str. (sym.) 2852 2880-2860 34 
C-H def. 
(asym.) 
1438 1470-1435 33 
C-H def. (sym.) 1365 1395-1370 33 
Aromatic 
C-H str. 2929 2980-2940 34 
C=C str. 1519 1585-1480 33 
C-H I.p.(def) 1072 1125-1000 34 
C-H o.o.p. 
(def) 
667 700-600 33 
Thiophene >C=S str. 1556 1590-1550 35 
Mannich base 
C-N str. 1365 1380-1310 48 
C-O-C str. 
(sym.) 
1035 1075-1020 34 
Amide >C=O str. 1666 1695-1660 33 
Amine -NH-str 3271 3350-3000 35 
S
NH
CH3
O
N
O
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NMR SPECTRAL STUDIES OF N-(MORPHOLINO(THIOPHEN2-YL) 
METHYL)ACETAMIDE  
 
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (500MHz) 
 
 
Sr. No. Chemical shift in ppm Relative No. of proton Multiplicity Inference 
1 1.98-2.0 3H singlet -CH3 
2 2.44-2.46 4H multiplet -2CH2 
3 3.65-3.66 4H multiplet -2CH2 
4 5.90 1H singlet -CH 
5 6.99-7.00 1H multiplet -Ar-H 
6 7.17-7.19 1H multiplet -Ar-H 
7 7.57-7.75 1H multiplet -Ar-H 
8 9.10 1H singlet -NH 
S
NH
CH3
O
N
O
a a'
b b'
Studies on chemical… 
155   Aminobenzylated Mannich bases 
Expanded aromatic region of NMR spectra 
 
 
MASS SPECTRAL STUDIES OF N-(MORPHOLINO(THIOPHEN-2- 
YL)METHYL)ACETAMIDE. 
S
NH
CH3
O
N
O
m/z = 240
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PROPOSED MASS FRAGMENTATION OF N,N-((DIALKYL /ARYL AMINO) 
(THIOPHEN-2-YL)METHYL)ACETAMIDES 
S
NH CH3
ON
O
C11H16N2O2S
m/z = 240
S
NH
CH3
N
O
C10H16N2OS
m/z = 212
S
NH
ON
O
C10H14N2O2S
m/z = 226
S
NH2
N
O
m/z = 198
C9H14N2OS
S
N
O
C9H13NOS
m/z = 183
SH
N
O
m/z = 147
C6H13NOS
CH3
N
O
m/z = 115 (M
+2
)
C6H13NO
CH3
N
O
m/z = 101 (M
-1
)
C5H11NO
N
H
O
m/z = 87
C4H9NO
+ + +
+
+
+ +
+
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EXPERIMENTAL SECTION 
 
Melting points of all the synthesized compounds were taken in open capillary bath 
on controlled temperature heating mental. The crystallization of all the compounds was 
carried out in appropriate solvents. TLC was carried out on silica coated aluminum sheet 
(Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
[A] Synthesis of N-(Morpholino(thiophen-2-yl)methyl)acetamide. 
 A mixture of acetamide (4.40gm, 0.075mol) and morpholin (4.35ml, 0.05mol) 
was stirred to get a clear solution and it was cooled in ice bath. Thiophene 2-carbaldehyde 
(5.6 gm, 0.05mol) was added to the cold solution and the reaction mixture was stirred for 
3 hrs. at 5 °C in ice bath. A white semi solid was observed and stirred rarely. The crude 
product was washed with water and crystallized from methanol. Yield 57% m.p. 154 °C 
Anal. Cald. For C11H16N2O2S, : C, 54.98 ; H, 6.71 ; N, 11.66 % Found : C, 54.92 ; H, 6.74 
; N, 11.64 %.  
[B] Synthesis of N-((Piperidin-1-yl)(thiophen-2-yl)methyl)acetamide 
 A mixture of acetamide (4.40gm, 0.075mol) and piperidine (4.3ml, 0.05mol) was 
stirred to get a clear solution and it was cooled in ice bath. Thiophene 2-carbaldehyde (5.6 
gm, 0.05mol) was added to the cold solution and the reaction mixture was stirred for 
2hrs.at 5 °C in ice bath. The resulting solution was kept at room temperature for a week 
and stirred intermittently. The crude product was washed with water and CCl4, dried and 
crystallized from methanol. Yield 65% m.p. 123 °C Anal. Cald. For C12H18N2OS, : C, 
60.47 ; H, 7.61 ; N, 11.75 % Found : C, 60.48 ; H, 7.58 ; N, 11.71 %.  
[C] Synthesis of N-((1H-Indol-1-yl)(thiophen-2-yl)methyl)acetamide 
 A mixture of acetamide (4.40gm, 0.075mol) and indole (11.7gm, 0.1mol) was 
stirred to get a clear solution and it was cooled in ice bath. Thiophene 2-carbaldehyde (5.6 
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gm, 0.05mol) was added to the cold solution and the reaction mixture was stirred for 
1hrs.at 5 °C in ice bath. The solution was kept at room temperature for 3 days and stirred 
irregularly. The product was washed with water and CCl4, dried and crystallized from 
methanol. Yield 58% m.p. 131 °C Anal. Cald. For C15H14N2OS, : C, 66.64 ; H, 5.22 ; N, 
10.36 % Found : C, 66.61 ; H, 5.19 ; N, 10.31 %.  
[D] Synthesis of N-((Diethyl amino)(thiophen-2-yl)methyl)acetamide 
 A mixture of acetamide (4.40gm, 0.075mol) and diethyl amine (0.73gm, 0.1mol) 
was stirred to get a clear solution and it was cooled in ice bath. Thiophene 2- 
carbaldehyde (5.6 gm, 0.05mol) was added to the cold solution and the reaction mixture 
was stirred for 6 hrs. at 5 °C in ice bath. The resulting solution was kept at room 
temperature for 5 days and stirred occasionally. The crude product was crystallized from 
methanol. Yield 71% m.p. 156 °C Anal. Cald. For C11H18N2OS, : C, 58.37 ; H, 8.02 ; N, 
12.38 % Found : C, 58.35 ; H, 8.01; N, 12.31 %. 
[E] Antimicrobial activity of N,N-((Dialkyl/Arylamino)(thiophen-2-yl) meth- 
yl)acetamides. 
 Antimicrobial testing was carried out as described in Part-I, Section (D). 
The zones inhibitions of the compounds are recorded in Table No.9b. 
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Table-9a: Physical constants of N,N-((Dialkyl/arylamino)(thiophen-2-yl)methyl)  
      acetamides. 
 
H
N
S
R
H O
CH3
 
  
  
 
 
 
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd./Found 
C H N 
9a 
CH3
N
O
 
C11H16N2O2S 
240.32 
154 57 
54.98 
(54.82) 
6.71 
(6.54) 
11.66 
(11.44) 
9b 
N
 
C12H18N2OS 
238.34 
123 65 
60.47 
(61.36) 
7.61 
(7.58) 
11.75 
(11.61) 
9c 
N
CH3  
C15H14N2OS 
270.34 
131 58 
66.64 
(66.51) 
5.22 
(5.19) 
10.36 
(10.21) 
9d 
CH3
N
CH3 CH3
 
C11H18N2OS 
226.33 
156 71 
58.37 
(58.15) 
8.02 
(7.91) 
12.38 
(12.11) 
 
 TABLE 9B : ANTIMICROBIAL ACTIVITY OF N,N-((DIALKYL/ARYLAMINO)(THIOPHEN-2-YL)         
       METHYL)ACETAMIDES (in µg/ml) 
No. Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus 
aureus 
Bacillus subtilis Escherichia coli
Salmonella 
paratyphi B 
Aspergillus niger Candida albicans
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 
1. 9a - - - - - - + + - + + - + + + + + + 
2. 9b - - - - - - - - - - - - + + - + + - 
3. 9c + + - + + - + + - + + - + + - + + - 
4. 9d + + + + + + - - - - - - + + - + + - 
           Where (+)  =  New synthesized compounds were active against microorganism 
          (-)  =  New synthesized compounds were inactive against microorganism 
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INTRODUCTION 
 
 Bridge nitrogen containing fused heterocycles represents important building 
blocks in both natural and synthetic bioactive compounds which have been shown to 
possess diverse therapeutic activities
1
. Hence they are interesting target to be prepared to 
our research on medicinally interesting heterocyclic entities. Aza-indolizine are of two 
types, imidazo[1,2-α]pyridine (1) and imidazo[1,5-α]pyridine (2). 
 
N
N
N
N
(1) (2)  
 The aza-indolizine contains a phenyl ring fused to a imidazole ring is indicated in 
the structure, hence it is also known as imidazo[1,2-α]pyridine2. Several procedure for 
their synthesis have been extensively studied. Such studies have been stimulated by 
various promising applications, especially in the case of bridgehead nitrogen containing 
fused heterocyclic entities. 
 The constitution of imidazo[1,2-α]pyridine was reviewed by W. L. Mosby3 in 
1961. Imidazo[1,2-α]pyridine derivatives not only known for their pharmacological 
applications, they are also used in disperse dyes
4
. 
SYNTHETIC ASPECT 
 Classical methods have been reported in the literature for the synthesis of 
imidazo[1,2-α]pyridines. The procedure for synthesizing imidazo[1,2-α]pyridines have 
been described as under. 
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1. The synthesis of imidazo[1,2-α]pyridine from 2-aminopyridine with ω-
bromoacetophenone was reported by Tschitschibabine
5
. 
2. 2-Acetylimidazo[1,2-α]pyridine6 can be constructed by the cyclocondensation of 
2-aminopyridine with bromo butanedione. 
N
N
CH3
O
 
3. Reaction of 2-chloropyridine with 1,2,3-triazoles and subsequent elimination of 
nitrogen’s give the imidazo[1,2-α]pyridine7. 
NH
N
N N
N
+
N Cl  
4. Shankarappa A Biradar8 have synthesized 6-bromo-2-(3,4-dichlorophenyl) 
imidazo[1,2-α]pyridine using microwave irradiation from 5-bromo-2-
aminopyridine And 2-bromo-1-(3,4-dichlorophenyl)ethanone. 
 
N
Br
NH2
+ Cl
Cl
O
Br
microwave 
DMF N
N
Br
Cl
Cl
 
5. Jumat Salimon9 et al. synthesized imidazo[1,2-α]pyridine-3(2H)-one & 3-
Substituted-4-yl imidazo[1,2-α] pyridine from 2-aminopyridine. 
  
Studies on chemical… 
 
165      Introduction 
 
N NH2
N N
(a)
N N N N
O
(c)
(b)
(i) (ii) (iii)
(i) 4-pheny l phenacy l bromide
(ii) phenacy l chloride
(iii) chloro aceticacid
 
6. Synthesis of imidazo[1,2-α]pyridines using catalytic zinc chloride microwave 
irradiation from 2-aminopyridine and aryl aldehyde by Amanda L. Rousseau
10
. 
N NH2
R-CHO
R
2
NC 
catalyst
N
N
R
NH R
2
 
 
7. Synthesis of Cu(OTf)2-catalyzed imidazo[1,2-α]pyridines from a-diazoketones 
and 2-aminopyridines by J. S. Yadav
11
 
N NH2
Cu(OTf) 2+
O
N2Cl
CF3 DCE,80'C
Cl
CF3
N N
 
 
8. Paudler et al.12 have synthesized 5-amino-3-formylimidazo[1,2-α]pyridine from 
acid catalyzed hydrolysis of 1,4-diazacycl[3,2,2]azine. 
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N
N N
H
+
H3O
+ N
NH N
OH
H
N
N
ONH2
 
 
9. Zhu Dongjian et al.13 have synthesized imidazo[1,2-α]pyridines from 2-
aminopyridine and phenasyl bromide at R.T. 
N
CH3
NH2
+ PhC(=O)CH 2Br
10 min, rt N
N
CH3
Ph
 
MECHANISM 
N
NH2
R4
R3
R2
R1
+
X
R5 R6
O
N
+
NH2
R4
R3
R2
R1 R5
R6
O
X-
N
N
R4
R3
R2
R1
R5
R6
(3) (4) (5) (6)  
 The majority of imidazo[1,2-α]pyridine have been synthesized by the reaction of 
2- aminopyridine with a α-halocarbonyl compound which form oniumhalide which is 
further cyclize at room temperature to gives imidazo[1,2-α]pyridine. 
BIOLOGICAL EVALUATION 
 Imidazo[1,2-α]pyridines are potential bioactive agents due to their wide spectrum 
of therapeutic importance. A large number of substituted imidazo[1,2-α]pyridine 
derivatives are prepared and tested for varieties of biological activities such as, 
1. Anti-inflammatory, anti cancer14 
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2. Antiviral15,16 
3. Antianxiety17 
4. Antiulcer18,19 
5. Antifungal agents20 
6. Anthelmintic21 
7. Antibacterials22,23 
8. Hypnotic24 
9. Antiherpetie25,26 
10. Gastric antisecretory27,28 
11. Hypnoselective and anxioselective29 
12. b-Amyloid formation inhibitors30 
13. Benzodiazepine receptor agonists31 
14. Nonsedative anxiolytic32 
15. Active nonpeptide bradykinin B2 receptor antagonists
33
 
16. Cardiotonic agents34 
17. Anticytomegalo-zoster and antivaricellazoster virus35-37 
18. Long-acting local anesthetic38 
19. Calcium channel blockers39 
 
 Alexander C. Humphries and co-workers
40
 have synthesized 8-fluoro imidazo[1,2-
α]pyridine derivatives (7) and evaluated as a bioisosteric replacement for imidazo[1,2-
α]pyridine in an allosteric modulator ligand of the GABAA receptor. Carlos Jaramillo, 
and co-workers
41
 reported Stereo dynamics of Ar–CO rotation and conformational 
preferences of 2-amino-3-(2,4-difluorobenzoyl)-imidazo[1,2-α]pyridine. I. Aramori et 
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al.
42
 have been synthesized imidazo[1,2-α]pyridine derivatives which are highly potent 
and selective non-peptide bradykinin receptor antagonist (8). 
N
N
F
F
NC
CH3
CH3
OH
N
N
O
N
CH3
NH
O
O
N
O
CH3
CH3
CH3
Br
(7) (8)  
 
 Several imidazo[1,2-α]pyridine nucleus already in market which include 
alpidem
43
 [a ligand of both the central benzodiazepine receptors and the peripheral type 
(Mitochondrial) benzodiazepine receptor] has sedative and anxiolytic properties and 
zolpidem
43
 [a selective ligand for the central benzodiazepine receptor] is a hypnotic drug. 
Both alpidem and zolpidem have higher affinity for benzodiazepine-1 than for 
benzodiazepine-2 receptors
44
 and their interaction with various receptor has been 
reported
45
. 
N
N
O
N
Cl
Cl
CH2-CH2-CH3
CH2-CH2-CH3
Alpidem
N
N
O
N
CH3
CH3
CH3
CH3
Zolpidem  
 James J. Kaminski and co-workers
46
 have investigated imidazo[1,2-α]pyridine 
derivative 3-(cyanomethyl)-2-methyl-8-(phenylmethoxy)imidazo[1,2-α]pyridine (9) for 
an antiulcer activity. On the basis of the reported metabolism of zolimidine, they reported 
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that the 3-cyanomethyl and 8-phenylmethoxy group have been established as metabolic 
sites. 
O
N
N
CH3
NCH2C
(9)
N
N
PhSO2CH3-P
Zolmidine  
 Brian A. Johns et al.
47
 and Chaouni-Bendallah A. et al.
48
 synthesized a novel 
imidazo[1,2-α]pyridines (10) with potent activity against Herpes Simplex viruses. J. T. 
Starr et al.
49
 have synthesized 5-(2-Pyrimidinyl)-imidazo[1,2-α]pyridines (11) from 2-
amino-4-bromo-6-ethoxycarbonylpyridine and evaluated as a anti bacterial agent. 
N
N
N
N
NH
NH
F
(10)
N
N
NN
N
NH
NHEt
O
(11)  
 Sebastien Follot et al.
50
 have synthesized 2-(4-Fluorophenyl)-6-iodo-3-pyridin-4- 
limidazo[1,2-α]pyridine (12) from 6-iodo-2-(4-fluorophenyl)imidazo[1,2-α]pyridine and 
evaluated as anti-apoptosis agents. Imidazo[1,2-α]pyridine units appear as important 
building blocks in both natural and synthetic bioactive compounds
51-53
 and recognition on 
DNA binding and to yield different pharmacokinetic profile. 
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N
N
N
I
F
(12)  
 Mohamed A. Ismail and co-workers
54 
have synthesized some newer diamine 
imidazo[1,2-α]pyridine (13), 5,6,7,8-tetrahydo imidazo[1,2-α]pyridines and their 
corresponding N-hydroxy and N-methoxy analogues and evaluated against Trypanosoma 
b. rhodesiense (T. B. rhodesiense) and Plasmodium falciparum (P. falciparum). Luke R. 
Odell and co-workers
55
 have synthesized 6-substituted 3-amino-imidazo[1,2-α]pyridines 
(14) which has active against Mycobacterium tuberculosis glutamine synthetase 
inhibitors. R. B. Lacerda and co-workers56 have find out a novel analgesic and anti-
inflammatory 3-arylamine- imidazo [1,2-α] pyridine. 
N
N
NH
NH2
O
NH2
NH
(13)
N
N
NH
R
1
OH
O
CH3
(14)
 Thus the important role displayed by imidazo[1,2-α]pyridine and its derivatives 
for various therapeutic and biological activities prompted us to synthesize some 
Chalcones, Acetyl pyrazolines, Cyano pyridines, Thiopyrimidines, Oxopyrimidines, 
Mannich bases Isoxazoles, Schiff bases, Imidazolinone derivatives bearing Imidazo[1,2-
α]pyridine moiety in order to achieve compounds having better therapeutic activities 
described as in the following parts. 
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PART-I    :     SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL  
  SCREENING OF PYRAZOLES.  
PART-II  :   SYNTHESIS, CHARACTERIZATION AND BIOLOGICAL  
  SCREENING OF ARYLAMINOMETHYL MANNICH BASE  
  DERIVATIVES. 
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INTRODUCTION 
The term Chalcone was first coined by Kostanecki and Tambor
1
, who did 
pioneering work in the synthesis of natural coloring compounds. The chemistry of 
chalcones has generated intensive precise studies all over the world, especially interesting 
for their biological and industrial applications. Chalcones are colored compounds because 
of the presence of the chromophore and auxochromes. They are known as 
benzalacetophenones or benzylidene acetophenones.  
Chalcones (1) are characterized by their possession of a structure in which two 
aromatic rings are linked by an aliphatic three carbon chain. 
O
 
(1) 
The chalcones were known from different names like phenyl styryl ketones, 
beanzalacetophenone, α-phenyl acrylphenone, γ-oxo-α,γ-diphenyl-α-propylene and α-
phenyl-α-benzoethylene. 
SYNTHETIC ASPECT 
Claisen-Schmidt condensation 
A significant variety of methods are existing in literature for the synthesis of 
chalcones. The most convenient way is the Claisen-Schimidt condensation which 
involves aryl methyl ketones with aryl aldehyde in presence of alcoholic alkali
2
. 
Various modifications have been applied to Claisen-Schimidt condensation to get 
better yield and to synthesize biologically active analogs. Different catalysts have been 
reported to increase the yield of the reaction. Microwave synthesis strategies have also 
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applied to shorten the reaction time. Solid phase synthesis and combinatorial chemistry 
has made possible to generate library of chalcone derivatives.  
Solid-Phase Synthesis 
During the past two decades, combinatorial chemistry has appeared as one of the 
most valuable tools used to accelerate drug discovery and lead optimization processes.  
The emergence of this new field has promoted the transfer of solution-phase functional 
group transformations to the solid phase. 
A. R. Katritzky and coworker have synthesized chalcone derivatives by using 
sodium methoxide as a catalyst and Wang resin as a solid support
3
. Jian Cao and group 
reported polymer-supported selenium-induced solid–phase synthesis4. Recently Kamal 
Ahmed et al demonstrated solid-phase synthetic protocol for the chalcone and its 
derivatives
5
. 
Liquid-Phase Synthesis 
In the solid phase synthesis there are some disadvantages of this methodology 
compared to standard solution-phase synthesis, such as difficulties to monitor reaction 
progress, the large excess of reagents typically used in solid-phase supported synthesis, 
low loading capacity and limited solubility during the reaction progress and the 
heterogeneous reaction condition with solid phase
6
. 
Recently S. Yongjia et al reported soluble polymer-supported synthesis of 
chalcone derivatives
7
. Saravanamurugan and coworker used ZSM-5 catalyst and Liquid   
phase synthesis strategy for the derivative preparation
8
. E. V. Stoyanov and group 
demonstrated liquid phase synthesis of 2'-hydroxychalcone derivatives
9
.      
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Microwave Assisted Synthesis 
Microwave irradiation (MWI) has become an established tool in organic 
synthesis, because of the rate enhancements, higher yields and often, improved selectivity 
with respect to conventional reaction conditions
10
. 
In recent years, solvent free reactions using either organic or inorganic solid 
supports have received increasing attention. K. Mogilaiah and coworker describe 
synthesis of chalcones with p-toluene sulphonic acid (PTSA) as a catalyst under 
microwave irradiation and solvent free conditions
11
, S. Katade et al. reported recently the 
synthesis of chalcones with microwave irradiation and reported the reaction time 
decreases and overall yield of the product was increases
12
. 
Catalysts 
The other catalysts employed in synthesis and some time with advantages are 
alkali of different strength
13,14
, hydrochloric acid
15,16
, phosphorous oxychloride
17
, 
piperidine
18
, anhydrous aluminium chloride
19
, boron trifluoride
20
, amino acids
21
, 
perchloric acid
22
 etc. recently S. Ryo and group reported synthesis using Ruthenium as a 
catalyst and get better yield
23
.  
Chalcones can also be synthesized by condensing several other reagents instead of 
an aldehyde and ketone. 
1.  Nencki reaction with cinnamic acid on an aromatic compounds
24
. 
2.  Diazo coupling of phenyl diazonium chloride with benzoyl acrylic acid
25
. 
3.  Friedel craft's cinnamoylation
26
. 
4.  Fries rearrangement of aryl cinnamates
27
. 
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REACTION MECHANISM 
The following two mechanisms have been suggested for the synthesis of 
chalcones. 
(A) Base catalyzed 
(B)  Acid catalyzed 
 
(A)  Base catalyzed: 
Two alternative mechanisms were advanced for the reaction of benzaldehyde with 
acetophenone in the presence of a basic catalyst
28
.  
CH3
O
R
+ OH - CH2
-
O
R
+ OH2
H
O
R
1
C
+
H
O
-
R
1
CH2
-
O
R
C
+
H
O
-
R
1 + C
H
O
-
R
1
CH2 C
O
R
C
H
O
-
R
1
CH2 C
O
R + OH2 C
H
OH
R
1
CH2 C
O
R + OH
-
C
H
OH
R
1
CH2 C
O
R
- H2O
CHR
1
CH C
O
R
 
The intermediate aldol type products formed readily undergoes dehydration even 
under mild condition, particularly when R and R’ are aryl groups. 
(B) Acid catalyzed: 
 The formation of chalcones by the acid catalyzed condensation of acetophenones 
and aldehydes has been studied.
29
 The rate of reaction depends on the first power of the 
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concentration of aldehyde and the Hammet acidity function. Also the condensation step 
has been shown to be the rate determining step in this reaction. The following mechanism 
seems to be operable.  
CH3
O
R
CH2
OH
R
H
O
R
1 H
O
+
R
1
H
CH2
OH
R
H
O
+
R
1
H
+ R C CH
H
OH
C
R
1
OH
R C CH
H
O
+
C
R
1
OH
HOH H
R C C
H
C
R
1
O
R C CH
H
O
+
C
R
1
OH
HOH
H
R C C
H
C
R
1
O
+
H
 
REACTIVITY OF CHALCONES 
The chalcones have been initiated to be useful for the syntheses of multiplicity of 
heterocyclic compounds are as under.  
1. Chalcones with alkaline hydrogen peroxide in methylene dichloride gives 
oxirane.
30
 
2.  Chalcones with tertiary amine and N-methylmorpholinium salt in acetonitrile by 
using o-(diphenyl phosphinyl)hydroxylamine produces aziridines.
31
 
3.  Chalcones on reaction with benzamidine hydrochloride under microwave assisted 
condition in DMF affords dihydropyrimidines.
32 
4.  Chalcones on reaction with 2-aminopyridine in glacial acetic acid affords 
 pyridopyrimidines.
33
 
5.  Chalcone gives imine derivatives with amine in presence of sulfuric acid as 
 catalyst.
34
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6.  Chalcones on condensation with malononitrile in pyridine forms 2-amino-3- 
 cyanopyrans.
35
 
7.  Chalcones on reaction with thiourea in presence of alkali/acid yields 2- 
 thienopyrimidines.
36
 
8.  Chalcones react with P2S5 yielded 2-isothiazolidines.
37
 
9.  Chalcones react with sodium nitrile in presence of glacial acetic acid in ethanol 
 produces 2-1H-pyrimidines.
38
 
10.  Isoxazoles
39
 can be prepared by the treatment of chalcones with hydroxylamine 
 hydrochloride and sodium acetate. 
11.  Chalcones on condensation with 2-aminobenzothiazole in ethanol forms 2,3-
 dihydro-1,5-benzothiazepine.
40
 
12.  Pyrazoline
41
 and its derivatives can be prepared by the condensation of chalcones 
 with hydrazine hydrate and acetic acid. 
13.  Chalcones on treatment with guanidine hydrochloride in presence of alkali affords 
2-amino pyrimidines.
42
 
14.  Cyanopyridone derivatives
43
 can be prepared by the condensation of chalcones 
 with ethyl cyanoacetate.  
BIOLOGICAL EVALUATION 
Chalcones are potential biocides, some naturally occurring antibiotics and amino 
chalcones probably own their genetic activity due to the presence of α,β-unsaturated 
carbonyl group. Few of them are as below. 
1. Antibecterial44 
2. Antifeedant45 
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3. Antitubercular46 
4. Antimalarial47,48 
5. Antioxidant49 
6. Antifilarial50,51 
7. Anti-oedematogenic52 
8. Antimicrobial53-55 
9. Antihistaminic56,57 
10. Anticancer58,59 
11. Anti-Leishmania60 
12. Anti-inflammatory61 
Nakahara Kazuhiko et al.
62
 have synthesized chalcones as carcinogen inhibitors. 
Antitubercular agents of chalcone derivatives have been prepared by Lin Yuh-Meei et 
al.
63
 Ko Horng-Huey et al.
64
 have reported chalcones as anti-inflammatory agents. Some 
of the chalcones have been reported for their use for treatment of glaucoma
65
 and showed 
antifungal,
66
 aldose reductase inhibitors,
67
 anticancer
68
 activities. Satyanarayana M. et 
al.
69
 have synthesized chalcone (2) derivatives as anti hyperglycemic activity. 
O
ON
CH3
CH3 OH
R
(2)  
Hollosy F. et al.
70
 have prepared some new chalcones as plant derived protein 
tyrosine kinase inhibitors as anticancer agents. Meng C. Q. et al.
71
 have discovered some 
novel heteroaryl substituted chalcones as inhibitors of TNF-alpha-induced VCAM-1 
expression. V. K. Ahluwalia et al.
72
 have noted that 5-cinnamoylchalcones have exposed 
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good as antibacterial agents. Woo Duck Seo et al.
73
 have synthesized chalcone 
derivatives (3) reported as α-glucosidase inhibitors. 
O
R
(3)
S
O
O
NH CH3CH3
 
A. Araico and co-workers
74
 have synthesized chalcone derivatives as inhibitor of 
cyclo-oxygenase-2 and 5-lipoxygenase. Alcaraz M. J. et al.
75
 have described the role of 
nuclear factor-kappa-B and hemeoxygenase-1 in the action of an anti-inflammatory 
chalcone derivatives in RAW 264.7 cells. Xue C. X. et al.
76
 documented chalcones as 
antimalarial agents. Prem P. Yadav and co-workers
77
 have synthesized nitrogen and 
sulfur containing furanoflavonoids and thiophenylflavonoids which have been screened 
for antifungal and antibacterial activity. Opletalova Veronika et al.
78
 have synthesized 
chalcones and screened for their cardiovascular agents. H. H. Ko et al.
79
 have prepared 
some new chalcones for potent inhibition of platelet aggregation. S. Khatib et al.
80
 
synthesized some novel chalcones as potent tyrosinase inhibitors. Fu Y. et al.
81
 have 
demonstrated chalcones as licochalcone-A. O. Nerya et al.
82
 have prepared some new 
chalcones as potent tyrosinase inhibitors. Sung Hee Lee and co-workers
83
 have designed 
and synthesized chalcones and reported their anti-inflammatory activity. Paula Boeck, 
Camila Alves and Bartira Rossi-Bergmann
84
 have synthesized some newer chalcone 
analogues (4) which shows antileishmanial activity. 
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O
R1
R2
OH
O
CH3
O
CH3
CH3
(4)  
 Xiang Wu et al.
85
 have synthesized ferrrocenyl chalcones and reported their 
antiplasmodial activity. Ban H. S. et al.
86
 have synthesized some newer chalcones as 
inhibition of lipopolysaccharide-induced expression of inducible nitric oxide syntheses 
and tumor necrosis factor-alpha by 2'-hydroxychalcone derivatives in RAW 264.7 cells. 
Simon Feldbaek Nielsen et al.
87 
have described some chalcone derivatives (5) as 
antibacterial agents. 
N
H
N
N
N
O
(5)  
 Morever, Aneta Modzelewska et al.
88
 have prepared novel chalcone and bis 
chalcone derivatives having anticancer activity. Seo et al.
89
 reported the chalcones as a 
glucosidase inhibitors. 
Work done from our laboratory  
V. V. Kachhadia
90
 have synthesized some chalcone  derivatives (6) as 
antimicrobial and antitubercular agent. K. H. Popat
91,92
 have synthesized some chalcone  
derivatives(7) as antitubercular agents from 3-chlorobenzaldehyde. 
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S
Cl
O
NH
O
R
Cl
R
O
(7)(6)  
Synthesis of some chalcone  derivatives from aromatic aldehyde have been 
reported by P. T. Chovatia.
93
 D. H. Vyas
94
 reported some new pyrazoline (8) and 
isoxazole derivatives as antitubercular and antimicrobial agent and he also synthesized 
some new cyanopiperidinones (9) and cyanopyridones
95
, pyrazoline derivatives
96 
as a 
antimicrobial agent. 
N
N
O
R
S CH3
(8)
Br
Br
O
CH3
R
O
(9)  
D. J. Paghdar
97
 have reported chalcone derivatives bearing 4-(methylsulfonyl) 
phenyl nucleus (10) as potent antitubercular and antimicrobial agents Synthesis and 
evaluation of pharmacological activity of chalcone  derivatives (11) have been reported 
by M. R. Patel.
98
 Synthesis of some new pyrazolo[3,4-d]pyrimidines and thiazolo[4,5-
d]pyrimidines from arylidine and reported their antimicrobial activities by J. D. Akbari.
99
 
S
O
R
O
O
CH3
(10)
N
N
Cl
O
R
O
(11)  
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Chalcones have been proved to be an important intermediate for the synthesis of 
many heterocyclic compounds in organic chemistry. These facts pormpted us to 
synthesize some new chalcone derivatives bearing imidazo[1,2-a]pyridine nucleus, in 
order to achiving better therapeutic agents described as under.  
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF (2E)-3-(2-(4- 
  FLUOROPHENYL)-6-METHYLH-IMIDAZO[1,2-a]PYRIDIN-3- 
  YL)-1-ARYLPROP-2-EN-1-ONES  
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SECTION-I 
SYNTHESIS AND BIOLOGICAL SCREENING OF (2E)-3-(2-(4-FLUOROPHENYL)-6-
METHYLH-IMIDAZO[1,2-a]PYRIDIN-3-YL)-1-ARYLPROP-2-EN-1-ONES. 
 With the biodynamic activities of chalcones and as a fine synthon for different 
heterocyclic rings, the awareness has been paying attention on the creation of new 
chalcones. With a observation to obtained compounds having better therapeutic activity, 
we have synthesized (2E)-3-(2-(4-fluorophenyl)-6-methylH-imidazo[1,2-a]pyridin-3-yl)-1-
arylprop-2-en-1-ones. by the condensation of 2-(4-fluorophenyl)-6-methylH-imidazo[1,2-
α]pyridine-3-carbaldehyde. with various aromatic ketones by using alkali as catalyst. 
N
N
CH3
F
O
+
O
CH3 R
40% NaOH
N
N
F
O
R
CH3
 
       Type (X) R= Aryl 
 
 
 The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy and 
further supported by mass spectrometry.  
All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger, Candida albicans at a 
concentration of 2000/1000/500 µg/ml. The biological activity of the synthesized 
compounds have been compared with standard drugs. Some compounds have been 
found to have moderate activity as compared to known antibiotics recorded on Table 
No10b. 
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REACTION SCHEME 
  
 
N NH2CH3
+ F
O
Cl
DMF
140 C
N
N
CH3
F
DMF + POCl 3
Reflux 8-hrs
N
N
CH3
F
O
R-COCH3
40% alkali
N
N
CH3
F
R
O
Type (X)
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IR SPECTRAL STUDIES OF (2E)-3-(2-(4-FLUOROPHENYL)-6-METHYLH-
IMIDAZO[1,2-a]PYRIDIN-3-YL)-1-(4-METHOXYPHENYL)PROP-2-EN-1-ONE. 
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Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr 
pallet  method) 
Type Vibration Mode 
Frequency in cm
-1
 
Ref. 
Observed Reported 
Alkane 
C-H str. 
(asym.) 
2951 2975-2940 101 
C-H str. (sym.) 2845 2880-2860 101 
C-H def. 
(asym.) 
1456 1470-1435 102 
C-H def. (sym.) 1394 1395-1370 100 
Aromatic 
C-H str. 2951 2980-2930 100 
C=C str. 1541 1585-1480 101 
C-H I.p.(def) 1030 1125-1000 101 
C-H o. o. p. 
(def) 
669 700-600 100 
Imidazo[1,2-a 
]pyridine 
C=N 1599 1612-1593 100 
C-N 1166 1220-1020 100 
Chalcone 
C=C str. 1577 1580-1550 101 
C=O str. 1647 1640-1700 102 
Vinyl CH=CH str 3024 3050-3000 102 
Ether C-O-C str 1222 1260-1200 102 
Halide C-F str. 1166 1200-1000 101 
N
N
F
O
CH3
O
CH3
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NMR SPECTRAL STUDIES OF (2E)-3-(2-(4-FLUOROPHENYL)-6- METHYLH-
IMIDAZO[1,2-a]PYRIDIN-3-YL)-1-(4-METHOXYPHENYL)PROP-2-EN-1-ONE. 
 
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (500MHz) 
  
Sr. 
No. 
Chemical shift 
in ppm 
Relative No. 
of proton 
Multiplicity Inference J value in Hz 
1 2.45 3H singlet -CH3 - 
2 3.89 3H singlet -OCH3 - 
3 6.96-6.98 2H doublet -Ar-Ha-a' 9.0 
4 7.19-7.26 3H multiplet -Ar-H - 
5 7.44-7.47 2H multiplet -Ar-H - 
6 7.62-7.64 1H doublet -CH=CH 8.5 
7 7.69-7.70 1H doublet -CH=CH 7.5 
8 7.76-7.82 1H multiplet -Ar-H - 
9 7.91-7.93 2H doublet -Ar-Hb,b' 8.5 
10 8.29 1H singlet -Ar-H - 
N
N
F
O
CH3
O
CH3
a
a'
b
b'
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Expanded aromatic region of NMR spectra 
 
 
MASS SPECTRAL STUDIES OF (2E)-3-(2-(4-FLUOROPHENYL)-6- METHYLH-
IMIDAZO[1,2-a]PYRIDIN-3-YL)-1-(4-METHOXYPHENYL)PROP-2-EN-1-ONE. 
 
N
N
F
O
CH3
O
CH3
m/z = 386
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PROPOSED MASS FRAGMENTATION OF  (2E)-3-(2-(4-FLUOROPHENYL)-6- METHYLH-
IMIDAZO[1,2-a]PYRIDIN-3-YL)-1-(4-METHOXYPHENYL)PROP-2-EN-1-ONE. 
N
N
F
O
CH3
O
CH3
m/z = 386
C24H19FN 2O2
N
N
O
CH3
O
CH3
m/z = 368
C24H20N2O2
N
N
O
CH3
F
m/z = 356
C23H17FN 2O2
N
N
O
m/z = 324 (M
-1
)
C22H16N2O
N
N
O
CH3
F
C17H13FN 2O
m/z = 280
N
N
CH2
F
CH3
N
N
F
O
CH3
CH3
m/z = 294 (M
-2
)
C18H15FN 2O
m/z = 252
C16H13FN 2
N
N
F
CH3
m/z = 226 (M
-1
)
C14H11FN 2
N
N
CH3
C14H12N2
m/z = 208
N
N
CH3
CH3
m/z = 146 (M
+2
)
C9H10N2
+ + +
+
+
+
+
+
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary bath 
on controlled temperature heating mental. The crystallization of all the compounds was 
carried out in appropriate solvents. TLC was carried out on silica coated aluminum sheet 
(Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
[A] Synthesis of 2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-α]pyridine.  
 A solution of 6-methylpyridin-2-amine (27.0gm, 0.25mol) in DMF(100 ml) was 
added to 2-chloro-1-(4-fluorophenyl)ethanone (15.4gm, 0.1mol) and the reaction mixture 
was refluxed with stirring for 6 hrs. Cool the content, the solid separated was filtered and 
dried in vacuo. Yield 68%, m.p192 °C, Anal. Calcd. for C11H14FN2: Require: C, 74.32, 
H, 4.90, N, 12.38 % ; Found: C, 74.30, H, 4.96, N, 12.35 %. 
[B] Synthesis of 2-(4-Fluorophenyl)-6-methylH-imidazo [1,2-α]pyridine-3-carbal- 
dehyde.  
 To a well stirred solution of phosphorus oxychloride (11 ml), chloroform (32 ml) 
and DMF (8 ml) maintained at 0-10 °C. was added slowly to a solution of 2-(4-
Fluorophenyl)-6-methylH-imidazo[1,2-α]pyridine. (4.52gm, 0.02mol) in chloroform (140 
ml). The mixture so obtained was refluxed for 8 hrs., the solution was evaporated to 
dryness in vacuo. the residue was treated with cold water and filtered and crystallized 
from methanol. Yield 59%, m. p. 186 °C , Anal. Calcd. for C15H11FN2O Require: C, 
70.86, H, 4.36, N, 11.02 %; Found: C, 70.81, H, 4.29, N, 11.01 %. 
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[C] Synthesis of (2E)-3-(2-(4-Fluorophenyl)-6-methylH-imidazo [1,2-α]pyridin-3-
yl)-1-(4-methoxyphenyl)prop-2-en-1-one. 
 To a solution of 2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-α]pyridine-3-
carbaldehyde (2.54gm, 0.01mol), p-methoxyacetophenone (1.5gm, 0.01mol) in ethanol 
(25 ml) and 40% NaOH solution was added till the solution become basic. The reaction 
mixture was stirred for 24 hrs. The content was poured on to crushed ice. Upon 
neutralization the solid separated was crystallized from ethanol. Yield 61%; m.p.209 °C. 
Anal. Calcd. For C24H19FN2O2; Required : C, 74.60; H, 4.96; N, 7.25%; Found: C, 74.55; 
H, 4.91; N, 7.19%. 
 Similarly other (2E)-3-(2-(4-fluorophenyl)-6-methylH-imidazo[1,2-α]pyridin-3-
yl)-1-arylprop-2-en-1-ones.  have been  prepared.  The physical constants are recorded in 
Table No.10a. 
[E] Antimicrobial activity of (2E)-3-(2-(4-Fluorophenyl)-6-methylH-imidazo 
 [1,2-α]pyridin-3-yl)-1-arylprop-2-en-1-one. 
 Antimicrobial testing was carried out as described in part-(I), section-I(D). 
The zones of inhibition of compounds are recorded in Graphical Chart No.10b. 
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Table-10a:  Physical constants of (2E)-3-(2-(4-Fluorophenyl)-6-methylH-imidazo  
         [1,2-α]pyridin-3-yl)-1-arylprop-2-en-1-ones.  
N
N
F
O
CH3
R
 
 
 
 
 
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd. (Found) 
C H N 
10a C6H5- 
C23H17FN2O 
356.39 
166 65 
77.51 
(77.39) 
4.81 
(4.64) 
7.86 
(7.79) 
10b 4-CH3-C6H4- 
C24H19FN2O 
370.41 
147 62 
77.82 
(77.64) 
5.17 
(5.01) 
7.56 
(7.44) 
10c 2-CH3-C6H4- 
C24H19FN2O 
372.43 
158 58 
77.82 
(77.69) 
5.17 
(5.00) 
7.56 
(7.31) 
10d 2,5-(CH3)2-C6H3- 
C25H21FN2O 
384.44 
152 59 
78.10 
(78.04) 
5.51 
(5.34) 
7.29 
(7.17) 
10e 4-OCH3-C6H4- 
C24H19FN2O2 
386.41 
209 61 
74.60 
(74.45) 
4.96 
(4.81) 
7.25 
(7.19) 
10f 2,4-(Cl)2-C6H3- 
C23H15Cl2FN2O 
425.28 
176 47 
64.96 
(64.11) 
3.56 
(3.48) 
6.59 
(6.38) 
10g 4-Cl-C6H4- 
C23H16ClFN2O 
390.83 
165 69 
70.68 
(70.44) 
4.13 
(4.04) 
7.17 
(7.01) 
10h 3-Cl-C6H4- 
C23H16ClFN2O 
390.83 
158 68 
70.68 
(70.41) 
4.13 
(4.07) 
7.17 
(7.06) 
10i 4-NO2-C6H4- 
C23H16FN3O3 
 401.38 
189 55 
68.82 
(68.79) 
4.02 
(3.93) 
10.47 
(10.39) 
10j 4-F-C6H4- 
C23H16F2N2O  
374.38 
197 49 
73.79 
(73.66) 
4.31 
(4.19) 
7.48 
(7.38) 
TABLE 10B : ANTIMICROBIAL ACTIVITY OF (2E)-3-(2-(4-FLUOROPHENYL)-6-METHYLH-IMIDAZO 
[1,2-a]PYRIDIN-3-YL)-1-ARYLPROP-2-EN-1-ONES.  (in µg/ml) 
No. Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus 
aureus 
Bacillus subtilis Escherichia coli
Salmonella 
paratyphi B 
Aspergillus niger Candida albicans
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500
1 10a - - - + + - - - - - - - + + - + + - 
2 10b + + - + + - + + + + + + + + + + + + 
3 10c + + + + + + + + - + + + + + + + + + 
4 10d - - - + + - - - - - - - + + - + + - 
5 10e - - - + + - - - - - - - + + - + + - 
6 10f + + - + + + + + - + + + + + - + + + 
7 10g + + - + + - + + + + + + + + + + + + 
8 10h + + + + + + + + - + + - + + - + + - 
9 10i + + + + + + + + - + + + + + + + + - 
10 10j + + - + + - + + + + + + + + + + + + 
                   Where (+)  =  New synthesized compounds were active against microorganism 
         (-)  =  New synthesized compounds were inactive against microorganism 
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INTRODUCTION 
The chemistry of pyrazoles has been reviewed by C. H. Jarobe in 1967. Pyrazoles 
have attracted attention of medicinal chemists for both with regard to heterocyclic 
chemistry and the pharmacological activities associated with them. Pyrazole have been 
studied extensively because of ready accessibility, diverse chemical reactivity, broad 
spectrum of biological activity
1 
and varieties of industrial applications
2
. 
Pyrazole has three possible tautomeric structures, but 2-pyrazole (1) consist a 
unique class of nitrogen containing five member heterocycles. 
N
N
H  
(1) 
As evident from the literature in recent years a significant portion of research 
work in heterocyclic chemistry has been devoted to pyrazoles containing different alkyl, 
aryl and heteroaryl groups as substituents. 
SYNTHETIC ASPECT 
Different methods are available from the literature for the preparation of 2-
pyrazole derivatives. The most common procedure for the synthesis of 2-pyrazoles is the 
reaction of an aliphatic or aromatic hydrazine with α,β-unsaturated carbonyl compounds. 
R
1
O
R
2 NH2 NH
R
+ N
N
R
R
2
R
1
 
Alternative synthetic routes for improved yield, shorter reaction time and milder 
conditions to synthesize new analogs 
Solid-Phase Synthesis 
L. L. De
3
 reported cellulose beads as a new versatile solid support for 
Microwave-assisted synthesis of pyrazole and isoxazole libraries. 
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Cellulose NH2
R
O
YO
R
1
CSA (cat.)
MW
Cellulose
R
O
Y
O
R
1
NH
NH2XH
MW
Cellulose NH2
X
N
R
Y
O R
1
N
N
CH(OCH3)2  
Wang resin supported solid - phase synthesis of pyrazoledicarboxylic acid 
derivatives by functionalization of cyanoformate was reported by C. F. Morelli et al.
4 
OH O
CN
O
O
O N
N
R
3
R
1
O
O
R
2
 
 Similarly many other solid phase synthesis of pyrazole motif were reported using 
different solid support such as (4-formyl-3-methyoxyphenoxy)methylpolystyrene (FMP) 
resin
5
, polymer-supported vinylsulfone
6
, Kenner „safety catch‟ resin7, KOH powder8. 
 Liquid-Phase Synthesis 
X. L. Ren and coworkers
9
 have synthesized pyrazole derivatives using liquid 
phase synthesis strategy.   
R
1
R
2
R
CH3
N
NH
R
1
NH2R
NH2NH2 . HCl
 
V. N. Pathak and group reported 3,5-diarylpyrazole synthesis using phase transfer 
catalyst
10,11
, heterocyclic  pyrazole was synthesized by the W. C. Shen and coworkers
12
. 
Microwave Assisted Synthesis 
Microwave irradiation and solvent-free conditions was reported for the rapid and 
efficient synthesis by M. A. H. Zahran
13
. 
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R CHO +
NH2
XH
MW
NR
H
OH
N
X
R
 
 New "Green" approaches to the synthesis of pyrazole derivatives were reported 
by A. Corradi et al.
14
 
H
R H
O
R
1
NH2NHTs, K2CO3
MW, 130  °C
H
R H
N
R
1
NH Ts
N
N
R
R
1
H
 
Similarly in literature there are number of the report that uses the microwave 
irradiation for the rapid synthesis, high yield or towards the green approach of the 
reaction under solvent free conditions some of them are reported as below. 
 S. S. Chauhan derives pyrazoles from diaryl 1,3-diketones
15
 and also several 
author documented pyrazoles from 1,3-dipolar cycloaddition of diazo compounds to 
acetylene derivatives
16
, regiospecific synthesis of 5-trifluoromethyl-4,5-
dihydropyrazoles
17
, micro wave mediated combinatorial synthesis
18
, under dry media
19
, 
synthesis of trichlorometh- ylpyrazolines
20
, catalyzed by p-toluenesulphonic acid
21
, 
microwave studies on  synthesis
22
. 
P. D. Sauzem
23
 reported deign and microwave-assisted synthesis  of 5-
trifluoromethyl-4,5-dihydro-1H-pyrazoles, and one step synthesis of 3,5-disubstituted 
pyrazoles were  carried out by M. Outirite
24
. 
Catalysts 
 Many of the organic chemists prefer to use catalyst to get the desire product with 
high yield and within sort reaction time and to convert the reaction condition from drastic 
to easily operational with some specific catalyst.  
R. Ali reported stereoselective synthesis of N-vinyl pyrazoles in solvent-free 
conditions using dipotassium hydrogen phosphate powder
25
, Zinc-catalyzed synthesis of 
pyrazolines and pyrazoles via Hydrohydrazination were reported by K. Alex.
26
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NH
NH2
+
CH
OH 5 mol % Zn(OTf)2 N
N
CH3
CH
3
COOH, air N
N
CH3
R
R R
 
In literature there are number of the catalysts are used for the synthesis of 
pyrazole system like Conjugate base
27
, Iodine(III)
28
, Hafnium chloride
29
, 
Tungstophosphoric acid
30
, p-toluenesulphonic acid
31
, Sulfamic acid
32
, 
Ytterbium(III)perfluorooctanoate
33
, Silver(I)
34
, organocatalysts
35
.   
 
REACTION MECHANISM 
The following mechanism seems to be operable for pyrazoline by the 
condensation of chalcones with hydrazine hydrate
36
.
 
R
O
R
1
R CH
-
O
R
1
NH2
+ NH
R
2
NH
2
NH - R2
. .
H+ transfer
R
C
+
CH
-
OH
R
1
NH
NH
R
2
R
O
R
1
NH
NH
R
2
N N
H
R
1
OH
R
R
2
N N
H
R
1
R
2
R
- H
2
O
( I ) ( II )
( III ) ( IV )( V )
  
Nucleophillic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl 
system I forms species II, in which the negative charge is mainly accommodated by the 
electronegative oxygen atom.  
Proton transfer from the nitrogen to oxygen produces an intermediate and which 
simultaneously ketonises to ketoamine III. Another intramolecular nucleophillic attack by 
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the primary amino group of ketoamine on its carbonyl carbon followed by proton transfer 
from nitrogen to oxygen leads ultimately to hydroxyl amine IV. The later with a hydroxy 
group and amine group on the same carbon loses water easily to yield the pyrazolines V. 
BIOLOGICAL EVALUATION 
From the literature survey, it was revealed that 2-pyrazolines are better 
therapeutic agents. They possess valuable bioactivities like 
1.  Antiinflammatory
37,38
 
2. Analgesic
39,40
 
3.  Bactericidal
41
 
4.  Fungicidal
42,43
 
5.  Anticonvulsant
44
 
6.  Pesticidal
45,46
 
7.  Antidepressant
47
 
8.  Antiamoebic
48 
9. Insecticidal
49
 
10. Antineoplastic
50,51
 
11.  Herbicidal
52
 
 M. K. Shivnanda and co-workers
53
 have prepared pyrazolines and reported their 
antibacterial activity. Antimycotic activity of pyrazoline derivatives (2) have been 
reported by Joanna Matysiak and Andrzej Niewiadomy
54
. J. Almstead et al.
55
 have 
prepared pyrazolines as vascularization agent. T. Z. Gulhan and coworkers
56
 have 
prepared pyrazolines as a hypotensive agent. 
R
1
R
2
NH N
H
N
R
3
(2)  
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S. Sharma et al.
57
 have synthesized pyrazolines and tested their anti-inflammatory 
activity. Antiamoebic activity of pyrazoline derivatives have been reported by Asha 
Budakoti and co-workers
58
. J. H. Ahn et al.
59
 have reported as inhibition of cyano-
pyrazoline (3) derivatives as potent antidiabetic agents. T. S. Jeong et al.
60
 have 
synthesized some novel 3,5-diaryl pyrazolines (4) as human acyl-Co A: cholesterol 
acyltransferase inhibitors. G. Ucar et al.
61
 reported pyrazolines as cholinstearase 
andselective monoamine oxidase-B inhibitiors for the treatment of parkinson and 
alzheimer‟s diseases. M. N. Nasr et al.62 have reported the synthesis of newer 
arylthiazolylpyrazoline derivatives as anti-inflammatory agents. M. A. Berghot et al.
63 
have prepared for convergent synthesis and antibacterial activity of pyrazole and 
pyrazoline derivatives of diazepam. 
N
N
CN
O
NH
R
  
N N
H
OH OH
R
R
2
R
1
t - Bu  
( 3 )      ( 4 ) 
N. Gokhan et al.
64
 have synthesized the pyrazoline derivatives of 1-N-substituted 
thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines (5) as MAO inhibitors. Mohammad 
Abid and Amir Azam
65
 have synthesized 1-N-substituted cyclized pyrazoline of 
thiosemicarbazones (6) and reported as antiamoebic agents. V. Malhotra et al.
66
 have 
documented new pyrazolines as a cardiovascular agents. Antidepressant activity of 
pyrazoline derivatives have been reported by Y. R. Prasad and co-worker
67
. 
N
N
S
S
NH
R
1
R
(5)
 
N
N R
CH3
Cl
(6)
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 Abd El-Galil E. Amr et al.
68
 have synthesized some new 3-substituted 
androstano[17,16-c]-5,2-aryl-pyrazolines and reported their antiandrogenic activity. B. 
Bizzarri et al.
69
 have reported in vitro selective anti-helicobacter pylori activity (7) of 
pyrazoline derivatives. Bhat and co-workers
70
 reported cytotoxic properties of pyrazoline 
derivatives. Antibacterial activity of pyrazoline derivatives have been reported by A. M. 
Gandhi and co-workers
71
. B. S. Holla et al.
72
 have synthesized pyrazolines as 
antibacterial agents. S. P. Hiremath et al.
73
 have synthesized pyrazolines as analgesic, 
anti-inflammatory and antimicrobial agents. Rajendra Prasad et al.
74
 have synthesized 
some 1,3,5-triphenyl-2-pyrazolines (8) and 3-(2"-hydroxynaphthalen-1"-yl)-1,5-
diphenyl-2-pyrazolines and reported as antidepressant agents. J. H. M. Lange et al.
75
 
synthesized and reported 3,4-diaryl pyrazoline analogues as potent and selective CB1 
cannabinoid receptor antagonists. N. T. Ha- Duong et al.
76
 have been synthesized some 
pyrazole derivatives as inhibitors for the active sites of human liver cytochromes P450 of 
the 2C subfamily.  
NN
R
2
R
R
1
    
N
N
R
R
1
 
  ( 7 )       ( 8 ) 
X. Zhang and co-workers
77
 have been prepared pyrazoline derivatives (9) as 
potent selective androgen receptor modulators. M. E. Camacho and co-workers
78
 have 
been reported 4,5-dihydro pyrazoles (10) as Inhibitory nNOS activity in rat brain. 
N
H
N
O
NH
R
6
R
5
R
3
R
2
R
1
R
4
(9)  
N
N
R
1
R
NH2
R
2
(10)  
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 F. Chimenti and co-workers
79
 have been demonstrated a novel series of 1-acetyl-
3-(4-hydroxy-and 2,4-dihydroxyphenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole derivatives 
(11) and investigated for the ability to selectively inhibit the activity of monoamine 
oxidase (MAO). Y. R. Huang et al.
80
 have been prepared a series of 4-alkyl-1,3,5-
triarylpyrazoles (12) as ligands for the estrogen receptor. C. D. Cox et al.
81
 and J. R. 
Goodell et al.
82
 have been reported separately some pyrazoline derivatives as anti-obesity 
agents by antagonizing CB1 receptors and therapeutic candidates for parkinson‟s disease. 
A series of 3-(4-fluorophenyl)-4,5-dihydro-N-[4-(trifluoromethyl)-phenyl]-4-[5-
(trifluoromethyl)-2-pyridyl]-1H-pyrazole-1-carboxamide has been synthesized and 
studied for their potent foliar activity against both lepidoptera and orthoptera insects by 
P. K. Leonard et al.
83
 Bruce G. Szczepankiewicz et al.
84
 have been prepared some 
pyrazole derivatives as ant mitotic agents with activity in multi-drug resistant cell lines. 
NN
O
CH3
R R
1
 
N N
CH3
R
1
R
2
 
           ( 11 )      ( 12 ) 
Guniz Kuchkguzel et al.
85
 have synthesized pyrazolines as a antimicrobial and 
anticonvulsant agents. Gulhan T. Z. and co-workers
86
 have prepared pyrazolines as a 
hypotensive agent.  
Work done from our laboratory  
K. S. Nimavat
87 
have synthesized 1-substituted 3-aryl-5-(3‟-bromophenyl)-
pyrazolines and studied anticancer, antitubercular and antimicrobial activity. D. H. 
Vyas
88
 reported synthesis and biological activity of some pyrazoline derivatives bearing 
3,5-dibromo-4-methoxybenzaldehyde nucleus.  
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P. T. Chovatia
89
 have been reported 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-
pyrazole derivatives as a antitubercular and antimicrobial agent. T. K. Dave
90
 reported 
synthesis, antitubercular and antimicrobial evaluation of pyrazole derivatives bearing 
nicotinic acid nucleus. Synthesis of some pyrazolo[3,4-d]pyrimidines and thiazolo[4,5-
d]pyrimidines and evaluation of their antimicrobial activities with derivatives of urea and 
thiourea was reported by J. D. Akbari
91,92
. 
Literature survey reveals that the compounds bearing pyrazole moiety possess 
potential drug activity. Looking to the diversified biological activities we have 
synthesized some pyrazole derivatives in order to achieving better therapeutic agents. 
These studies are described in following section. 
SECTION-II :- SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(5-(2-(4-
       FLUOROPHENYL)-6-METHYLH-IMIDAZO[1,2-a]PYRIDIN-3-
       YL)-4,5-DIHYDRO-3-ARYLPYRAZOL-1-Yl)ETHANONES. 
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SECTION-II 
SYNTHESIS AND BIOLOGICAL SCREENING OF 1-(5-(2-(4-FLUOROPHEN- 
YL)-6-METHYLH-IMIDAZO[1,2-a]PYRIDIN-3-YL)-4,5-DIHYDRO-3-ARYL 
PYRAZOL-1-Yl)ETHANONES. 
 Pyrazolines play a vital role owing of their wide range of biological activity and 
with an aim to getting better drug, it was considered worthwhile to synthesize some new 
acetyl pyrazolines. The preparation of 1-(5-(2-(4-fluorophenyl)-6-methylH-imidazo[1,2-
α]pyridin-3-yl)-4,5-dihydro-3-arylpyrazol-1-yl)ethanones. Type(XI) have been under 
taken by cyclocondensation of chalcones of Type (X) with hydrazine hydrate in glacial 
acetic acid. 
NH2-NH2.H2O
gl. CH3COOH
N
N
F
O
CH3
R
N
N
F
N
N
O
CH3 R
CH3
 
Type (X) R= Aryl              Type (XI) R= Aryl 
 The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 
1
H nuclear magnetic resonance spectroscopy and 
further supported by mass spectrometry. Purity of all the compounds have been 
checked by thin layer chromatography. 
 All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger, Candida albicans at a 
concentration of 2000/1000/500 µg/ml. The biological activity of the synthesized 
compounds has been compared with standard drugs. Some compounds have been 
found to have moderate activity as compared to known antibiotics recorded on Table 
No.11b. 
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IR SPECTRAL STUDIES OF 1-(5-(2-(4-FLUOROPHENYL)-6-METHYLH-IMIDAZO[1,2-
α]PYRIDIN-3-YL)-4,5-DIHYDRO-3-(4-METHOXYPHENYL) PYRAZOL-1-Yl)ETHANONE. 
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 Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr pallet 
method) 
 
Type Vibration Mode Frequency in cm
-1
 Ref. 
Observed Reported 
Alkane 
C-H str. 
(asym.) 
2933 2975-2930 93 
C-H str. (sym.) 2877 2880-2860 93 
C-H def. 
(asym.) 
1442 1470-1435 95 
C-H def. (sym.) 1396 1395-1370 95 
Aromatic 
C-H str. 2933 2980-2930 94 
C=C str. 1545 1585-1480 94 
C-H I.p.(def) 1033 1125-1000 96 
C-H o.o.p. 
(def) 
615 700-600 96 
Imidazo[1,2-
α]pyridine 
C=N str. 1589 1612-1593 94 
C-N str. 1033 1220-1020 95 
 Acetyl 
Pyrazoline 
C=O str. 1577 1700-1612 94 
C=N str. 1656 1612-1593 95 
Ether C-O-C str 1240 1260-1200 96 
Halide C-F str. 1091 1200-1000 96 
N
N
F
N
N
O
CH3
CH3
O
CH3
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NMR SPECTRAL STUDIES OF 1 -(5-(2-(4-FLUOROPHENYL)-6-METHYLH -
IMIDAZO[1,2-α]PYRIDIN-3-YL)-4,5-DIHYDRO-3-(4-METHOXYPHENYL)  
PYRAZOL-1-Yl)ETHANONE.   
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument: BRUKER Spectrometer (500MHz) 
Sr. 
No. 
Chemical shift 
in ppm 
Relative No. 
of proton 
Multiplicity Inference J value in Hz 
1 1.24 3H singlet -CH3 - 
2 1.77-1.78 1H doublet -CH 8.0 
3 1.97-1.98 1H doublet -CH 8.0 
4 2.44 3H singlet -COCH3 - 
5 3.79 3H singlet -OCH3 - 
6 5.14-5.26 1H multiplet -CH - 
7 7.19-7.26 4H multiplet -Ar-4Ha,a'&b,b' - 
8 7.44-7.45 1H multiplet -Ar-H - 
9 7.62-7.64 1H doublet -Ar-H 10.5 
10 7.68-7.71 1H multiplet -Ar-H - 
11 7.77-7.82 1H multiplet -Ar-H - 
12 7.91-7.93 2H doublet -Ar-Hc,c' 8.0 
13 8.29 1H singlet -Ar-H - 
N
N
F
N
N
O
CH3
CH3
O
CH3
b
b'
a
a'
c
c'
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Expanded aromatic region of NMR spectra 
MASS SPECTRAL STUDIES OF 1-(5-(2-(4-FLUOROPHENYL)-6-METHYLH-IMIDAZO [1,2-
α]PYRIDIN-3-YL)-4,5-DIHYDRO-3-(4-METHOXYPHENYL)PYRAZOL-1-Yl)ETHANONE. 
 
 
N
N
F
N
N
O
CH3
CH3
O
CH3
m/z = 442
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PROPOSED MASS FRAGMENTATION OF 1-(5-(2-(4-FLUOROPHENYL)-6-METHYLH-
IMIDAZO[1,2-α]PYRIDIN-3-YL)-4,5-DIHYDRO-3-(4-METHOXYPHENYL)PYRAZOL-1-
Yl)ETHANONE. 
N
N
F
N
N
O
CH3
CH3
O
CH3
m/z = 442
C26H23FN 4O2
N
N
F
N
N
O
CH3
O
CH3
m/z = 428
C25H21FN 4O2
N
N
N
N
O
CH3
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m/z = 410
C25H22N4O2
N
N
N
N
O
CH3
C24H20N4O
m/z = 380
N
N
F
N
N
O
CH3
CH3
CH3
m/z = 350
C20H19FN 4O
N
N
F
N
N
O
CH3
m/z = 322
C18H15FN 4O
NH
CH2
N
N
N
O
CH3
m/z = 280
C16H16N4O
NH
N
N
N
O
CH3
m/z = 178
C8H10N4O
N
N
N
N
O
CH3
OH
m/z = 396(M
-2
)
C24H20N4O2
+
+
+
+
+
+
+
+
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary bath 
on controlled temperature heating mental. The crystallization of all the compounds was 
carried out in appropriate solvents. TLC was carried out on silica coated aluminum sheet 
(Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
[A] Synthesis of (2E)-3-(2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-α]pyridin- 
 3-yl)-1-arylprop-2-en-1-ones. 
 See Part-III[A], Section-I [C]. 
[B] Synthesis of 1-(5-(2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-α]pyridin-3-
 yl)-4,5-dihydro-3-(4-methoxyphenyl)pyrazol-1-yl)ethanone.  
 A mixture of (2E)-3-(2-(4-fluorophenyl)-6-methylH-imidazo[1,2-α]pyridin-3-yl)-
1-arylprop-2-en-1-ones. (3.86gm, 0.01mol) and hydrazine hydrate (0.04mol, 99 %) in 20 
ml acetic acid was refluxed on an oil-bath for 10-11 hrs. The solution was poured on 
crushed ice. The product was isolated and crystallized from dioxane. Yield 65%, m. p. 
186 °C , Anal. Calcd. for C26H23FN4O2 Require: C, 70.57, H, 5.24, N, 12.66 %; Found: C, 
70.59, H, 5.28, N, 12.69 %. 
[E] Antimicrobial activity of 1-(5-(2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-
 α]pyridin-3-yl)-4,5-dihydro-3-(4-methoxyphenyl)pyrazol-1-yl)ethanone.
 Antimicrobial testing was carried out as described in part-(I), section-I(D). 
The zones of inhibition of compounds are recorded in Table No.11b. 
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Table-11a: Physical constants of 1-(5-(2-(4-Fluorophenyl)-6-methylHimidazo[1,2- 
        a]pyridin-3-yl)-4,5-dihydro-3-arylpyrazol-1-yl)ethanones. 
N
N
F
N
N
O
CH3
CH3
R
 
 
 
  
 
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd./Found 
C H N 
11a C6H5- 
C25H21FN4O 
412.15 
197 61 
72.80 
(72.68) 
5.13 
(5.01) 
13.58 
(13.25) 
11b 4-CH3-C6H4- 
C26H23FN4O 
426.48 
167 58 
73.22 
(73.04) 
5.44 
(5.23) 
13.14 
(13.01) 
11c 2-CH3-C6H4- 
C26H23FN4O 
426.48 
174 49 
73.22 
(73.05) 
5.44 
(5.39) 
13.14 
(13.03) 
11d 2,5-(CH3)2-C6H3- 
C27H25FN4O 
440.51 
152 66 
73.62 
(73.49) 
5.72 
(5.66) 
12.72 
(12.49) 
11e 4-OCH3-C6H4- 
C26H23FN4O2 
442.48 
186 65 
70.57  
(70.39) 
5.24 
(5.18) 
12.66 
(12.49) 
11f 2,4-(Cl)2-C6H3- 
C25H19ClFN4O 
481.90 
157 61 
62.38 
(62.26) 
3.98 
(3.86) 
11.64 
(11.54) 
11g 4-Cl-C6H4- 
C25H20ClFN4O 
446.34 
165 51 
67.19 
(67.01) 
4.51 
(4.26) 
12.54 
(12.36) 
11h 3-Cl-C6H4- 
C25H20ClFN4O 
446.34 
154 45 
67.19 
(66.04) 
4.51 
(4.22) 
12.54 
(12.31) 
11i 4-NO2-C6H4- 
C25H20FN5O3 
457.45 
163 53 
65.64 
(65.39) 
4.41 
(4.22) 
15.31 
(15.16) 
11j 4-F-C6H4- 
C25H20F2N4O 
430.44 
210 46 
69.76 
(69.36) 
4.68 
(4.47) 
13.02 
(12.92) 
 
          TABLE 11B : ANTIMICROBIAL ACTIVITY OF 1-(5-(2-(4-FLUOROPHENYL)-6-METHYLHIMIDAZO[1,2- 
         a]PYRIDIN-3-YL)-4,5-DIHYDRO-3-ARYLPYRAZOL-1-Yl(ETHANONES). (in µg/ml) 
No. Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus 
aureus 
Bacillus subtilis Escherichia coli
Salmonella 
paratyphi B 
Aspergillus niger Candida albicans
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 
1. 11a + + + + + + + + + + + - + + + + + + 
2. 11b + + - + + + + + + + + - + + - - - - 
3. 11c + + - + + + + + - + + + + + - + + + 
4. 11d + + + + + + + + - + + - + + + + + - 
5. 11e + + - + + + + + + + + + + + + + + - 
6. 11f + + - + + + + + + + + + + + + + + + 
7. 11g + + - - - - + + - - - - + + - - - - 
8. 11h + + - + + - + + - + + - + + - + + - 
9. 11i + + + + + + + + + - - - + + + + - - 
10. 11j + + - - - - + + + - - - + + - + + - 
           Where (+)  =  New synthesized compounds were active against microorganism 
          (-)  =  New synthesized compounds were inactive against microorganism 
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INTRODUCTION 
Azomethine derivatives have been found to be potent drug in pharmaceutical 
industries and possess a wide spectrum of biological activity. Azomethines are also 
known as schiff’s base named after Hugo schiff, and they are well known intermediate 
for the preparation of azetidinone, thiazolidinone, formazone, aryl acetamide and many 
other derivatives. These are the compounds contain characteristic -C=N group. B. S. 
Holla et al.
1
 have documented azomethine (1) having triazole moiety and possess good 
antibacterial activity.  
N
N
N
R
S
R
1
N
O
N
+
O
-
O
 
      ( 1 ) 
Azomethines are obtained mainly by warming the aldehyde and aromatic amine 
together. However, it is more convenient to work in a solvent such as alcohol, dilute 
acetic acid or glacial acetic acid. Some time the reaction is aided by trace of acid in other 
cases the hydrochloride of the amines can be used in the synthesis.  
In general schiff’s bases do not react further with either of the reagents used in 
their preparation as do most of the other types of simple intermediates. 
SYNTHETIC ASPECT 
Various methods for the preparation of azomethine derivatives have been cited in 
literature, some of the methods are as under. 
1. General account of the summary of reaction of aldehydes with amine (aromatic or 
aliphatic) has been reviewed by Murray.
2
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R
O
+ R1 NH2
R
N R
1
 
2. E. C. Creencia and group3 reported synthesis from ortho substituted aniline with 
55 % yield in 2 hrs. in benzene.    
NH2
Ar
+
O
N
Ar
R
R
Benzene
2hrs.
 
3. D. Bleger et al.4 have synthesized schiff’s base of aniline and benzaldehyde in 
ethanol with short reaction time of 4 hrs. and reported E isomer as major product.  
NH2
+
O
EtOH N
E
4hrs.
 
4. U. K. Roy and coworkers5 have reported preparation of schiff’s base with 100 % 
of yield with toluene as a solvent.  
NH2
+
O
N
PhMe
24hrs.
 
5. L. B. Pierre and coworkers6 have synthesized (E)-N-phenyl methylene 
glycineethyl ester by the cyclocondensation of glycine ethyl ester hydrochloride, 
t-butylmethyl ether (TBME), benzaldehyde was added followed by anhydrous 
Na2SO4 and triethylamine. 
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HCl.
+
O
Et3N, TBME
Na2SO4 N
O
O
CH3
NH2
O
O
CH3
 
6. J. G. Amanda et al.7 have prepared schiff bases by condensation of equimolar 
quantity of 3,6-diformylcatechol and substituted o-phenylenediamine. 
O
O
OH
OH
+
OR
OR
NH2
NH2
O
OH
OH
N
CH3
OR
CH3
 
7. L. Somogyi8 reported some azomethine derivatives of phenylhydrazide in 99 % 
yield and with short reaction time of 3.5 hours in polar solvent. 
NHO
NH2
+
O
N
R
R
3.5hrs.
 
8. Schieff’s base of o-phenelene diamine with substituted benzaldehyde was 
reported by M. Zintl and coworkers
9
. 
NH2
NH2
+ Ar
O
EtOH N
Ar
N
Ar
 
BIOLOGICAL EVALUATION 
 
Schiff bases exhibit a wide range of pharmacological activities like antifungal, 
antibacterial, antiviral, anti-inflammatory etc. R. H. Mehta et al.
10
 have synthesized 
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coummarin schiff’s base derivatives (2) and examined for their antibacterial activity. A. 
K. Khalafallah and M. E. Hassan
11
 have prepared some styryl schiff’s bases spiro 
derivatives as potential antibacterial and antifungal activity. P. Perumal
12
 have 
synthesized some azomethine derivatives (3) having good antibacterial activity. 
O O
N
R
NO N
R 
      ( 2 )              ( 3 ) 
M. D. Deshmukh and A. G. Doshi
13
 prepared some new schiff’s bases show good 
antimicrobial activity against test organism S. aureus, E. coli, Saigella dysenteridse and 
Salmonella typhi. Wang et al.
14
 have synthesized diazomethines having good plant 
hormone activity. Das Arima et al.
15
 have prepared schiff’s bases of aminohydroxy 
guanidine (SB-AHG5) and tested for antiviral activity against Herpes Simplex virus Type 
I (HSV-1) and adenovirus Type-5 (Ad-5). 
Ali, yusuf et al.
16
 have synthesized some schiff’s base derivatives of glucose 
containing acetylenic bond. The prepared schiff bases were tested for their bactericidal 
activity against E. coli and S. aureus. 
B. S. Holla et al.
17
 have prepared schiff’s bases and reported them as 
antimicrobial agents. Pandey Taruna et al.
18
 prepared azomethines and their boron 
complexes and screened for their antifungal and antibacterial properties. It is evident that 
azomethines along with quite toxic but their activity increased after complexation. Omar 
et al.
19
 have determined cyclocondensation of azomethines having good antischistosomal 
activity. Chohan and coworkers
20,21
 have synthesized a novel class of acetyl ferrocene 
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derived from schiff bases possess antimicrobial activity. Some azomethine derivative 
screened for various antibacterial strains. 
Das Joydip et al.
22
 have synthesized trans-N-refinylidene-n-butylamine (4) which 
found stabilized in liposome’s of phophatidylcholine. The rate of formation of the 
schiff’s base is found to decrease with increasing cholesterol concentration in the 
membrane. V. M. Patel
23
 has synthesized some new schiff’s bases having good 
antibacterial activity. 
 
CH3 CH3
CH3 CH3
N
But
(4)
 
Ram Tilak et al.
24
 have synthesized some schiff’s bases, of 2-chloro 
phenothiazines and screened against carrageenin-induced edema in albino rats. A. 
Cascaval et al.
25
 have synthesized azomethines, which have good analgesic and 
antipyretic properties. S. N. Pandeya et al.
26
 have synthesized schiff bases showed good 
activity against Vibrio cholerae non-o., Shigella boydii, Enterococcus faecalis and 
Edwaredsiella torla with MIC in the rang of 10-25 μg/ml. Some compounds were found 
to be active against Salmonellal typhi and Vibro cholerae-0, (MIC 25-150 μg/ml). 
K. N. Venugopal et al.
27
 have synthesized schiff base of 4-hydroxy-6-
carboxyhaydrazino benzothiophene analog with different substituted aldehydes and 
determined pharmacological study. Ergenc and coworkers
28
 have synthesized azomethine 
derivatives having antifungal activity. B. Yadav and S. S. Sangapure
29
 have synthesized 
some azomethines and tested for their biological activity. B. S. Holla et al.
30
 have 
prepared some new schiff’s bases having anticancer activity. 
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R. V. Chambhare et al.
31
 have prepared some azomethines and tested for their 
antimicrobial activity. M. S. Karthikeyan et al.
32
 have synthesized azomethines (5) 
having antibacterial and anti-inflammatory activity. 
N
S
Cl
Cl
Cl
NH
N
O
R
(5)
 
Work done from our laboratory  
K. M. Thaker
 
et al.
33
 have prepared some schiff bases bearing benzo[b]thiophene 
nucleus and tested for their antitubercular and antimicrobial activity. S. L. Vasoya
34
 
reported facile synthesis of some new azomethines bearing benzo[b]thiophene nucleus as 
a potent biological active agent.T. K. Dave
35,36
 have been reported synthesis and 
pharmacological study of Mannich bases of 4-amino-3-mercapto-5-pyridin-3'-yl-[1,2,4]-
triazole and schiff base bearing nicotinic acid nucleus with antitubercular and 
antimicrobial evaluation. 
Looking to the interesting properties of azomethines, we have synthesized some 
new azomethines, which have been described as under.  
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2-(4-  
             FLUOROPHENYL)-6-METHYLH-IMIDAZO [1,2-α]PYRIDIN-3- 
  YL]METHYLENE)-4-ARYLAMINES. 
SECTION-II: SYNTHESIS AND BIOLOGICAL SCREENING OF N-((2-(4-  
  FLUOROPHENYL)-6-METHYLH-IMIDAZO [1,2-α]PYRIDIN-3- 
  YL)METHYL)-4-ARYLAMINES. 
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SECTION-I 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2-(4-FLUOROPHENYL)-6-
METHYLH-IMIDAZO [1,2-α]PYRIDIN-3-YL]METHYLENE)-4-ARYLAMINES. 
Looking to the interesting properties of azomethines, with an intension to 
synthesizing better therapeutic agents, azomethine derivatives of Type (XII) have been 
synthesized by the condensation of 2-(4-Fluorophenyl)-6-methylH-imidazo[1,2- 
α]pyridine-3-carbaldehyde with different aromatic amines in order to study their 
biodynamic behavior. 
N
N
F
N
R
CH3N
N
F
O
CH3
R-NH2
gl. CH3COOH
 
       Type (XII) R= Aryl 
The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 
1
H nuclear magnetic resonance spectroscopy and further 
supported by mass spectrometry. Purity of all the compounds have been checked by thin 
layer chromatography. 
All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger, Candida albicans at a concentration of 
2000/1000/500 µg/ml. The biological activity of the synthesized compounds have been 
compared with standard drugs. Some compounds have been found to have moderate 
activity as compared to known antibiotics recorded on Table No.12b.
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IR SPECTRAL STUDIES OF N(2-(4-FLUOROPHENYL)-6-METHYLH-
IMIDAZO[1,2-α]PYRIDINE-3-YL)METHYLENE)-4-METHYLBENZENAMINE.  
500750100012501500175020002500300035004000
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Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr 
pallet method) 
 
 
Type Vibration Mode 
Frequency in cm-1 
Ref. 
Observed Reported 
Alkane 
C-H str. 
(asym.) 
2962 2975-2940 37 
C-H str. (sym.) 2868 2880-2860 38 
C-H def. 
(asym.) 
1448 1470-1435 37 
C-H def. (sym.) 1373 1395-1370 38 
Aromatic 
C-H str. 2962 2980-2930 40 
C=C str. 1487 1585-1480 40 
C-H I.p.(def) 1070 1125-1000 39 
C-H o.o.p. 
(def) 
638 700-600 39 
Imidazo[1,2-
α]pyridine 
C=N str. 1602 1615-1593 37 
C-N str. 1070 1220-1020 38 
Schiff base C=N str. 1583 1660-1580 37 
Halide C-F str. 1070 1200-1000 39 
N
N
F
N
CH3
CH3
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NMR SPECTRAL STUDIES OF N(2-(4-FLUOROPHENYL)-6-METHYLH-
IMIDAZO[1,2-α]PYRIDINE-3-YL)METHYLENE)-4-METHYLBENZENAMINE.  
 
 
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (500MHz) 
 
Sr. 
No. 
Chemical shift 
in ppm 
Relative No. 
of proton 
Multiplicity Inference J value in Hz 
1.  2.35 3H singlet -CH3-Ar - 
2.  2.48 3H singlet -CH3 - 
3.  7.25-7.26 3H doublet -Ar-H 6.5 
4.  7.31-7.32 2H doublet -Ar-Ha,a’ 8.0 
5.  7.39-7.42 3H triplet -Ar-H 5.0 
6.  7.53-7.55 3H doublet -Ar-H 9.5 
7.  7.76-7.78 1H doublet -Ar-H 10.0 
N
N
F
N
CH3
CH3
a'
a
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Expanded aromatic region of NMR spectra 
 
 
MASS SPECTRAL STUDIES OF N(2-(4-FLUOROPHENYL)-6-METHYLH-
IMIDAZO[1,2-α]PYRIDINE-3-YL)METHYLENE)-4-METHYLBENZENAMINE.  
 
N
N
F
N
CH3
CH3
m/z = 343
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PROPOSED MASS FRAGMENTATION OF N(2-(4-FLUOROPHENYL)-6-METH- YLH-
IMIDAZO[1,2-α]PYRIDINE-3-YL)METHYLENE)-4-METHYLBENZENAMINE.  
N
N
F
N
CH3
CH3
m/z = 343
C22H18FN 3
N
N
F
N
CH3 CH2
m/z = 279
C17H14FN 3
N
N
F
NH
CH3
m/z = 253
C15H12FN 3
N
N
F
CH3
m/z = 226
C11H14FN 2
N
N
CH3
CH3
m/z = 222
C15H14N2
NH
N
CH3
C10H10N2
m/z = 158
NH
N
C9H8N2
m/z = 144
NH2
F
C7H8FN
m/z = 125
NH2
m/z = 107
C7H9N
+
+
+
+ +
+
+
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary bath 
on controlled temperature heating mental. The crystallization of all the compounds was 
carried out in appropriate solvents. TLC was carried out on silica coated aluminum sheet 
(Merck prepared plates) as stationary phase. Various proportion of Ethyl acetate in 
hexane was used as a mobile phase. 
[A] Synthesis of 2-(4-Fluorophenyl)-6-methyl-H-imidazo[1,2-α] pyridine-3-carbal 
dehyde. 
    See, Part-C [A], Section-I [B]. 
[B] Synthesis of N-(2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-α]pyridin-3-yl] 
methylene)-4-methylbenzenamine. 
 A mixture of 2-(4-fluorophenyl)-6-methylH-imidazo[1,2-α]pyridine-3-carbal- 
dehyde (2.54gm, 0.01mol) and p-toludine (1.08gm, 0.01mol) in methanol (20 ml) in 
presence of catalytic amount of glacial acetic acid was refluxed for 6 hrs. The contents 
were cooled and product isolated was crystallized from methanol. Yield, 52%, m.p. 188 
°C, C18H22FN3 ; Found : C, 76.98%; H, 5.33%; N,12.29%; Requires : C, 76.95%; H, 
5.28%; N, 12.24%. 
 Similarly, other N-(2-(4-fluorophenyl)-6-methylH-imidazo [1,2-α]pyridin-3-
yl]methylene)-4-arylamines were prepared. The physical constants are recorded in Table 
No. 12a. 
[A] Antimicrobial activity of N-(2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-α] 
pyridin-3-yl]methylene)-4-arylamines. 
Antimicrobial testing was carried out as described in part-(I), section-I(D). The 
zones of inhibition of compounds are recorded in Table No.12b.
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Table-12a: Physical constants of  N-(2-(4-fluorophenyl)-6-methylH-imidazo[1,2-α]         
         pyridin-3-yl]methylene)-4-arylamines. 
 
 
N
N
F
N
CH3
R
 
 
 
 
 
 
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd./Found 
C H N 
12a C6H5- 
C21H16FN3 
329.37 
163 81 
76.58 
(76.49) 
4.90 
(4.78) 
12.76 
(12.69) 
12b 4-CH3-C6H4- 
C22H18FN3 
343.39 
154 72 
76.95 
(76.80) 
5.28 
(5.18) 
12.24 
(12.13) 
12c 2-CH3-C6H4- 
C22H18FN3 
343.39 
147 86 
76.95 
(76.84) 
5.28 
(5.16) 
12.24 
(12.19) 
12d 2,5-(CH3)2-C6H3- 
C23H20FN3 
357.42 
158 78 
77.29 
(77.16) 
5.64 
(5.44) 
11.76 
(11.59) 
12e 4-OCH3-C6H4- 
C22H18FN3O 
359.39 
110 73 
73.52 
(73.39) 
5.05 
(5.91) 
11.69 
(11.55) 
12f 2,5-(Cl)2-C6H3- 
C21H14Cl2FN3 
398.26 
159 66 
63.33 
(63.21) 
3.54 
(3.39) 
10.55 
(10.39) 
12g 4-Cl-C6H4- 
C21H15ClFN3 
363.81 
168 70 
69.33 
(69.28) 
4.16 
(4.09) 
11.55 
(11.34) 
12h 4-F-C6H4- 
C21H15F2N3 
347.36 
113 67 
72.61 
(72.49) 
4.35 
(4.18) 
12.10 
(12.06) 
 TABLE 12B: ANTIMICROBIAL ACTIVITY OF (17E)-N-((2-(4-FLUOROPHENYL)-6-METHYLH- 
IMIDAZO [1,2-α]PYRIDIN-3-YL]METHYLENE)-4-ARYLAMINES. (in µg/ml) 
No. Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus 
aureus 
Bacillus subtilis Escherichia coli
Salmonella 
paratyphi B 
Aspergillus niger Candida albicans
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 
1. 12a + + - + + + + + - + + - + + + + + - 
2. 12b + + - + + + - - - + + - + + + - - - 
3. 12c + + + + + + + + + + + + + + - + + - 
4. 12d + + - + + - + + - + + - + + - + + - 
5. 12e - - - + + - + + - + + - - - - - - - 
6. 12f + + - + + + - - - - - - + + - + + - 
7. 12g + + + + + + - - - - - - - - - - - - 
8. 12h + + + + + + - - - - - - + + - + + - 
             Where (+)  =  New synthesized compounds were active against microorganism 
                  (-)  =  New synthesized compounds were inactive against microorganism 
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SECTION-II 
SYNTHESIS AND BIOLOGICAL SCREENING OF N-((2-(4-FLUOROPHENYL)-6-
METHYLH-IMIDAZO[1,2-α]PYRIDIN-3-YL]METHYL)-4-ARYLAMINES. 
 Aminomethyl derivatives of heterocyclic compounds are associated with diverse 
therapeutical activities. These finding prompted us to synthesize some representative 
aminomethyl derivative of Type (XIII) bearing imidazo[1,2-α]pyridine moiety obtained 
by selective reduction of (imine group) schiff’s bases of Type (XII) with sodium 
borohydride in controlled experimental condition as shown in the reaction 
scheme.
N
N
F
NH
R
CH3
Type (XIII)   R= Aryl
N
N
F
N
R
CH3
Anh.NaBH 4
Type (XII)   R= Aryl  
The constitution of newly synthesized compounds have been supported by using 
elemental analysis, infrared and 
1
H nuclear magnetic resonance spectroscopy and further 
supported by mass spectrometry. Purity of all the compounds have been checked by thin 
layer chromatography. 
 All the compounds have been screened for their in vitro biological assay like 
antibacterial activity towards Gram positive and Gram negative bacterial strains and 
antifungal activity towards Aspergillus niger, Candida albicans at a concentration of 
2000/1000/500 µg/ml. The biological activity of the synthesized compounds have been 
compared with standard drugs. Some compounds have been found to have moderate 
activity as compared to known antibiotics recorded on Table No.13b.
Studies on chemical… 
241    Arylaminomethyl 
 
IR SPECTRAL STUDIES OF N-((2-(4-FLUOROPHENYL)-6-METHYLH-
IMIDAZO[1,2-α]PYRIDIN-3-YL)METHYL)-4-METHYLBENZENAMINE. 
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 Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr pallet 
method) 
 
Type Vibration Mode 
Frequency in cm-1 
Ref. 
Observed Reported 
Alkane 
C-H str. 
(asym.) 
2941 2975-2940 37 
C-H str. (sym.) 2848 2880-2860 38 
C-H def. 
(asym.) 
1437 1470-1435 37 
C-H def. (sym.) 1390 1395-1370 38 
Aromatic 
C-H str. 2941 2980-2930 40 
C=C str. 1504 1585-1480 40 
C-H I.p.(def) 1078 1125-1000 39 
C-H o.o.p. 
(def) 
669 700-600 39 
Imidazo[1,2-
α]pyridine 
C=N str. 1614 1615-1593 37 
C-N str. 1024 1220-1020 38 
Amine  -NH str. 3356 3400-3200 37 
Halide C-F str. 1161 1200-1000 39 
N
N
F
NH
CH3
CH3
Studies on chemical… 
242    Arylaminomethyl 
 
NMR SPECTRAL STUDIES OF N-((2-(4-FLUOROPHENYL)-6-METHYLH-
IMIDAZO[1,2-α]PYRIDIN-3-YL)METHYL)-4-METHYLBENZENAMINE.  
 
 
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer  (500MHz) 
  
Sr. 
No. 
Chemical shift 
in ppm 
Relative No. 
of proton 
Multiplicity Inference J value in Hz 
1 2.74 3H singlet Ar-CH3 - 
2 2.91 3H singlet -CH3 - 
3 3.87-3.90 2H singlet -CH2 - 
4 6.530 2H doublet -Ar-Ha-a' - 
5 6.30-6.92 2H doublet -Ar-Hb,b' 8.5 
6 7.20-7.22 1H doublet -Ar-H 10.0 
7 7.32-7.34 1H doublet -Ar-H 10.0 
8 7.38-7.42 1H triplet -Ar-H 10.0 
9 7.54-7.56 2H triplet -Ar-Hc,c' 12.0 
10 7.67-7.64 1H singlet -NH - 
11 7.93-7.96 2H multiplet -Ar-Hd,d' - 
N
N
F
NH
CH3
CH3
a
b
a'
b'
c
c'
d
d'
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Expanded aromatic region of NMR spectra 
 
MASS SPECTRAL STUDIES OF N-((2-(4-FLUOROPHENYL)-6-METHYLH-
IMIDAZO[1,2-α]PYRIDIN-3-YL)METHYL)-4-METHYLBENZENAMINE. 
 
 
N
N
F
NH
CH3
CH3
m/z = 345
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    PROPOSED MASS FRAGMENTATION OF  N((2-(4-FLUOROPHENYL)-6-METHYL  
H-IMIDAZO[1,2-α]PYRIDINE-3-YL)METHYLENE)-4-METHYLBENZENAMINE. 
 
N
N
F
NH
CH3
CH3
m/z = 345
C22H20FN 3
N
N
F
NH2
CH3
m/z = 255
C15H14FN 3
N
N
F
CH3
m/z = 226
C11H14FN 2
N
N
CH3
m/z = 208 (M
-2
)
C14H12N2
NH
N
CH3
C10H10N2
m/z = 158
NH2
F
C7H8FN
m/z = 125 (M
+2
)
NH2
m/z = 107
C7H9N
N
N
NH
CH3
CH3
m/z = 327
C22H21N3
+
+ +
+ +
+
+
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EXPERIMENTAL SECTION 
 Melting points of all the synthesized compounds were taken in open capillary bath 
on controlled temperature heating mental. The crystallization of all the compounds was 
carried out in appropriate solvents. TLC was carried out on silica coated aluminum sheet 
(Merck prepared plates) as stationary phase. 55 % Ethyl acetate in hexane was used as a 
mobile phase. 
 
[A] Synthesis of N-((2-(4-Fluorophenyl)-6-methylh-imidazo[1,2-α]pyridin-3-
yl)methylene)-4-methylbenzenamines. 
 See, Part-III [A], Section-I [B]. 
[B] Synthesis of N-((2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-α]pyridin-3-
yl)methyl)-4-methylbenzenamine. 
 Sodium borohydride (0.15mol, 0.57gm) was added to a methanolic solution of  N-
((2-(4-fluorophenyl)-6-methylH-imidazo[1,2-α]pyridin-3-yl]methylene)-4-meth- 
ylbenzenamines. (0.01mol, 3.43gm) over a period of 30 minutes at temperature 5-10 
o
C 
with constant stirring. The reaction mixture was kept over night at room temp. The excess 
sodium borohydride was neutralized by adding water and the product was extracted with 
ether. The ether extract was washed with water untill  become neutral, then dried over 
anhydrous Na2SO4 and finally the ether was evaporated to give aminomethyl derivatives. 
Crystallized from ethanol. Yield, 65%, m.p. 163 °C, C22H20FN3; Found : C, 76.34; H, 
5.71; N, 12.02 %; Requires : C, 76.50; H, 5.84; N, 12.17 %.  
 Similarly, other (17Z)-N-((2-(4-fluorophenyl)-6-methylH-imidazo[1,2-α]pyridin-
3-yl)methylene)-4-arylamines were prepared. The physical constants are recorded in 
Table No. 13a. 
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[C] Antimicrobial activity of N-((2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-α] 
pyridin-3-yl)methyl)-4-arylamines. 
 Antimicrobial testing was carried out as described in part-(I), section-I(D). 
The zones of inhibition of compounds are recorded in Graphical Chart No.13b. 
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Table-13a: Physical constants of N-((2-(4-Fluorophenyl)-6-methylH-imidazo[1,2-α]                                                         
         pyridin-3-yl)methyl)-4-arylamines. 
 
 
N
N
F
NH
CH3
R
 
 
 
 
 
 
 
 
Sr. No. 
Substitution 
R 
Molecular Formula/ 
Molecular Weight 
M.P. 
°C 
Yield 
% 
% Composition 
Calcd./Found 
C H N 
13a C6H5- 
C21H16FN3 
331.38 
185 58 
76.11 
(76.02) 
5.47 
(5.29) 
12.68 
(12.43) 
13b 4-CH3-C6H4- 
C22H20FN3 
345.41 
163 65 
76.50 
(76.34) 
5.84 
(5.71) 
12.17 
(12.02) 
13c 2-CH3-C6H4- 
C22H20FN3 
345.41 
174 75 
76.50 
(76.39) 
5.84 
(5.74) 
12.17 
(12.09) 
13d 2,5-(CH3)2-C6H3- 
C23H22FN3 
359.43 
160 63 
76.85 
(76.64) 
6.17 
(6.01) 
11.69 
(11.61) 
13e 4-OCH3-C6H4- 
C22H20FN3O 
361.41 
198 55 
73.11 
(73.04) 
5.58 
(5.29) 
11.63 
(11.41) 
13f 2,5-(Cl)2-C6H3- 
C21H14Cl2FN3 
398.26 
188 45 
63.01 
(62.72) 
4.03 
(3.89) 
10.50 
(10.19) 
13g 4-Cl-C6H4- 
C21H17ClFN3 
365.83 
176 63 
68.95 
(68.65) 
4.68 
(4.52) 
11.49 
(11.32) 
13h 4-F-C6H4- 
C21H17F2N3 
349.37 
186 49 
72.19 
(72.03) 
4.90 
(4.62) 
12.10 
(11.83) 
 
TABLE 13B : ANTIMICROBIAL ACTIVITY OF N-((2-(4-FLUOROPHENYL)-6-METHYLH-IMIDAZO[1,2-          
α]PYRIDIN-3-YL]METHYL)-4-ARYLAMINES. (in µg/ml) 
No. Code No. 
Antibacterial activity Antifungal activity 
Gram +ve Bacteria Gram -ve Bacteria Uni/Multicellular Fungi
Staphylococcus 
aureus 
Bacillus subtilis Escherichia coli
Salmonella 
paratyphi B 
Aspergillus niger Candida albicans
2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 2000 1000 500 
1 13a + + - + + - + + - + + - + + + + + - 
2 13b - - - + + - - - - + + - + + + - - - 
3 13c + + - + + + + + + + + + + + - + + - 
4 13d + + - + + - + + - + + - + + - + + - 
5 13e - - - + + - + + - + + - - - - - - - 
6 13f + + - - - - - - - - - - + + - + + - 
7 13g - - - - - - - - - - - - - - - - - - 
8 13h + + - - - - - - - - - - + + - + + - 
                   Where (+)  =  New synthesized compounds were active against microorganism 
                    (-)  =  New synthesized compounds were inactive against microorganism 
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